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This thesis presents a contribution to the active research area of functional data analysis
(FDA) and is concerned with the analysis of data from complex experimental designs in
which the responses are curves. High resolution, closely correlated data sets are encoun-
tered in many research fields, but current statistical methodologies often analyse simplistic
summary measures and therefore limit the completeness and accuracy of conclusions drawn.
Specifically the nature of the curves and experimental design are not taken into account.
Mathematically, such curves can be modelled either as sample paths of a stochastic process
or as random elements in a Hilbert space. Despite this more complex type of response, the
structure of experiments which yield functional data is often the same as in classical exper-
imentation. Thus, classical experimental design principles and results can be adapted to the
FDA setting.
More specifically, we are interested in the functional analysis of variance (ANOVA)
of experiments which use orthogonal designs. Most of the existing functional ANOVA ap-
proaches consider only completely randomised designs. However, we are interested in more
complex experimental arrangements such as, for example, split-plot and row-column de-
signs. Similar to univariate responses, such complex designs imply that the response curves
for different observational units are correlated.
We use the design to derive a functional mixed-effects model and adapt the classical
projection approach in order to derive the functional ANOVA. As a main result, we derive
new functional F tests for hypotheses about treatment effects in the appropriate strata of the
design. The approximate null distribution of these tests is derived by applying the Karhunen-
Loève expansion to the covariance functions in the relevant strata. These results extend
ii
existing work on functional F tests for completely randomised designs.
The methodology developed in the thesis has wide applicability. In particular, we con-
sider novel applications of functional F tests to gait analysis. Results are presented for two
empirical studies. In the first study, gait data of patients with cerebral palsy were collected
during barefoot walking and walking with ankle-foot orthoses. The effects of ankle-foot
orthoses are assessed by functional F tests and compared with pointwise F tests and the
traditional univariate repeated-measurements ANOVA. The second study is a designed ex-
periment in which a split-plot design was used to collect gait data from healthy subjects. This
is commonly done in gait research in order to better understand, for example, the effects of
orthoses while avoiding confounded analysis from the high variability observed in abnormal
gait. Moreover, from a technical point of view the study may be regarded as a real-world
alternative to simulation studies. By using healthy individuals it is possible to collect data
which are in better agreement with the underlying model assumptions.
The penultimate chapter of the thesis presents a qualitative study with clinical experts
to investigate the utility of gait analysis for the management of cerebral palsy. We explore
potential pathways by which the statistical analyses in the thesis might influence patient
outcomes.
The thesis has six chapters. After describing motivation and introduction in Chapter
1, mathematical representations of functional data are presented in Chapter 2. Chapter 3
considers orthogonal designs in the context of functional data analysis. New functional F
tests for complex designs are derived in Chapter 4 and applied in two gait studies. Chapter
5 is devoted to a qualitative study. The thesis concludes with a discussion which details the
extent to which the research question has been addressed, the limitations of the work and the
degree to which it has been answered.
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It is increasingly common to encounter experiments in which the individual responses are not
real numbers but curves or surfaces which are observed over some continuous domain due
to advances in laboratory equipment and imaging technology. Mathematically, responses of
this kind can be regarded as functions and the relatively new and thriving area of statistics
which is known as functional data analysis (FDA) is concerned with developing methods for
analysing data that are functions.
Functional data not only arise in experiments and generalisations of classical multivari-
ate statistical techniques (Johnson and Wichern, 2007), such as principal component anal-
ysis, have attracted considerable attention. However, in this thesis we will be concerned
with experiments and explore how well-established principles of experimental design can be
adapted to the FDA setting. The applications that will be considered come from the field of
gait research and the responses of interest are typically curves depicting the movements of
lower limb joints over time. Despite the complexity of functional responses, the scientific
questions an experiment is supposed to answer are often similar to those in classical experi-
1
ments with univariate responses and often amount to comparing different treatments, where,
as usual in the statistical literature, the generic term “treatment” refers to all conditions of
interest that can be actively varied by the experimenter (Hinkelmann and Kempthorne, 1994,
p. 26).
In the simplest case, one may be interested in investigating if there is a difference in
the “mean responses” of two independent groups of patients of which one is treated with a
placebo and one with an active treatment. A main challenge in this situation is that contrary
to classical experiments the “mean response” is now a function itself rather than a single
parameter. Moreover, comparing entire functions and deriving appropriate statistical tests
for this purpose is more involved than testing hypothesis which only involve real parameters.
The analysis becomes increasingly complicated in experiments where, in addition to the
functional responses, the units, for example patients, to which treatments are applied and for
which observations are being taken possess some structure. Such structure may be inherent,
such as the fact that a person’s legs “reside” within that person and cannot necessarily be
regarded as independent entities. Likewise, when each person is observed under different
conditions, the repeated measurements taken for this person form a group of observations
which needs to be distinguished from the groups of observations that are obtained for other
individuals in the same experiment. Moreover, structure of the units in an experiment may
also be a consequence of administrative, logistic or other aspects of the how the experiment
is conducted (Bailey, 2008, p. 55). For example, if an experiment includes data recorded
at various times over several days, then both the day and the time of the data collection
impose some structure on the data. Likewise, if in preparation for data recordings people are
equipped with marker sets by, say, one of two assistants, then this again adds some structure
to the experiment since the data may be grouped under the different assistants.
The reason why the structure of the units is important is that the factors which impose
structure are associated with sources of variation which can influence the comparison of
2
the treatments which is the primary goal of the experiment. For this reason it is important
to reflect the structure of the units properly in the analysis of the experiment. Failing to
do so may result in incorrect conclusions being drawn. In classical experimentation with
univariate responses this problem occurs, for instance, when there are large units to which
a treatment is applied and responses are measured on smaller sub-units. Often the sub-units
are then mistakenly regarded as providing independent observations with the consequence
that “significant” treatment effects are found by using incorrect residual sums of squares and
degrees of freedom in the analysis of variance (ANOVA). More technically, this problem
typically arises when an experiment with a complex design, that is structure of the units, is
analysed as a completely randomised design.
Similar issues occur in structured experiments with functional responses. Despite the
more complex type of response such experiments often have a structure which is the same
as in a classical experiment. Accounting for the structure of the experiment in the analysis
is a problem that can largely be dealt with without having to worry about the fact that the
responses are functions. In particular, it is possible to attribute variation to different sources
in an ANOVA. Some of these sources are associated with factors that determine the structure
of the units while others are associated with the treatment comparisons of primary inter-
est. Formally, the division of the variation is accomplished by decomposing a total sum of
squares into sums of squares for structural and treatment factors. This is achieved by using
established theory for so-called orthogonal designs which will be presented later.
By using the theory of orthogonal designs, for experiments with univariate responses it
is possible to allocate every treatment factor to a unique stratum of the design (Bailey, 2008,
p. 198), that is, a specific part of the experimental structure, and to derive F tests for testing
whether the treatment factor affects the responses. In this process, residual sums of squares
and corresponding degrees of freedom are derived which determine the distribution of the F
statistic under the null hypothesis of no treatment effect.
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Generalising this approach to functional data poses however new challenges. Although
the allocation of treatment factors to strata can be done as in the ANOVA for univariate re-
sponses, the derivation of a suitable test statistic is more complicated. First, the sums of
squares that are typically used to define the F statistic become random functions themselves.
In order to turn these functions into real random variables, integrated sums of squares are
computed by integrating the sums of squares over the domain on which the responses are
collected. Appropriate ratios of integrated sums of squares, divided by degrees of freedom,
for treatments and residuals in the relevant strata of the design are then used to define a test
statistic which is similar to a classical F statistic in the ANOVA for orthogonal designs. Sec-
ondly, determining the distribution of the test statistic thus defined under the null hypothesis
of no treatment effect requires the use of some results for stochastic processes, in particular
the so-called Karhunen-Loève expansion.
The idea to derive functional F tests for the ANOVA of functional data by using in-
tegrated sums of squares and the Karhunen-Loève expansion was originally proposed by
Shen and Faraway (2004) and subsequently used by Zhang (2013) for one-way and two-way
ANOVA problems. However, in this earlier work only completely randomised designs with
independent response curves were considered. Likewise, the univariate theory for orthogonal
designs with complex unit structures was developed by Nelder (1965a,b), Tjur (1984) and
Bailey (2008). The main methodological contribution of the current thesis is to link these
two approaches in order to produce novel methods for analysing complex experiments with
functional responses. Figure 1.1 summarises the research question, the two main areas on
which the methodological research in the thesis is based and more specific topics which will
be presented in subsequent chapters.
The work presented in the thesis is the outcome of an interdisciplinary project and
applying the methods developed here to data from real experiments is of particular interest.
We will consider two applications in which the response curves represent measurements of

































Figure 1.1: Research question (Layer 1), relevant topics (Layer 2) and existing techniques (Layer 3,
where boxes show the literature of existing techniques)
study, data were collected from both legs of 14 patients with cerebral palsy while walking
both barefoot and wearing prescribed ankle-foot orthoses (AFO). One objective of such gait
studies is to assess the effect of an AFO on the response gait curves, which may be grouped
with respect to both patients and legs within patients. Because of this structure, the different
response curves should not be regarded as being independent and the functional F test for a
completely randomised design should not be used. Instead, by using the theory of orthogonal
designs and applying it to existing data, we identify the appropriate stratum for testing the
effect of wearing (or respectively not wearing) an AFO and use the new functional F test
from Chapter 4 to test the treatment effect in the appropriate stratum of the design.
In the second study, the functional F tests from Chapter 4 are applied to another gait
study where a split-plot design was used to collect data from 9 healthy subjects whilst walk-
ing on an instrumented treadmill at different speeds and under different orthosis conditions:
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a control condition (barefoot), a unilateral orthosis condition and a bilateral orthoses con-
dition. Experiments with healthy subjects avoid the weak ambulatory capability of patients
with cerebral palsy and high variability of pathological gait data and thus are expected to
generate data which are in better agreement with the underlying model assumptions. Specif-
ically, it can be expected that participants with cerebral palsy would have greater variance
than those without cerebral palsy between individuals (units) and the sub-units of limbs
within a subject. This would therefore introduce extra variability which could obscure the
comparison of statistical approaches.
Human gait data is interesting in that it is quasi-cyclic, repeatable and an easily recognis-
able pattern, while at the same time providing sufficient complexity to allow for a functional
approach to data analysis. Having tested a new approach in participants with essentially nor-
mal gait, the added complexity of stochasticity present in pathological gait patters found in
cerebral palsy gait provides a fertile ground for statistical analysis with clinical applications
which may ultimately benefit patient care. Clinicians play an intermediate role in the clinical
application of quantitative gait analysis and in the thesis their experiences with and opinions
about the method have been explored by using semi-structured interviews. The results of
this qualitative investigation will be presented in Chapter 5.
In the remainder of this chapter, I first present a review of the relevant literature, includ-
ing hypothesis tests and correlated functional data in the field of FDA, orthogonal designs
and previous applications of FDA to gait studies, in Section 1.2. Aims and the potential
impact of my research are described in Section 1.3 and a more detailed outline of the thesis
is provided in Section 1.4.
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1.2 Literature review
1.2.1 Functional data analysis
In 1982, Ramsay proposed the idea of extending the statistical techniques to functional data
(Ramsay, 1982), and Ramsay and Silverman (2005) explored both the theory and application
of FDA, which has been applied in many other fields, such as biomedicine (Song et al., 2008),
biomechanics (Crane et al., 2010) and linguistics (Koenig et al., 2008). There is a wide range
of topics in FDA, which have been reviewed by Ullah and Finch (2013), Cuevas (2014),
Morris (2015) and Wang et al. (2016) from different perspectives, including applications of
FDA, models and statistical inference for functional data. In my thesis, two topics of FDA
are particularly important for experiments with functional responses - hypothesis tests for
functional data and correlated functional data.
Hypothesis tests for functional data
A straightforward approach to testing hypotheses for functional data is the pointwise ap-
proach (Ramsay and Silverman, 2005). With this approach, the domain over which the re-
sponse curves are observed is discretised into a set of points and a univariate statistical test is
performed at each of these points. However, the pointwise approach has two disadvantages.
Significant differences at some or even all of these points do not necessarily imply a sig-
nificant difference between two entire curves over the whole domain (Górecki and Smaga,
2015). Moreover, multiple simultaneous tests cause the common problem of multiplicity.
As a consequence, the (uncontrolled) overall Type I error of pointwise tests can be unac-
ceptably high (Abramovich and Angelini, 2006). Although, in principle, this issue could be
addressed by using the well-known Bonferroni correction, this approach is not recommended
for functional data because of the correlation within functions (Vsevolozhskaya et al., 2015).
As an alternative, global tests for functional data have been proposed. These tests treat
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the response curves as entities and summarise information over the whole domain on which
the curves are observed. To test two nested functional regression models, Faraway (1997)
presented a bootstrap-based method, and Shen and Faraway (2004) developed a functional
F test. Under the assumption that the error terms in the regression model are independent
realisations of a Gaussian process, the numerator and denominator of the test statistic can
be transformed into linear combinations of independent χ2 random variables. By using the
Welch-Satterthwaite approximation (Satterthwaite, 1941, 1946; Welch, 1947), the null distri-
bution of the functional F test can be approximated by an F distribution with adjusted degrees
of freedom. Zhang (2013) used a similar test, which he called an F-type test, to explore one-
sample, two-sample, one-way and two-way ANOVA problems. Furthermore, Zhang (2005),
Zhang and Chen (2007), Zhang (2013) and Zhang and Liang (2014) considered an L2-norm-
based test and a bootstrap test.
Górecki and Smaga (2015) reviewed the statistical tests mentioned above for the one-
way ANOVA problem for comparing means of several independent groups of random func-
tions. They further discussed tests proposed by Fan and Lin (1998) and Cuevas et al. (2004)
and presented a new test where functional data were fitted by B-splines and multivariate tests
were applied to the coefficients of the spline functions. Furthermore, a hypothesis test for
a functional fixed-effects ANOVA was developed by Cuesta-Albertos and Febrero-Bande
(2010) where the response functions were assumed to belong to the separable Hilbert space
of square-integrable functions.
Correlated functional data
In the literature on FDA, the term correlated functional data refers to correlations among
entire functions. Such correlations arise from experimental structures, such as nested or
crossed designs (Morris and Carroll, 2006; Di et al., 2009; Aston et al., 2010; Crainiceanu
et al., 2012; Staicu et al., 2014; Shou et al., 2015), or spatial locations where data are mea-
sured (Baladandayuthapani et al., 2008; Staicu et al., 2010, 2015). Spatial-temporal data are
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sometimes analysed as spatially correlated functional data, for example, electroencephalo-
graphic signals from various parts of the brain (Staicu et al., 2010) or data on waste produc-
tion from various locations in Venice Province produced between 1991 and 2011 (Bernardi
et al., 2017).
The structure of correlated functional data is complicated due to correlations within
and between functions. Staicu et al. (2010) proposed a multi-level framework for correlated
functional data and in the current work I use a similar framework to illustrate the structure
of data that are generated in a complex design as follows: (1) subject groups, (2) subjects,
(3) functions within the subject, and (4) measurements within the function. This multi-level
framework has a wide scope of application. For example, Pataky et al. (2013) described a
dataset which contains curves of muscle forces of 16 healthy subjects and 27 patients with
Patello-Femoral Pain. The data were collected from each subject during walking and running
and can be described by the multi-level framework. At level (1), two groups contained
healthy subjects and patients respectively; at level (2), all subjects were independent; at level
(3), two curves (functions) within each subject were correlated; and at level (4), data were
measured at 101 time points for each curve and were correlated.
Most studies of FDA limit their scope to level (4) in the above structure under the
assumption of independent functions. However, for correlated functional data, at least one
of the preceding levels (1) - (3) needs to be taken into account. Correlation at level (4)
results from the nature of functional data, that is, the fact that, for instance, measurements are
taken over time, whereas correlations at levels (1) - (3) are determined by the experimental
structure. The structure of a dataset may differ from the framework given above, according
to the specific structure of an experiment.
A useful tool to study correlated functional data is the functional mixed-effects model,
where correlations between functions can be modelled by random-effect terms. Although
Guo (2002) proposed the term functional mixed-effects model, the random-effect term was
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used to represent the curve-specific deviation, that is the variability of measurements within
the curve, and correlations between curves were not accounted for. A more general func-
tional mixed-effects model for correlated functional data was developed by Morris and Car-
roll (2006), where functions were represented by linear combinations of wavelet basis func-
tions and the model was estimated using a Bayesian approach.
Several studies have extended hypothesis tests to correlated functional data. To compare
two correlated groups of functions, Crainiceanu et al. (2012) employed a bootstrap method,
whereas Staicu et al. (2014) used a likelihood ratio test. Staicu et al. (2015) proposed a global
L2-norm based test to compare mean functions of multiple groups of correlated functional
data, along with a block bootstrap method which can be applied to a study with a small
sample size. Zhang and Großmann (2016) extended the F-type test of Shen and Faraway
(2004) to examine treatment effects in a split-plot design with functional responses.
1.2.2 Orthogonal designs
The systematic study of the univariate analysis of variance for orthogonal designs was ini-
tiated by Nelder (1965a,b). Subsequently, these ideas were extended and refined by Tjur
(1984) and Bailey (2008).
Nelder (1965a) emphasized the distinction between the block structure and the treat-
ment structure in the analysis of designs. Block structure derives from the internal structure
of observational units regardless of treatments, while treatment structure describes the struc-
ture on the set of treatments and how treatment factors are allocated to observational units.
Nelder (1965a,b) presented a framework to analyse both block structure and treatment struc-
ture of the design with an orthogonal block structure. Orthogonality induces a set of mutually
orthogonal idempotent matrices, which are fundamental to the ANOVA of block structures
(Nelder, 1965a). However, a formal definition for orthogonal designs was not provided in
Nelder (1965a,b).
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Tjur (1984) generalised the approach proposed by Nelder (1965a,b) to more general
orthogonal designs, where all factors are orthogonal. Moreover, Tjur (1984) clarified the
definition of orthogonality, that is, two factors are orthogonal if the corresponding subspaces
are geometrically orthogonal, as will be explained later in Chapter 3. For an orthogonal
design, the vector space where responses are observed can be uniquely decomposed into a
direct sum of orthogonal subspaces, each of which is associated with one factor in the design.
Projection matrices onto the subspaces that are associated with block factors are equivalent
to “a set of mutually orthogonal idempotent matrices” in Nelder (1965a). The concept of
orthogonality in Tjur (1984) is also applicable to treatment factors.
A precise mathematical definition of orthogonal designs was provided by Bailey (2008)
and in this thesis we only consider designs that fulfill all three conditions of an orthogonal
design (Bailey, 2008, p. 198). Briefly, an orthogonal design is determined by the orthogonal
block structure, the orthogonal treatment structure and the design function which is used to
allocate treatments to observational units. These conditions are composed of twelve spe-
cific conditions (Bailey, 2008), which can be checked by using a Mathematica package of
Großmann (2014).
Apart from the definition of orthogonal designs, some classical design tools can also be
applied to functional data. For instance, a null experiment which ignores treatments can be
used to study the block structure and results be summarised in a null ANOVA table (Nelder,
1965a); projection matrices onto the corresponding orthogonal subspaces can be used to
derive sums of squares in the ANOVA (Tjur, 1984); a skeleton ANOVA table describes the
structure of a design without taking responses into account and Hasse diagrams are used to
display the treatment structure and block structure (Bailey, 2008).
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1.2.3 Applications of FDA to gait analysis
Gait analysis
Data collected from gait analysis typically results in curves that provide a measure of the
gait cycle, which indicates the time interval between two consecutively repetitive events
during walking (Whittle, 2007, p. 52), e.g. between the initial foot contact to the next initial
contact by the same foot. In gait analysis, the stance phase lasts from initial contact to toe
off, whereas the swing phase starts from toe off until the next initial contact, as shown in
Figure 1.2.
Perry (1992, p. 11) identified the following gait phases for normal gait patterns: initial
contact (0-2% of gait cycle), loading response (0-10% of gait cycle), mid-stance (10-30% of
gait cycle), terminal stance (30-50% of gait cycle), pre-swing (50-60% of gait cycle), initial
swing (60-73% of gait cycle), mid-swing (73-87% of gait cycle) and terminal swing (87-
100% of gait cycle). The initial contact, when the foot just touches the floor, is sometimes
not considered as a gait phase. Both the start (loading response) and the end (pre-swing) of
the stance phase are periods when two feet have contact with the floor, and, hence regarded
as double support. The stance phase accounts for the first 60% of the gait cycle, while the
Figure 1.2: Positions of the leg (black) and the contralateral leg (grey) when major gait events (initial
contact, toe off and the next initial contact) occur during the gait cycle
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swing phase during which the foot is propelled forward ready for the next step accounts for
approximately 40% of the gait cycle (Richards, 2008, p. 52).
Figure 1.3: Reference planes (Whittle, 2007, p. 3)
Common measurements in gait lab-
oratories include joint angles, joint mo-
ments and ground reaction forces. In the
thesis, I focus on 3-dimensional joint an-
gles and segmental position of the lower
limbs, including pelvis, hip joint, knee
joint, ankle joint and foot. In gait anal-
ysis, joint angles (which are also called
joint rotations) in the coronal plane, sagit-
tal plane and horizontal plane are com-
monly reported. Reference planes are ex-
plained by Whittle (2007, p. 3). More
specifically, the sagittal plane divides the
body into right and left portions; the coronal plane divides the body into front and back
portions; and the horizontal plane divides the body into upper and lower portions. In a gait
report, gait curves are usually plotted against the percentage of the gait cycle, not real time.
FDA in gait analysis
Statistical methods used to analyse single data points may not be adequate for curves and
some studies have applied more advanced FDA techniques to analyse gait data. As sum-
marised by Duhamel et al. (2004), statistical tools in clinical gait analysis are used to identify
whether gait data of a new subject should be classified into a clinically normal group or not,
or to compare differences of gait data from different groups. FDA has been applied for both
gait classification (Sutherland et al., 1988; Olshen et al., 1989; Lenhoff et al., 1999) and gait
comparison (Duhamel et al., 2006; Ryan et al., 2006; Donoghue et al., 2008).
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Sutherland et al. (1988) and Olshen et al. (1989) proposed bootstrap prediction regions
to classify gait patterns. Joint rotations were represented as functions of the percentage of
the gait cycle using a Fourier basis system. Data collected from 38 children, who were five
years old and had clinically ‘normal’ gait, were used as a training set and bootstrap predic-
tion regions were constructed based on the training set. The gait curve of a test subject was
displayed together with the bootstrap prediction region and it was examined whether the test
curve was covered by the prediction region or not. In addition, bootstrap distribution per-
centiles were used to identify the abnormality of joint movements for a test subject. This
bootstrap method was compared with pointwise prediction bands by Lenhoff et al. (1999)
with an application to knee flexion angles of 28 healthy subjects. The bootstrap bands cov-
ered more gait curves than the pointwise bands, but required intensive computations. To
improve the efficacy, pointwise prediction bands were adjusted by a Bonferroni correction.
However, as pointed out by Lenhoff et al. (1999), a typical gait curve with at least 100 data
points results in a conservative evaluation, since the width of Bonferroni corrected prediction
bands increases with the number of points. Furthermore, the bootstrap approach takes the
correlation between measurements within a curve into account, which is neglected by the
pointwise approach.
Functional principal component analysis (PCA) developed by Ramsay and Silverman
(2005) is commonly used for gait comparison. By using functional PCA, main features of
gait curves are represented by principal components and then classical statistical tools can
be applied to principal component scores. In order to compare gait patterns of 12 Parkinso-
nian patients under different treatment conditions, Duhamel et al. (2006) applied functional
PCA to gait data smoothed by cubic B-splines to reduce the dimension and then principal
component scores were analysed by a linear discriminant analysis to measure the differences
between treatment groups. Similarly, Ryan et al. (2006) used F tests of principal component
scores to compare knee joint angles of children at different developmental stages. Donoghue
et al. (2008) applied ANOVA models to principal component scores, in order to assess the
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effects of orthoses on running kinematics of patients with chronic Achilles tendon injury.
Despite the advanced FDA techniques used to extract the information from these curves,
univariate statistical methods, such as ANOVA models and F tests, were still used in these
papers. Therefore, Donoghue et al. (2008) pointed out the need for an extension of experi-
mental analysis to functional data, such as the work presented in this thesis.
1.3 Aims and impact
The overarching aim of this thesis was to develop statistical methodology for functional
data that are collected from complex orthogonal designs and to explore applications of FDA
to gait analysis. The potential impact of this research would be to provide tools to analyse
correlated functional data, where the correlation stems from the experimental structure. Such
methods will be applied to gait data, with the ultimate goal of improving gait analysis by
considering the entire curve in the analysis, rather than single values.
The following list summarises secondary aims and specific objectives:
(1) To explore links between existing techniques of FDA and design of experiments. The
specific objective is to explore the mathematical concepts of functional data and or-
thogonal designs.
(2) To analyse orthogonal designs with functional responses. The specific objective is to
construct ANOVA for functional data. We consider an experiment where responses are
time-dense curves. Despite the complicated responses, the structure of the experiment
does not depend on time. Therefore, we will start with a skeleton ANOVA, where
responses are not taken into account and then develop a full ANOVA, which contains
calculations of functional responses, such as, sums of squares.
(3) To develop hypothesis tests for functional data. The specific objective is to examine
the treatment effects of an orthogonal design with functional responses. Previous sta-
15
tistical tests have not yet considered functional data and the complicated structure of
the design together.
(4) To explore novel applications of FDA in gait analysis. The specific objective is to
analyse gait data using the proposed statistical methods. We will test the effects of
AFO on 3-dimensional joint angles of patients with cerebral palsy. Moreover, we will
analyse gait data of healthy subjects in a split-plot design.
(5) To investigate the potential utilisation of our approach in clinical gait assessment. The
specific objective is to explore how clinicians perceive quantitative gait analysis in the
management of cerebral palsy.
1.4 Outline of thesis
This thesis consists of 6 chapters including this introductory chapter and the remainder of
this thesis is organised as follows.
Chapter 2 introduces mathematical background of functional data. Two different per-
spectives exist to explain functional data. The first representation of functional data is as
sample paths of a stochastic process and under the second perspective, functional data are
realisations of a random element defined on a probability space and taking values in a Hilbert
space. Existing FDA theories are developed respectively from these two perspectives. How-
ever, these two perspectives are not always equivalent. In this chapter, conditions under
which a stochastic process is also a random element of a Hilbert space are clarified. Under
such conditions, the Karhunen-Loève expansion is introduced and two theorems are subse-
quently proposed, which will be used later in the functional ANOVA to derive distributions
of sums of squares.
Chapter 3 explores the analysis of orthogonal designs with functional responses. Since
the experimental structure is time-independent, we introduce orthogonal designs without
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taking responses into account and then construct a functional mixed-effects model where re-
sponses are functions. In this thesis, design matrices of the functional mixed-effects model
are determined by the experimental structure, and thus are the same as in a general lin-
ear model. The random-effect terms of the model are associated with the block structure,
whereas the fixed-effect terms are associated with the treatment structure of the design.
Moreover, the result that the column space of a design matrix is equal to the V-subspace
(Bailey, 2008) of the corresponding factor of the design links FDA and orthogonal designs.
Orthogonal projections calculated from design matrices are used to derive functional sums
of squares. The ANOVA table for an orthogonal design with functional responses consists
of the analysis of the block and treatment structures, and functional sums of squares.
Chapter 4 covers the theory and practice of functional F tests in orthogonal designs.
According to the block and treatment structure given in Chapter 3, a functional F test is
derived to examine treatment effects. Under the null hypothesis that a treatment factor has
no effect, the integrated sums of squares for both the treatment factor and the corresponding
residual can be represented as linear combinations of independent χ2 random variables. It
can then be shown that under the null hypothesis the F statistic of the functional F test
is approximately distributed as an F distribution. Two applications of functional F tests
to gait data are introduced in Section 4.2 and Section 4.3, respectively. The gait study of
patients with cerebral palsy aims to examine the effects of AFO on kinematics in lower
limbs. However, there are limitations in this study concerning the experimental design. In
particular, treatments were not randomised since the children with cerebral palsy are fatigue
prone during walking. This issue becomes further exacerbated during barefoot walking. In
order to explore more applications of functional F tests, we designed a split-plot experiment
to collect gait data from healthy subjects. Functional F tests are used to examine effects of
AFO, walking speeds and their interaction.
Chapter 5 explores clinical gait analysis. Although gait data are analysed by the pro-
posed approach in Chapter 4 for a research purpose, the ultimate purpose of gait analysis
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is to improve patient outcomes. Therefore, this chapter reports a qualitative study which
aims to explore clinicians’ experience and opinions of using 3-dimensional gait data and gait
analysis in the management of cerebral palsy. We recruited clinicians who had frequently
conducted gait assessment in clinical routine for semi-structured interviews and participants
included physiotherapists, orthotists, a specialist orthopaedic surgeon and clinical scientists.
Based on their understanding and needs of gait analysis, we explore the potential that our
study can be utilised in the assessment or treatment of patients with movement disorders.
Chapter 6 summarises the main findings of the thesis and draws conclusions from the





This chapter describes the conceptual background of functional data. The chapter starts
with an example of functional data in Section 2.1. Mathematically, functional data may be
regarded as either the sample paths of a stochastic process (stochastic process perspective)
or realisations of a random element (random element perspective). These two perspectives
are not always equivalent. We consider conditions to ensure a stochastic process to be a
random element in the Hilbert space L2(T ,B(T ), µ), as will be explained in Section 2.2. In
Section 2.3 mean-square continuous stochastic processes, of which the mean and covariance
functions are well-defined and continuous, are of particular interest, since the Karhunen-
Loève expansion expressed in Section 2.4 is applied to mean-square continuous stochastic
processes with zero mean to represent a stochastic process by a series of random variables
and functions.
Moreover, a mean-square continuous stochastic process, which is also a random element
in L2(T ,B(T ), µ), is square integrable referring to both the interval T and the probability
space Ω. Thus, the square integration of the stochastic process with respect to the Lebesgue
measure µ is a real-value random variable. In particular, if the stochastic process is Gaus-
sian distributed, the random variable derived from Lebesgue integral of the squared process
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has the identical distribution to a linear combination of χ2 random variables (Zhang, 2013,
Theorem 4.2, p. 86) by applying the Karhunen-Loève expansion. A similar theorem, where
multiple Gaussian processes are considered, is stated as Theorem 2.4, which is the basis to
derive distributions of sums of squares in ANOVA and functional F tests in Chapters 3 and
4.
2.1 An example of functional data
This study is motivated by data which consist of gait curves and a simple example of gait
data is shown in Figure 2.1 as a prototype for functional data. In this example, gait data were
collected from healthy adults (age: 18 - 50, free from lower limb injury and musculoskeletal
disease in the past 6 months) in the Human Performance Laboratory at Queen Mary Univer-
sity of London. We focus on angles that are formed by segments of lower limbs, including
the angles of pelvis, hip, knee, ankle and foot.
In Figure 2.1, knee angles of two subjects (subject 3 and subject 6) are plotted against
the percentage of gait cycle as an example. Gait curves collected at the fast, medium and
slow speeds are indicated by the solid, dashed and dotted curves, respectively. Since each
participant walked at all three speeds, it is necessary to consider the correlation between
different gait curves from the same participant when we assess the effects of walking speeds
on gait patterns.
More details of this example will be introduced in Section 4.3, where the structure of
data is more complicated than what is shown in Figure 2.1, since we analyse gait data that
were collected when participants walked barefoot and wearing orthoses which are commonly
prescribed to patients with movement disorders. To analyse such gait data, each curve can
be viewed as a continuous function of the percentage of the gait cycle. Before we explore
statistical analysis for functional data, we first discuss how to represent functional data math-
ematically.
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Figure 2.1: Angles of knee joints in the sagittal plane of two healthy subjects during their barefoot
walking on an instrumented treadmill at the fast speed (solid curves), the medium speed (dashed
curves) and the slow speed (dotted curves).
2.2 Two perspectives of functional data
In FDA, every observation is regarded as a (real) function f : T → R with t 7→ f (t) (e.g.
curves in Figure 2.1). In what follows, T is a closed interval in R. There are two main
approaches to modelling random observations that are curves.
One possibility is to start with a stochastic process (Rt : t ∈ T ) on a probability space
(Ω,A ,P), where Rt is a real random variable for every t ∈ T . In other words, Rt : Ω→ R
is an A -B(R)-measurable function which for every ω ∈ Ω yields the value Rt(ω), where
B(R) is the Borel σ -field on R. For every ω ∈ Ω the sample path at ω is the mapping
rω : T → R where rω(t) := Rt(ω). Observed functions f can then be regarded as sample
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paths. This is called the stochastic process perspective (Hsing and Eubank, 2015, p. 175).
Alternatively, one may start with the probability space (Ω,A ,P) and a measurable space
(E,M ), where E⊂RT is a subset of the set RT of all function f : T →R and M is a suitable
σ -field on E. Every A -M -measurable function R : Ω→ E is then the analogue of a (real)
random variable and, due to the more complicated image space, called a random function
(Bosq, 2000, p. 16) or a random element, if E is a Hilbert space which is equipped with
the Borel σ -field B(E) (Hsing and Eubank, 2015, p. 176). In this setting, every observed
function f may be regarded as a realisation R(ω) of R. This is called the random element
perspective (Hsing and Eubank, 2015, p. 175).
If one starts with a stochastic process (Rt : t ∈ T ) and the corresponding sample paths
rω : T → R for ω ∈ Ω, then the two perspectives can be linked by defining R : Ω→ RT
through R(ω) := rω for every ω ∈Ω. The function R defined in this way obviously produces
functions from T to R as its “values”. However, the mapping R : Ω→ RT is not always
measurable. As indicated in Bosq (2000, p. 21), RT is generally a too large space, such that
there are irregular functions in this space. For R to be a random function or element, one
also needs to specify a suitable measurable space (E,M ) where E⊂ RT and to show that R
is A -M -measurable and, hence, a random element.
Often, E= L2(T ,B(T ), µ) is the Hilbert space of functions f for which the integral of
f 2 with respect to the Lebesgue measure µ is finite, that is,
∫
T | f |2dµ < ∞ ( f is said to be
square integrable). The corresponding σ -field is the Borel σ -field B(E) on E, which is the
smallest σ -field containing all open subsets of E (Karatzas and Shreve, 1998, p. 1). It is then
natural to ask which properties the stochastic process (Rt : t ∈ T ) and its paths rω need to
possess in order to ensure that R, where R(ω) = rω , is A -B(E)-measurable, and, hence, a
random element.
We consider the condition that was proposed by Bosq (2000, p. 23). For a stochastic
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process (Rt : t ∈ T ) with sample paths in E= L2(T ,B(T ), µ), if the mapping
(t,ω) 7→ Rt(ω) : (T ×Ω,B(T )⊗A )→ (R,B(R)) (2.1)
is measurable (say, R is jointly measurable with respect to the product σ -field B(T )⊗A ),
then R is A -B(E)-measurable. Hence, R is a random element in L2(T ,B(T ), µ).
A sufficient condition to derive the joint measurability is the continuity of sample
paths. If every sample path is right-continuous, the stochastic process is jointly measurable
(Karatzas and Shreve, 1998, p. 5). Moreover, the sample path continuity implies the property
of indistinguishability. Two stochastic processes (Rt : t ∈ T ) and (St : t ∈ T ) defined on the
same probability space are modifications of each other, such that
P(Rt = St) = 1, for all t ∈ T .
However, modification does not imply
P(∩t∈T{Rt = St}) = 1,
which is referred to as indistinguishability and two indistinguishable stochastic processes
almost surely have the same sample paths. If two stochastic processes (Rt : t ∈ T ) and
(St : t ∈ T ) with right-continuous sample paths are modification of each other, they are indis-
tinguishable (Karatzas and Shreve, 1998, p. 2; Bosq, 2000, p. 17). All results also hold for
left-continuity.
In FDA, it is convenient to consider a jointly measurable stochastic process which
takes values in L2(T ,B(T ), µ), i.e., the stochastic process is also a random element in
L2(T ,B(T ), µ).
If the stochastic process (Rt : t ∈ T ) is joint measurable, sample paths t 7→ Rt(ω) for
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ω ∈Ω are B(T )-measurable; and if random variables Rt have well-defined expectations for
t ∈ T , the mean function η : t 7→ E(Rt), which will be discussed more later, is also B(T )-
measurable with E being the expectation with respect to a probability measure P on (Ω,A ).
Moreover, for a stochastic process which is also a random element in L2(T ,B(T ), µ),






























is satisfied, the stochastic process (Rt : t ∈ T ) is regarded as an L2-stochastic process (Wang
et al., 2016) or the random element R is said to be square integrable with integration referring
to the probability space (Ω,A ,P) (Kokoszka and Reimherr, 2017, p. 40). Condition (2.3) is
desirable in FDA from both the stochastic process perspective and random element perspec-




and is finite, which is important to derive the distributions for sums of squares in functional
ANOVA, as will be introduced in the following chapter.
In Chapter 3 and 4, observed functional data are viewed as sample paths of stochastic
processes (y(1)t : t ∈ T ),(y
(2)
t : t ∈ T ), . . . ,(y
(N)
t : t ∈ T ), where i = 1,2, . . . ,N for (y
(i)
t : t ∈ T )
are indices of stochastic processes. Moreover, to analyse the experiment where functional
data are collected, we are interested in sums of squares, which are calculated by the or-
thogonal projections of responses onto the corresponding subspaces. The sum of squares
for a factor can be represented by a sum of squared independent stochastic processes
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(R(1)t : t ∈ T ),(R
(2)
t : t ∈ T ), . . . ,(R
(d)
t : t ∈ T ) with d being the degrees of freedom of this
factor, as will be explained in Chapter 3. Definitions that are related to stochastic processes
in Section 2.3 are applicable to responses and sums of squares, while theorems in Section
2.4 will be applied to (R(1)t : t ∈ T ),(R
(2)
t : t ∈ T ), . . . ,(R
(d)
t : t ∈ T ) in the following study.
2.3 Mean-square continuous stochastic process
Suppose (Rt : t ∈ T ) is a stochastic process. Then, the mean function is defined by:
η(t) := E(Rt), for t ∈ T , (2.4)
and the covariance function is defined by:






, for s, t ∈ T . (2.5)
According to the mean function and covariance function, we can define the following
stochastic processes.





for every t ∈ T .
Definition 2.2 A second-order process (Rt : t ∈ T ) is a Gaussian process, if for any k points
t1, . . . , tk ∈ T , (Rt1 , . . . ,Rtk) follows a multivariate Gaussian distribution.
In what follows, a Gaussian process (Rt : t ∈ T ) with mean function η and covariance
function θ will be denoted by R∼ GP(η ,θ).
Definition 2.3 A second-order process (Rt : t ∈ T ) is mean-square continuous, if its mean
and covariance functions are continuous, that is, the mean function η : T → R with η(t) =
E(Rt) and the covariance function θ : T ×T → R with θ(s, t) =Cov(Rs,Rt) are continuous.
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The stochastic processes which are mean-square continuous can be studied by using the
Karhunen-Loève expansion, which is a useful tool in FDA, and details will be introduced in
the next section.
Now, we consider two stochastic processes (Rt : t ∈ T ) and (St : t ∈ T ). The cross-
covariance function of two stochastic processes is defined by:






, for s, t ∈ T , (2.6)
where ηR(s) = E(Rs) and ηS(t) = E(St).
Two stochastic processes (Rt : t ∈ T ) and (St : t ∈ T ) on a common set T are indepen-
dent, if for all finite subset T1,T2 ⊂ T ,
P({Rti ≤ rti : ti ∈ T1}∩{St j ≤ st j : t j ∈ T2}) = P({Rti ≤ rti : ti ∈ T1})P({St j ≤ st j : t j ∈ T2}).
Independent stochastic processes (Rt : t ∈ T ) and (St : t ∈ T ) imply that each random
variable Rs for s∈ T is independent to the random variable St for t ∈ T . Thus, Cov(Rs,St) = 0
for all s, t ∈ T .
2.4 Karhunen-Loève expansion
In this section, we will introduce the Karhunen-Loève expansion of a mean-square continu-
ous stochastic process, as will be applied in Chapters 3 and 4. To state the Karhunen-Loève
expansion, we first need definitions of the covariance operator, eigenvalues and eigenfunc-
tions.
The covariance function θ(s, t) of a mean-square continuous process (Rt : t ∈ T ) is con-





2(s, t)dµ(s)dµ(t) < ∞. The
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integral operator R : L2(T ,B(T ), µ)→ L2(T ,B(T ), µ), defined by
(R f )(t) :=
∫
T
θ(s, t) f (s)dµ(s), for all t ∈ T (2.7)
with f ∈ L2(T ,B(T ), µ), is referred to as the covariance operator of the stochastic process
(Rt : t ∈ T ).
Suppose there exist λ ∈ R and nonzero φ ∈ L2(T ,B(T ), µ), such that
∫
T
θ(s, t)φ(s)dµ(s) = (Rφ)(t) = λφ(t), t ∈ T .
Then λ is an eigenvalue of the covariance operator R with the corresponding eigenfunction






φr(t)φl(t)dµ(t) = 0, for r, l ≥ 1, and r 6= l,
then φ1,φ2, . . . are called a system of orthonormal eigenfunctions of the covariance operator.
Since the covariance operator R is compact (Hsing and Eubank, 2015, Theorem 4.6.2,
p. 117), the set of nonzero eigenvalues for R is either finite or consists of a sequence which
tends to zero (Hsing and Eubank, 2015, Theorem 4.2.4, p. 98). Therefore, we can arrange
all eigenvalues in a nonincreasing order, such that λ1 ≥ λ2 ≥ ·· · ≥ 0.
These definitions are applied in the following Mercer’s theorem (Mercer, 1909; Riesz
and Szökefalvi-Nagy, 1955, p. 245), which is needed to derive the Karhunen-Loève expan-
sion.
Theorem 2.1 (Mercer’s theorem) Let θ(s, t) be a continuous, nonnegative definite and sym-
metric covariance function with the corresponding covariance operator R defined by Equa-
tion (2.7). Then there exists a sequence of eigenvalues and orthonormal eigenfunctions
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λrφr(s)φr(t), s, t ∈ T ,
with the series converging absolutely and uniformly.
The proof of Mercer’s theorem can be found in Hsing and Eubank (2015, p. 122).
As mentioned in Hsing and Eubank (2015, p. 122) and Gohberg and Kreı̆n (1969, Corol-








Hence, if a stochastic process (Rt : t ∈ T ) with zero mean function and continuous covariance
function θ(s, t) is also a random element in L2(T ,B(T ), µ), then θ(t, t) = E(Rt)2 and by















θ(t, t)dµ(t)< ∞. (2.8)
Now we are ready to state the Karhunen-Loève expansion (Loève, 1977, p. 151), which
represents a stochastic process to a linear combination of uncorrelated random variables and
functions in L2(T ,B(T ), µ) space.
Theorem 2.2 (Karhunen-Loève expansion) Let (Rt : t ∈ T ) be a stochastic process with zero
mean function and continuous covariance function θ(s, t). Then, with (λr,φr)∞r=1 defined in





urφr(t), t ∈ T ,
where the series converges uniformly with respect to the L2(Ω,A ,P)-distance and (ur)∞r=1
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are uncorrelated random variables with E(ur) = 0 and E(u2r ) = λr.
The Karhunen-Loève expansion is proved by applying the Mercer’s theorem and the
proof can be found in Bosq (2000, p. 25) and Hsing and Eubank (2015, p. 188).
In addition, if R is also a random element in L2(T ,B(T ), µ), then
∫
T Rtφr(t)dµ(t) is
an L2(Ω,A ,P) random variable (Ash and Gardner, 1975, p. 34; Hsing and Eubank, 2015,





for the Karhunen-Loève expansion.
As explained by Hsing and Eubank (2015, p. 193) that Karhunen-Loève expansion does
not depend on the condition that R a random element in L2(T ,B(T ), µ) space, since we can
always find an L2(Ω,A ,P) random variable to play the role of
∫
T Rtφr(t)dµ(t). However,
Equation (2.9) only works when the mean-square continuous stochastic process (Rt : t ∈ T )
is also a random element in L2(T ,B(T ), µ), which we will use in this thesis.
Moreover, if (Rt : t ∈ T ) is also a Gaussian process, ur defined by Equation (2.9) for
r = 1,2, . . . are independent random variables, each of which follows a normal distribution
N(0,λr).
Next, we consider the Karhunen-Loève expansions for two stochastic processes.
Theorem 2.3 Let (Rt : t ∈ T ) and (St : t ∈ T ) be two stochastic processes with zero mean
function and continuous covariance functions. Moreover, R and S are random elements in
L2(T ,B(T ), µ) space.
If the cross-covariance function θR,S(s, t) = 0 for s, t ∈ T , then Rt = ∑∞r=1 u1rφ1r(t) and




l=1 are all uncorrelated.
Proof. By applying the Karhunen-Loève expansion along with that R is a random element
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in L2(T ,B(T ), µ) space, u1r =
∫
T Rtφ1r(t)dµ(t) for r = 1,2, . . . are uncorrelated.
Likewise, u2l =
∫
T Stφ2l(t)dµ(t) for l = 1,2, . . . are uncorrelated. In what follows, we
prove each pair of u1r and u2l for r, l = 1,2, . . . from Karhunen-Loève expansions of different
stochastic processes are uncorrelated.
Since (Rt : t ∈ T ) and (St : t ∈ T ) have zero mean function, the cross-covariance function
is
θR,S(s, t) = E(RsSt) = 0 s, t ∈ T .



























)1/2(E(u22l))1/2 < ∞ by applying the Cauchy-Schwarz inequality
allows us to exchange the order of the expectation and integrals (Fubini’s theorem). There-
fore, all (u1r)∞r=1 and (u2l)
∞
l=1 are uncorrelated.
Mercer’s theorem and Karhunen-Loève expansion are commonly applied in FDA. In
this thesis, we will not apply them directly, but need the following theorem which is derived
from the Karhunen-Loève expansions for independent stochastic processes and similar to
Zhang (2013, Theorem 4.10, p. 90).
Throughout this thesis, A1,A2, . . .
i.i.d.∼ D denotes that A1,A2, . . . are independent random
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variables or functions, which are identically distributed as D, and A d.= B denotes that random
variables or functions A and B have the same distribution.
Theorem 2.4 Let (R(1)t : t ∈ T ), . . . ,(R
(d)
t : t ∈ T ) be d independent Gaussian processes with
zero mean function and the continuous covariance function θ(s, t), that is, R(1), . . . ,R(d) i.i.d.∼













i.i.d.∼ χ2d as a χ2 distribution with the degrees of freedom being equal to d.
Moreover, λ1 ≥ λ2 ≥ ·· · ≥ 0 are the eigenvalues of the covariance operator with the corre-
sponding covariance function θ(s, t).
Proof. Suppose (λr,φr)∞r=1 are the eigenvalues and orthonormal eigenfunctions of the co-
variance operator that is associated with θ(s, t). By using the Karhunen-Loève expansion
expressed in Theorem 2.2, we have that R(i)t = ∑
∞





r = 1,2, . . . and i = 1, . . . ,d.
Recall that the inner product of the Hilbert space L2(T ,B(T ), µ) is usually defined
by 〈 f ,g〉 =
∫
T f (t)g(t)dµ(t) and the norm is || f || = 〈 f , f 〉1/2 for f ,g ∈ L2(T ,B(T ), µ).
By applying Hsing and Eubank (2015, Theorem 4.2.4, p. 98), the system of orthonormal
eigenfunctions {φr} is a complete orthonormal system for L2(T ,B(T ), µ); and hence for





















































Due to the independence between Gaussian processes, all random variables uir ∼
N(0,λr) for r = 1,2, . . . and i = 1, . . . ,d are independent by applying Theorem 2.3. We




























































i.i.d.∼ N(0,1), we have (Ar)∞r=1














where λ1 ≥ λ2 ≥ ·· · ≥ 0 are the eigenvalues of the covariance operator that is associated
with the covariance function θ(s, t).














2dµ(t) has a well-defined expectation. Similarly,





2dµ(t) also have a finite expectation, which is actually
equal to ∑∞r=1 λr×d < ∞.
Theorem 2.4 shows that the sum of squared integrals with respects to the Lebesgue mea-
sure µ of independent Gaussian processes has the same distribution as a linear combination
of random variables, all of which follow a χ2 distribution with the degrees of freedom being
equal to the number of processes. However, according to Theorem 2.3 and the proof of The-
orem 2.4, we have the same result if processes are not independent but the cross-covariance
of each two Gaussian processes is zero.
We have used (y(i)t : t ∈ T ) with i = 1,2, . . . ,N for stochastic processes. However, this is
not commonly used in the literature of FDA. A more straightforward way to express stochas-
tic process is {yi(t) : t ∈ T} for i = 1,2, . . . ,N, where yi(t) : ω 7→ yi(t,ω) is a random variable
and the same as y(i)t : ω 7→ y
(i)
t (ω) at fixed t ∈ T . In the following chapters, we will use the
latter expression {yi(t) : t ∈ T}.
Moreover, in the remainder of this thesis we will only consider stochastic pro-
cesses which are jointly measurable, mean-square continuous and with sample paths
in L2(T ,B(T ), µ) space, that is, all stochastic processes are also random elements in
L2(T ,B(T ), µ) space, unless otherwise stated. L2(T ,B(T ), µ) will be simplified to L2(T )
without stating the corresponding Borel σ field and Lebesgue measure µ .
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Chapter 3
Functional analysis of variance
In this chapter, we consider orthogonal designs where the responses are curves. In spite of
functional responses, the experimental structure is not affected by time, which allows us to
apply well-known principles to analyse experiments. Functional data collected from a com-
pletely randomised design are viewed as sample paths of independent stochastic processes.
The functional ANOVA for such data has been proposed by Zhang (2013), and in this chap-
ter we consider the functional ANOVA for more general orthogonal designs, which allow
correlations between stochastic processes.
As for non-functional data, where we investigate the effects of explanatory or inde-
pendent variables on responses in a regression model or ANOVA model, we apply a func-
tional mixed-effects model to study functional data. Since the experimental structure is time-
independent, design matrices of the functional mixed-effects model are the same as those in
a traditional ANOVA model with a univariate response variable though the effect of a factor
is a function. Moreover, the column spaces of design matrices are equal to the V-subspaces
of the factors, which links the functional mixed-effects model and orthogonal designs. In
functional ANOVA, sums of squares are calculated by using the orthogonal projections onto
the corresponding subspaces and we summarise all calculations in the ANOVA table.
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3.1 Orthogonal designs
Suppose N functions of t ∈ T are observed from an orthogonal design, each of which is
mathematically viewed as a sample path of a stochastic process. In practice, functional
data are usually observed discretely over a large number of points. In this study, we sup-
pose functional data are collected from a design, where the experimental structure is fixed
across all time points. For instance, data are collected over a fine grid of m equally spaced
points t1, t2, . . . , tm in a closed interval T . At each time point t`, for ` = 1,2, . . . ,m, values
y1(t`), . . . ,yN(t`) can be viewed as observations of an experiment with univariate responses
and the experimental structure for all time points is the same. Therefore, methods from
classical orthogonal designs can be applied.
An observational unit is the smallest unit in an experiment where a response is measured
(Bailey, 2008, p. 8), while treatments are the conditions that are actively varied and applied
to experimental units and which are under comparison in the experiment (Cheng, 2014, p. 1).
Usually, the experimental and observational coincide but sometimes every experimental unit
consists of or contains several observational units.
Observational units are also called plots in this thesis. Bailey (2008) used Greek letters,
such as ω , to denote observational units and the set of all observational units is denoted by
Ω with the total number of observational units being equal to N. In order to avoid potential
confusion of notation between the probability space and the set of observational units, I
is used here to denote the set of observational units. Accordingly, functional responses are
denoted by y(t) = {yi(t)}Ni=1, rather than {yω(t)}ω∈Ω. At each fixed time point, the vector
space for the design with univariate responses is RN .
3.1.1 Factors
The experimental structure is described by the set of factors which are defined on the ob-
servational units (block structure) or treatments (treatment structure). A mapping I →B,
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where I is the set of observational units, is called a block factor. Following the notational
convention in Tjur (1984), B is also used to denote the block factor. Likewise, a mapping
T → G , where T is the set of treatments, is called a treatment factor, which as in Tjur
(1984) is also denoted by G .
Since the following results in this section are applicable to both block factors and treat-
ment factors, we will use F to indicate a general factor, which can either be a block factor
or a treatment factor. A factor F with nF levels can be viewed as a partition of the set of
observational units, respectively the set of treatments T into nF mutually disjoint subsets.
Each subset consists of the observational units, respectively treatments, to which the same
level of F is allocated, and these subsets are called F -classes (Bailey, 2008, p. 169). If for
a factor F all F -classes have the same size, F is called a uniform factor (Bailey, 2008,
p. 175; Cheng, 2014, p. 39) or a balanced factor (Tjur, 1984). In what follows, the number
of levels of a block factor B is denoted by qB and the number of levels of a treatment factor
G is denoted by pG .
Two factors F and F ′ which are defined on the same set are equivalent (F ≡F ′), if
they induce the same partition of the set. Otherwise, F and F ′ are said to be inequivalent.
We say that F is finer than F ′ (F ≺F ′), or say F ′ is coarser than F (F ′ F ), if every
F -class is contained within one F ′-class. Usually, if F ≺F ′, then F is said to be nested
in F ′ (Cheng, 2014, p. 39). Following Bailey (2008), we use F F ′ to indicate that F
is finer than or equivalent to F ′. The relation  is reflexive, antisymmetric (with equality
replaced by equivalence) and transitive and, hence, a partial order on the set of factors (Tjur,
1984; Cheng, 2014, p. 40). Note that it is possible that for some factors F and F ′ neither
F F ′ nor F ′ F may hold, for example, when every level of F occurs together with
every level of F ′, in which case F and F ′ are said to be crossed.
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Two special factors
On both, I and T , there are two special factors (Tjur, 1984; Bailey, 2008) . The universal
factor U is a constant mapping from the set (either I or T ) to an arbitrary set with a single
element and hence this factor makes no difference between observational units or treatments.
The equality factor E is an identity mapping (on either I or T ). The universal factor U
is the coarsest, while the equality factor E is the finest factors among all factors in a design.
Thus, for any factor F in an experiment, we have
E F U .
Infimum and supremum of two factors
The infimum and supremum of two factors F and F ′ are defined by Bailey (2008, Chapter
10). The infimum of two factors F and F ′ is the factor denoted by F ∧F ′ which satisfies:
(i) (F ∧F ′)F and (F ∧F ′)F ′;
(ii) any factor H , that is finer than or equivalent to both F and F ′, is also finer than or
equivalent to F ∧F ′, that is, H  (F ∧F ′).
The supremum of two factors F and F ′ is the factor denoted by F ∨F ′ which satisfies:
(i) F  (F ∨F ′) and F ′  (F ∨F ′);
(ii) any factor H , that is coarser than or equivalent to both F and F ′, is also coarser than
or equivalent to F ∨F ′, that is, (F ∨F ′)H .
Then, we have
(F ∧F ′)F  (F ∨F ′) and (F ∧F ′)F ′  (F ∨F ′).
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The infimum of two factors may be regarded as being similar to a “largest lower bound”
and the supremum to a “least upper bound” which relates the terms for factors to the corre-
sponding terms in calculus.
V-subspace and orthogonal factors
Definition 3.1 The V-subspace of a factor F consists of those vectors that take a constant
value for each level of F and is denoted by V(F ).
Suppose, for example, that B is a block factor with qB levels and that the components
of the vectors in V(B) are indexed by the observational units in I , then all components of
v ∈ V(B) will be equal for which the corresponding subscripts are in the same B-class.
For two factors in an experiment: (1) if F ≡F ′, then V(F ) =V(F ′); (2) if F ≺F ′,
then V(F )⊃ V(F ′) (see, e.g., Bailey, 2008, p. 178).
Now, we are ready to define orthogonal factors, similar to Tjur (1984).
Definition 3.2 Two factors F and F ′ are said to be orthogonal, if the corresponding V-
subspaces are geometrically orthogonal.
In Tjur (1984, p. 40), two V-subspaces V1 and V2 are said to be geometrically orthog-
onal, if the following conditions
(i) V1 =V0⊕V1 and V2 =V0⊕V2 with V0 = V1∩V2, V1 = V1∩V⊥0 and V2 = V2∩V⊥0
(ii) V1⊥V2, that is, for any vectors v1 ∈V1 and v2 ∈V2, vT1 v2 = 0,
are satisfied, where ⊕ denotes the direct sum of vector spaces; V⊥0 is the orthogonal comple-
ment of V0; V1⊥V2 means that V1 and V2 are orthogonal; and the superscript T denotes the
transposition of vectors and matrices.
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The definitions of orthogonal factors in Cheng (2014, p. 47) and Bailey (2008, p. 179)
are equivalent to the above. In the latter case, this follows from the fact that for any two
factors on the same set the V-space for the supremum is equal to the intersection of the
individual V-spaces for the factors (Bailey, 2008, p. 178).
3.1.2 Definition of orthogonal designs
As defined by Bailey (2008, p. 198) an orthogonal design has three components: an orthogo-
nal block structure B, an orthogonal treatment structure T, and a design function φ : I →T
from the set of observational units to the set of treatments which links the block and treatment
structures B and T. Throughout the thesis we make the mild assumption that φ is surjective.
Note that, here, the notation φ in Cheng (2014, p. 279) is used for the design function since
in this thesis the symbol T used by Bailey is used for the interval on which the functional
responses are collected.
In total, twelve conditions must be satisfied for the triple (B,T,φ) to be an orthogonal
design. The first six of these define the orthogonal block structure B as a set of mutually
inequivalent block factors which satisfies: (i) U ∈B, (ii) E ∈B, (iii) B,B′ ∈B⇒B∨
B′ ∈B, (iv) B,B′ ∈B⇒B∧B′ ∈B, (v) if B,B′ ∈B then B and B′ are orthogonal on
I and (vi) all factors B ∈B are uniform. The next three conditions define the orthogonal
treatment structure T in a similar way as a set of mutually inequivalent treatment factors
which satisfies: (vii) U ∈ T, (viii) G ,G ′ ∈ T⇒ G ∨G ′ ∈ T and (ix) if G ,G ′ ∈ T then G and
G ′ are orthogonal on T . It should be clear from the context that the universal factors which,
in (i) and (vii), are denoted by the same symbol U are defined on different sets.
The final three conditions can be better understood by noting that for every treatment
factor G ∈ T the design function φ induces a block factor G φ := G ◦ φ , that is G φ is the
composition “G after φ” (cf. Cheng, 2014, p. 279). This block factor indicates for every
observational unit the level of G that is applied to the unit. By using the block factors that
are induced by φ the conditions of Bailey (2008, p. 198) which refer to the design function
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can be rephrased as follows: (x) if G ,H ∈ T then G φ and H φ are orthogonal on I , (xi)
if B ∈B and G ∈ T then B and G φ are orthogonal on I , (xii) if B ∈B and G ∈ T then
B∨G φ ≡H φ for some treatment factor H ∈ T.
It is worthwhile to note that in most of his exposition of orthogonal designs Cheng
(2014) does not work with the set T of treatment factors defined on T but uses the set
Tφ := {G φ : G ∈ T}. As a consequence, most of his results are stated in terms of two
sets of block factors which correspond to the orthogonal block structure B and the set Tφ .
Nevertheless, the resulting analysis of variance is the same as in Bailey (2008).
At the core of the analysis of variance of orthogonal designs for univariate responses is
a decomposition of the space RN into the direct sum of mutually disjoint subspaces which
is exclusively derived from the orthogonal block structure B and which uses the properties
(i), (ii), (iii) and (v). By using the properties (xi) and (xii) it is possible to identify for
every treatment factor a unique block factor such that a subspace for the treatment factor
(or, more precisely, for the corresponding induced block factor) is a subset of the subspace,
the so-called stratum, for the block factor. Strata that contain treatment factors other than
the universal factor can be decomposed further into the direct sum of mutually orthogonal
subspaces and a residual subspace by using the orthogonal treatment structure and the design
function where the properties (vii), (viii), (ix) and (x) are used. Finally, by also using the
remaining properties (iv) and (vi) and assuming normal distributions, it is possible to test the
effect of every treatment factor in the corresponding stratum.
Sections 3.1.3 and 3.1.4 summarize the underlying mathematical results and give several
examples of orthogonal designs.
3.1.3 Block structure
To analyse the block structure, we use a null experiment (Nelder, 1965a), where all observa-
tional units receive the same treatment and thus the experimental structure depends only on
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how the observational units are grouped. Tjur (1984) called the analysis of variance without
treatments the null ANOVA.
Suppose that the orthogonal block structure of an orthogonal design is given by B =
{B0, . . . ,BK+1} where B0 = U is the universal factor on I and BK+1 = E is the equality
factor on I .
Definition 3.3 The W-subspace for Bk ∈B, k = 0, . . . ,K+1, is the subspace of RN defined
by
W(Bk) = V(Bk)∩ [ ∑
Bk′∈B:Bk≺Bk′
V(Bk′)]⊥ (3.1)
where the summation symbol denotes the sum of subspaces. Moreover, W(Bk) is called the
stratum for Bk ∈B.
Notice that the W-subspace of a block factor can be defined in the same way for sets of
block factors which do not possess all six properties of an orthogonal block structure. For
example, there is also a W-subspace for every block factor in the set Tφ of block factors
that are induced by the design function φ and the orthogonal treatment structure T of an
orthogonal design. The W-subspace of a block factor is determined within the block structure
and not affected by any treatment factor.
For every Bk ∈B let qBk be the number of levels as before, and dW(Bk) the dimension
of W(Bk). In an orthogonal design, we have the following properties for W-subspaces of
block factors; see Bailey (2008, pp. 182–183) and Cheng (2014, pp. 236–237).
Theorem 3.1 Let B be an orthogonal block structure. Then:
(1) W-subspaces for any two different block factors are orthogonal, i.e., W(Bk)⊥W(Bk′)
for all Bk,Bk′ ∈B with k 6= k′.
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In particular, RN = V(E ) =W(U )⊕W(B1)⊕·· ·⊕W(BK)⊕W(E ).
(3) For every Bk ∈B we have
dW(Bk) = qBk− ∑
Bk′∈B:Bk≺Bk′
dW(Bk′). (3.2)
Proof. For part (1), let Bk and Bk′ be different factors in B. Since the factors are orthog-
onal, we have V(Bk)∩ [V(Bk)∩V(Bk′)]⊥ is orthogonal to V(Bk′)∩ [V(Bk)∩V(Bk′)]⊥.
Moreover, as was noted earlier, V(Bk)∩V(Bk′) = V(Bk∨Bk′), and Bk∨Bk′ ∈B.
At least one of Bk and Bk′ is not equivalent to Bk ∨Bk′ . Suppose without loss of





(Bailey, 2008, p. 183), we have W(Bk) ⊆ V(Bk)∩V(Bk ∨Bk′)⊥ = V(Bk)∩ [V(Bk)∩
V(Bk′)]⊥.
From V(Bk′) = (V(Bk′)∩ [V(Bk)∩V(Bk′)]⊥)⊕ (V(Bk)∩V(Bk′)) it follows that
W(Bk) is orthogonal to V(Bk′). The proof is completed by noting that W(Bk′)⊆ V(Bk′).
Part (2) is proved by mathematical induction (Bailey, 2008, p. 183) and part (3) follows
immediately from part (2) by using the well-known formula for the dimension of the direct
sum of vector spaces.
The dimension of the W-subspace dW(Bk) is also called the degrees of freedom for the
factor Bk and thus we will use dBk for simplicity in the remainder of this thesis. Also, qk
will be used instead of qBk .
The block structure of a design can be visualised by using a Hasse diagram (Bailey,








N, N− (q1 +q2)+1
Figure 3.1: Hasse diagram for the
block structure of the row-column
design in Example 3.1
Table 3.1: Table for the block structure of the row-column design
in Example 3.1
Stratum Source W-subspace dW
mean U V(U ) 1
rows B1 V(B1)∩V(U )⊥ q1−1
columns B2 V(B2)∩V(U )⊥ q2−1
plots E [V(B1)+V(B2)]⊥ N− (q1 +q2)+1
Total RN N
a Hasse diagram) to the finest (at the bottom in a Hasse diagram) and then link two nested
factors by a straight line. Factors B and B′ for which neither B ≺ B′ nor B′ ≺ B are
represented at the same level in the diagram. The number of levels and degrees of freedom
for each factor are also provided in the Hasse diagram. Moreover, we also use a table to
display the block structure.
Example 3.1 (Row-column design) In a row-column design with q1 rows and q2 columns,
each of, in total, N = q1× q2 observational units belongs to one row and one column. Any
two observational units will belong to either different rows or different columns.
We use B1 and B2 to indicate the row factor and the column factor. Then, we have
E ≺B1 ≺U and E ≺B2 ≺U . Degrees of freedom can be calculated by using part (3) of
Theorem 3.1 as:
dU = q0 = 1,
dB1 = q1−dU = q1−1,
dB2 = q2−dU = q2−1,
dE = q1q2−dU −dB1−dB2 = N−q1−q2 +1.
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Notice that dE = dB1dB2 . The Hasse diagram and the table for the block structure of
this row-column design are shown in Figure 3.1 and Table 3.1.
From Example 3.1, we can see the Hasse diagram displays the relationships between
factors by linking the dots for factors and it is convenient to calculate degrees of freedom in
the diagram following Equation (3.2). Therefore, to analyse an orthogonal design, we start
with a Hasse diagram for the orthogonal block structure B and summarise the calculations
of the degrees of freedom in an ANOVA table. This table represents the null ANOVA of the
experiment. The table for the block structure can be expanded into a full ANOVA table by
adding calculations for the treatment structure and hypothesis tests as will be shown later.
3.1.4 Treatment structure
Suppose the orthogonal treatment structure of an orthogonal design is given by T =
{G0,G1, . . . ,GU}, where G0 = U . Then we use calculations similar to those for the block
structure. The V-subspace V(Gu) of any treatment factor Gu ∈ T is obtained by using Def-
inition 3.1 and the W-subspace for Gu is W(Gu) = V(Gu)∩ [ ∑
Gu′∈T:Gu≺Gu′
V(Gu′)]⊥. Notice,
however, that these spaces are subspaces of Rt , where t is the number of treatments.
By using the same arguments as in the proof of Theorem 3.1 it can be shown that the
W-subspaces for any two different treatment factors are orthogonal. Moreover, as in part (2)
of the theorem V(Gu) is equal to the direct sum of the W(Gu′) for the factors Gu′ ∈ T with
Gu  Gu′ . From this decomposition, and using the simpler notation pu instead of pGu for the
number of levels of Gu, one obtains the formula dGu = pu− ∑
Gu′∈T:Gu≺Gu′
dGu′ for the dimension
dGu of W(Gu), which is similar to Equation (3.2).
Similar to block factors, the degrees of freedom for a treatment factor are the dimension
of the W-subspace for the factor. The above formula shows that for treatment factors the
degrees of freedom can also be calculated by using a Hasse diagram. We consider the block
structure and treatment structure of the following split-plot design as an example.
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plot 1 . . . plot p2
...
plot 1 . . . plot p2
. . .
plot 1 . . . plot p2
...
plot 1 . . . plot p2
large block 1 large block q1
small block 1
small block p1
Example 3.2 (Split-plot design) We consider a split-plot design with q1 large blocks. Each
large block contains p1 small blocks (whole-plots) and each small block contains p2 plots
(split-plots). Thus, there are q2 = q1 p1 small blocks in total and N = q1 p1 p2 = q2 p2 plots
in the design. Two treatment factors A and B are applied to whole-plots and split-plots
respectively. Each of the p1 levels of the treatment factor A (whole-plot factor) is randomly
allocated to one small block per large block and each of the p2 levels of the treatment factor
B (split-plot factor) is randomly allocated to one plot per small block.
Factors for the large block and the small block are denoted by B1 and B2, whereas fac-
tors A and B are denoted by G1 and G2. The infimum G3 = G1∧G2 represents the interaction
of the factors A and B. Hasse diagrams for the block structure and the treatment structure of
this split-plot design are shown in Figure 3.2.
Separate Hasse diagrams are used to visualise the block structure and treatment struc-
ture, as shown in Figure 3.2. In order to distinguish the treatment structure and the block
structure, following Bailey (2008), we use a dot to indicate a block factor, whereas a circle
is used to indicate a treatment factor.
These diagrams are useful to illustrate the block structure and the treatment structure.
However, from separate Hasse diagrams, it is not clear which stratum a specific treatment












Figure 3.2: Hasse diagrams for the block structure (left) and the treatment structure (right) of the
split-plot design in Example 3.2
factor to a stratum. Contrary to the original statement of the result, we refer however ex-
plicitly to the induced block factors G φu where Gu ∈ T and φ is the design function of the
orthogonal design as before. Moreover, W(G φu ) is the W-subspace for G φu which is defined
as in Definition 3.3 with B being replaced by the set Tφ of induced block factors.
Theorem 3.2 Let Gu be a treatment factor in an orthogonal design with orthogonal block
structure B, orthogonal treatment structure T and design function φ . Then there exists a
unique block factor Bk ∈B such that
(1) Bk  G
φ
u ,
(2) Bk is the coarsest factor among all block factors in B that are finer than or equivalent
to G φu .
Moreover, Gu belongs to the stratum for Bk in the sense that W(G
φ
u )⊆W(Bk).
In Example 3.2, the whole-plot treatment factor is allocated to small blocks and the








Figure 3.3: Combined Hasse dia-
gram for the split-plot design in Ex-
ample 3.2
Thus, the whole-plot treatment factor G1 belongs
to the stratum W(B2), while the split-plot treatment
factor G2 and the interaction term G3 = G1 ∧G2 be-
long to the stratum W(E ). All factors, including both
block factors and treatment factors, can be visualised
together by using a combined Hasse diagram (Bailey,
2008). The combined Hasse diagram of Example 3.2
is shown in Figure 3.3.
For simplicity, the number of levels and degrees of freedom for each factor are not
shown in this diagram. We can see that the universal factor is represented by a dot within
a circle, which indicates that the universal factor is considered as both a block factor and a
treatment factor.
The properties (vii), (viii) and (ix) which characterise the orthogonal treatment structure
T of an orthogonal design carry over, with the obvious changes of notation, and by also
using property (x) to the set Tφ of induced block factors. This implies that a result which
is analogous to Theorem 3.1 also holds for the V-subspaces and the W-subspaces that are
associated with the induced block factors in Tφ since the prove of Theorem 3.1 only uses the
properties (viii) and (ix), that is, the fact that the supremum of any two factors in the relevant
set of block factors is in that set and that any two block factors in the set are orthogonal.
Moreover, it can be shown that for any Gu ∈ T the dimension of W(Gu)⊆ Rt is equal to the
dimension of W(G φu ) ⊆ RN . For these reasons, for practical purposes, such as calculations
of degrees of freedom for treatment factors, the orthogonal treatment structure T can be
identified with the set of induced block factors Tφ .
As a consequence of these considerations and of Theorem 3.2 it follows that a stratum
W(Bk) for Bk ∈ B that contains the treatment factors G1∗ , . . . ,GV ∗ ∈ T in the sense that
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⊥ is the orthogonal complement of the
direct sum of the W-subspaces for the induced block factors in the stratum for Bk.
The subspace W(resk) is called the residual subspace in the stratum. In the full ANOVA
table to be presented later, within any stratum that contains treatment factors other than the
universal factor this space will be represented by a line for the residual (cf. Bailey, 2008,
p. 27) which is indicated by using the notation resk. The corresponding degrees of free-
dom are the dimension of W(resk) which can be calculated by subtracting from the de-
grees of freedom for Bk ∈B the sum of the degrees of freedom for the treatment factors
G1∗ , . . . ,GV ∗ ∈ T.
Therefore, in the decomposition RN =W(U )⊕W(B1)⊕·· ·⊕W(BK)⊕W(E ) from
the null ANOVA, some of the strata can be decomposed further. If a stratum contains treat-
ment factors other than the universal factor, it is decomposed as shown in Equation (3.3). If
a stratum W(Bk) contains no treatment factor or only the universal factor, it remains in the
decomposition.
The statement “an orthogonal design determines a unique decomposition on the obser-
vation space as a direct sum of orthogonal subspaces, one for each factor of the design” in
Tjur (1984) refers to this decomposition. With respect to terminology it should be noted
that the “orthogonal subspace” in Tjur (1984) for each treatment factor is in this thesis the
W-subspace for the treatment factor (or, more precisely, for the corresponding induced block
factor), whereas the “orthogonal subspace” in Tjur (1984) for each block factor is the residual
subspace W(resk) in the stratum.
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3.2 Functional mixed-effects model for orthogonal designs
3.2.1 Functional mixed-effects model
A functional mixed-effects model was introduced by Guo (2002) and then further developed
by Morris and Carroll (2006). Moreover, the model constructed by Morris and Carroll (2006)
is applicable to more general functional data than those considered by Guo (2002).
We consider the following mixed-effects model for functional responses y(t) =
[y1(t), . . . ,yN(t)]T , t ∈ T :
y(t) = Xβ (t)+Zδ (t)+ ε (t), t ∈ T , (3.4)
where y is a vector of N stochastic processes; X and Z are N × p and N × q matrices;
β = [β1, . . . ,βp]T is a vector of fixed-effect functions and βa ∈ L2(T ) for a = 1, . . . , p;
δ = [δ1, . . . ,δq]T is a vector of stochastic processes with δ1, . . . ,δq
i.i.d.∼ GP(0,θ) for random-
effect terms; and ε = [ε1, . . . ,εN ]T is also a vector of stochastic processes with ε1, . . . ,εN
i.i.d.∼ GP(0,θe) for error terms. In the terminology of Chapter 2, δb for b = 1, . . . ,q and εi for
i = 1, . . . ,N are also random elements in L2(T ). Moreover, all random-effect terms and error
terms are independent. Then we have that
η := η (t) = E[y(t)] = Xβ (t), t ∈ T ,
is a vector of mean functions and
Γ := Γ(s, t) =Cov[y(s),y(t)] = ZZT θ(s, t)+ Iθe(s, t), s, t ∈ T ,
is a matrix of covariance functions, where I is an N×N indentity matrix.
Model equation (3.4) was proposed by Morris and Carroll (2006). By removing the
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random-effect term Zδ (t), the model is reduced to the functional regression model with
independent functional responses in Shen and Faraway (2004).
3.2.2 Design matrices
The mixed-effects model can be used to study an orthogonal design with functional re-
sponses. Suppose for an orthogonal design, all factors in the orthogonal treatment struc-
ture T = {G0, . . . ,GU} have fixed effects, while all factors in the orthogonal block structure
B= {B0, . . . ,BK+1} have random effects. As before, we assume that G0 =U is the univer-
sal factor on T , B0 = U is the universal factor on I , and BK+1 = E is the equality factor
on I .
Then, for a treatment factors Gu ∈ T with pu levels, the corresponding design matrix
Xu = [x(i,a)] is an N× pu matrix with elements:
x(i,a) =

1 if the level a of Gu is assigned to the i-th observational unit
0 otherwise,
(3.5)
where i = 1, . . . ,N and a = 1, . . . , pu. The vector β u(t) = [βu,1(t), . . . ,βu,pu(t)]
T indicates the
main effect of Gu for u = 0, . . . ,U .
Likewise, for a block factor Bk ∈ B with qk levels, the corresponding design matrix
Zk = [z(i,b)] is an N×qk matrix with elements:
z(i,b) =

1 if the i-th observational unit belongs to the level b of Bk
0 otherwise,
(3.6)
where i = 1, . . . ,N and b = 1, . . . ,qk. The vector δ k(t) = [δk,1(t), . . . ,δk,qk(t)]
T indicates the
random effect of Bk and δk,1, . . . ,δk,qk
i.i.d.∼ GP(0,θk) for k = 0, . . . ,K +1.
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Zkδ k(t)+ ε (t), t ∈ T , (3.7)
where each of terms {β u(t)}Uu=0, {δ k(t)}Kk=0 represents the effect of one factor in the design,
while ε (t) is related to the equality factor E = BK+1 ∈B. All other assumptions for this
model are the same as those in Equation (3.4).
In what follows, for every matrix M, let C(M) be the column space of the matrix.
Proposition 3.1 In an orthogonal design with block structure B, treatment structure T,
design function φ and design matrices as in Equations (3.5) and (3.6) we have:
(1) if Bk ∈B then C(Zk) = V(Bk),
(2) if Gu ∈ T then C(Xu) = V(G φu ).
Proposition 3.1 is an immediate consequence of the definitions of the design matrices
in Equations (3.5) and (3.6) and the definition of the V-subspace (Definition 3.1). This
result links functional mixed-effects models and orthogonal designs. See also Cheng (2014,
pp. 234–236) for a similar mixed-effects model for orthogonal designs with a univariate
response variable which does however not explicitly show the treatment factors.
3.2.3 Orthogonal projections
In order to analyse an orthogonal design, we will use a projection approach. A convenient
possibility to define orthogonal projections (Christensen, 2011, p. 426) will be introduced
first. We then consider the orthogonal projections onto the V-subspace and the W-subspace,
respectively.
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Definition 3.4 Let V be an arbitrary subspace of RN . Then PV : RN→RN is the orthogonal
projection from RN onto V , if and only if the following two conditions hold:
(i) for any v ∈V , we have PV (v) = v;
(ii) for any w ∈V⊥, we have PV (w) = 0.
It is well-known that for any subspace V of RN the orthogonal projection PV yields
vectors in V , that is, PV (v) ∈V for every v ∈ RN . Moreover, PV is a linear mapping.
In what follows, we will also use PV to denote the matrix that represents this mapping.
Hence, for PV (v) where PV is the mapping we can also writ PV v where PV is the matrix
which represents the orthogonal projection.
Orthogonal projection onto the V-subspace
Consider an orthogonal design with orthogonal block structure B, orthogonal treatment
structure T and design function φ . By applying Proposition 3.1, for a block factor Bk ∈B,
the matrix representing the orthogonal projection from RN onto the V-subspace for Bk can








where rBk = N/qBk is the replication of each level of Bk. Notice that rBk is the common
size of the Bk-classes.
Similarly, for a treatment factor Gu ∈ T the matrix representing the orthogonal projec-
tion from RN onto the V-subspace for the induced block factor G φu ∈ Tφ is equal to




A simplification of the matrix PV(G φu ) which is similar to that for PV(Bk) is not possible in
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general since the the treatment factors and the corresponding induced block factors are not
necessarily uniform. Even when all treatments are applied to the same number of levels, for
Gu ∈ T the induced block factor G φu ∈ Tφ does not have to be uniform.
Let B be a block factor, which can be either in B or Tφ and I = {1, . . . ,N}.
The orthogonal projection PV(B) onto the corresponding V-subspace transforms the vector
[y1(t), . . . ,yN(t)]T into a vector of averages:
[y1(t), . . . ,yN(t)]T −→ [ȳB(1)(t), . . . , ȳB(N)(t)]T , t ∈ T , (3.10)
that is, each yi(t) for i = 1,2, . . . ,N is replaced by ȳB(i)(t) with B(i) ∈ {1, . . . ,qB}, where
B(i) is the level of the factor B which occurs on plot i and ȳB(i)(t) is the average of re-
sponses belonging to the same level of the factor B as the plot i.
For instance, suppose N is even and Bk ∈B is a block factor with two levels 1 and 2
such that, for simplicity of exposition, the first half of the observational units in the experi-
ment have the first level and the second half of the observational units have the second level.
Then the design matrix Zk can be expressed as
Zk =

1 . . . 1 0 . . . 0
0 . . . 0 1 . . . 1

T
and the orthogonal projection onto V(Bk) is the mapping
PV(Bk) : [y1(t), . . . ,yN(t)]
T 7→ [ȳBk(1)(t), . . . , ȳBk(N)(t)]
T , t ∈ T ,
where Bk(1) = · · ·= Bk(N/2) = 1 and Bk(N/2+1) = · · ·= Bk(N) = 2 and the averages
of the responses for the two levels of Bk are equal to ȳ1(t) = 2(y1(t)+ · · ·+ yN/2(t))/N and
ȳ2(t) = 2(yN/2+1(t)+ · · ·+ yN(t))/N, respectively.
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Orthogonal projection onto the W-subspace
We continue to consider an orthogonal design with orthogonal block structure B, orthog-
onal treatment structure T and design function φ . As before it is assumed that B =
{B0, . . . ,BK+1} where B0 =U is the universal factor on I , and BK+1 = E is the equality
factor on I and that T= {G0, . . . ,GU} where G0 = U is the universal factor on T .
For Bk ∈B, the matrix representing the orthogonal projection from RN onto W(Bk) is
denoted by PW(B). Similarly, for Gu ∈ T the matrix for the orthogonal projection from RN
onto the W-subspace for the induced block factor G φu is PW(G φu ).
We first consider properties of PW(B).
Theorem 3.3 Let B ∈B. Then:
(1) For every factor B′ ∈B
PV(B)PW(B′) =

PW(B′) if B B′,
0 otherwise.
(2) PV(B) = ∑
B′∈B:BB′
PW(B′).
Proof. (1) Suppose first that B B′. Then W(B′) ⊆ V(B′) ⊆ V(B). For every v ∈
RN , since PW(B′)v ∈W(B′) ⊆ V(B), it follows from property (i) of the orthogonal
projection that PV(B)PW(B′)v = PW(B′)v which implies PV(B)PW(B′) = PW(B′).
Secondly, if B  B′ does not hold, then B′ 6= B and B′ is, in particular, not
coarser than B. Hence, W(B′) does not occur in the decomposition V(B) =⊕
B′′∈B:BB′′
W(B′′) of V(B) which is obtained by applying part (2) of Theorem 3.1.
Since, by part (1) of Theorem 3.1, W-subspaces for different block factors in B are
orthogonal it follows that W(B′) is orthogonal to V(B), that is W(B′)⊆ V(B)⊥.
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Since PW(B′)v ∈W(B′) for every v ∈ RN , it follows by using property (ii) of the
orthogonal projection that PV(B)PW(B′)v = 0 for every v ∈ RN . Hence, PV(B)PW(B′)
must be the zero matrix.
(2) Part (2) follows immediately from part (2) of Theorem 3.1 since V(B) =⊕
B′∈B:BB′
W(B′) .
It follows from part (2) of Theorem 3.3 that PW(B) = PV(B)− ∑
B′∈B:B≺B′
PW(B′) for
every B ∈ B. Hence, like for degrees of freedom, it is possible to calculate orthogonal
projections starting at the top of the Hasse diagram for B where PW(U ) = PV(U ) and then
to work down the Hasse diagram using the above equation at each dot.
Although it is not used in this thesis, there is an alternate method to compute orthogonal
projections from RN onto W-subspaces due to Tjur (1984, p. 44) who proved that PW(B) =
PV(B) ∏
B′∈B:B≺B′
[PV(B)−PV(B′)] for every B ∈B. The advantage of this method is that by
using only the V-subspaces, which can be easily determined, it avoids the more complicated
calculation of the W-subspaces for all factors in B that are coarser than B.
Since PV(E ) = I for the equality factor in B, where I is the N×N identity matrix, part
(2) of Theorem 3.3 yields the following result for every orthogonal block structure B =
{U ,B1, . . . ,Bk,E } that includes the equality factor E :
PW(U )+PW(B1)+ · · ·+PW(BK)+PW(E ) = I (3.11)
As was already mentioned before, the set Tφ of block factors which are induced by
the design function φ and the orthogonal treatment structure T inherits, by also using (x),
the properties that are necessary for proving Theorem 3.1, i.e. being closed under form-
ing suprema and orthogonality of factors, from T. Since only Theorem 3.1 was used to
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prove Theorem 3.3, there is also a version of the latter theorem, with the obvious notational
changes, which applies to Tφ . Hence, for every G φu ∈ Tφ the orthogonal projection PW(G φu )
from RN onto W(G φu ) can be calculated in a similar way as for the factors in the orthogonal
block structure B. Notice however that Tφ does usually not contain the equality factor E on
I .
The orthogonal projections onto the W-subspaces play a key role in ANOVA. In an or-
thogonal design, the sum of squares for each factor can be calculated by using the orthogonal
projection onto the corresponding W-subspace, as will be discussed later.
3.3 Analysis of block structure
The general model for a null experiment with the orthogonal block structure B =
{U ,B1, . . . ,BK ,E } is expressed as:




Zkδ k(t)+ ε (t), t ∈ T , (3.12)
where δ 0 and ε are associated with the universal and equality factors, while δ 1, . . . ,δ K
are associated with other block factors. We assume all block factors have random ef-
fects. Thus, the block structure does not affect the expectation but determines the covari-
ance structure. More specifically, δ 0(t) = [δ0(t), . . . ,δ0(t)]T with δ0(t) indicating the ran-
dom effect for the universal factor and δ0 ∼ GP(0,θ0); δ k(t) = [δk,1(t), . . . ,δk,qk(t)]T with
δk,b(t), for b = 1, . . . ,qk and k = 1, . . . ,K, indicating the random effect for the level b of
the k-th block factor, and δk,1, . . . ,δk,qk
i.i.d.∼ GP(0,θk); and ε (t) = [ε1(t), . . . ,εN(t)]T with
ε1, . . . ,εN
i.i.d.∼ GP(0,θe).
According to Equation (3.12), the mean function is E[y(t)] = 0 and the covariance func-
tion is




ZkZTk θk(s, t)+ Iθe(s, t), s, t ∈ T , (3.13)
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where J is an N×N all-1 matrix and I is an N×N identity matrix.
3.3.1 Sum of squares of a block factor
Since the experimental structure is time-fixed, at each specific time point t`, for t` ∈ T and
` = 1, . . . ,m, the sum of squares SS(t`) is calculated as in a traditional ANOVA. When t
traverses an interval T , the sum of squares SS(t) becomes a function of t and is called the
functional sum of squares. In this section, we use a projection approach to derive functional
sums of squares.
According to Equation (3.12), the functional sum of squares for the stratum W(Bk), or
say for the factor Bk ∈B, is calculated by
SSBk(t) = y(t)
T PW(Bk)y(t), t ∈ T . (3.14)
According to Equation (3.11), the total functional sum of squares of a design can be
partitioned as follows:
y(t)T y(t) = SSU (t)+SSB1(t)+ · · ·+SSBK(t)+SSE (t)
= y(t)T PW(U )y(t)+y(t)T PW(B1)y(t)+ . . .
+y(t)T PW(BK)y(t)+y(t)
T PW(E )y(t).








of the functional sum of squares over t ∈ T is called the integrated sum of squares.
The functional sum of squares is a random function, while the integrated sum of squares
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is a random variable. The distribution of the integrated sum of squares will be derived in the
following subsection.
3.3.2 Stratum-based covariance function
In order to further analyse the sum of squares of a block factor, the functional sum of squares
in Equation (3.14) can be transformed into the sum of squared functions, which are sample
paths of Gaussian processes. These Gaussian processes have zero mean function, a common
covariance function and zero cross-covariance function. I will call the covariance function
of these Gaussian processes the stratum-based covariance function.






Ri(t)Ri(t), t ∈ T ,
where R1, . . . ,RdBk ∼GP(0,ΛBk) and the cross-covariance between each two Gaussian pro-
cesses is zero. Furthermore, ΛBk is called the stratum-based covariance function and cal-
culated by
ΛBk(s, t) =Cov[Ri(s),Ri(t)] = ∑
Bk′∈B:Bk′Bk
rBk′θk′(s, t), s, t ∈ T ,
where Bk′ is every factor that is finer than or equivalent to Bk in B; rBk′ is the number of
observational units in each level of Bk′ and θk′(s, t) is the covariance function of random-
effect functions that are associated with the block factor Bk′ .
Proof. For a block factor Bk ∈B, the orthogonal projection PW(Bk) onto the W-subspace is
a symmetric and idempotent matrix with the rank being equal to the degree of freedom dBk .




where D = diag(ξ1, . . . ,ξN) is a diagonal matrix with ξ1 = · · ·= ξdBk = 1 and ξdBk+1 = · · ·=
ξN = 0 being the eigenvalues of PW(Bk) and U= [u1, . . . ,uN ] is a matrix with u1, . . . ,uN being
the corresponding orthonormal eigenvectors.
Therefore, SSBk(t) can be re-expressed by using the SVD of PW(Bk) as follows:
SSBk(t) = y(t)
T PW(Bk)y(t) = y(t)
T UDUT y(t) = R(t)T DR(t),
where R(t) = UT y(t) = [R1(t), . . . ,RN(t)]T with Ri(t) = uTi y(t) for i = 1, . . . ,N. The func-






Then, we will derive the distribution of Ri(t). The model for a null experiment is given
in Equation (3.12) with the mean and covariance functions shown as follows:




Zk′ZTk′θk′(s, t)+ Iθe(s, t).
We know that Ri(t) = uTi y(t), and hence we have the following calculations.
(1) Mean function
The mean function of Ri(t) is calculated by:
E[Ri(t)] = E[uTi y(t)] = u
T
i E[y(t)] = u
T
i 0 = 0.
(2) Covariance function
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Zk′ZTk′θk′(s, t)+ Iθe(s, t)]ui.
Since Zk′ZTk′ = rBk′PV(Bk′), we have





where ui is an orthonormal eigenvector of PW(Bk), PV(BK+1) = PV(E ) = I and
θK+1(s, t) = θe(s, t). By applying part (1) of Theorem 3.3, for Bk′ ∈B
PV(Bk′)PW(Bk) =

PW(Bk) if Bk′ Bk,
0 otherwise;
and since PW(Bk)ui = ui,
uTi PV(Bk′)ui =

uTi PV(Bk′)PW(Bk)ui = u
T
i PW(Bk)ui = u
T
i ui = 1 if Bk′ Bk,
0 otherwise;
Finally, we derive the covariance function as:
Cov[Ri(s),Ri(t)] = ∑
Bk′∈B:Bk′Bk
rBk′θk′(s, t), s, t ∈ T .
(3) Cross-covariance function
The cross-covariance function of Ri(t) = uTi y(t) and R j(t) = uTj y(t) for i 6= j and
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i, j = 1, . . . ,dBk is derived from:




























since the eigenvectors are mutually orthogonal.
Therefore, we can see that {Ri(t) : t ∈ T} for i = 1, . . . ,dBk are stochastic processes with
zero mean function and common covariance function. The cross-covariance function of
each two stochastic processes is a zero function. Due to the Gaussian process assumption in
Equation (3.12) and the notation of Ri(t) which is a linear combination of y1(t), . . . ,yN(t),
{Ri(t) : t ∈ T} for i = 1, . . . ,dBk are also Gaussian processes.
Finally, R1, . . . ,RdBk ∼ GP(0,ΛBk) with the cross-covariance function of each two
Gaussian processes being zero is proved.
Now, we are ready to derive the distribution of the integrated sum of squares.










i.i.d.∼ χ2dBk and λ1≥ λ2≥ ·· · ≥ 0 are the eigenvalues of the covariance operator
associated with the stratum-based covariance function ΛBk(s, t)= ∑
Bk′∈B:Bk′Bk
rBk′θk′(s, t),
for s, t ∈ T .

















where R1, . . . ,RdBk ∼ GP(0,ΛBk) with the cross-covariance function of each two Gaussian
processes being zero follows by Theorem 3.4.
Similar to the role that sums of squares play in the classical ANOVA, both functional
sum of squares and integrated sum of squares are useful to develop the functional ANOVA.
Functional sums of squares will be displayed in the null ANOVA table. By integrating the
functional sum of squares into the integrated sum of squares, information of observed func-
tional responses is concentrated. Furthermore, distributions of integrated sums of squares
will be used to derive functional F tests in Chapter 4.
3.3.3 Null ANOVA table
In this section, we summarise the analysis of the block structure by using a null ANOVA
table, which contains the structure of strata, functional sums of squares and functional ex-
pected mean squares.
Similar to the sum of squares, the pointwise expected mean square EMS(t`) can be
calculated at each time point t` ∈ T for ` = 1, . . . ,m. When calculating over t ∈ T , the
62













= ΛBk(t, t), t ∈ T ,
by using the previous result that R1(t), . . . ,RdBk (t)∼GP(0,ΛBk) with zero cross-covariance
function in Theorem 3.4. The functional expected mean square of a stratum is equal to the
main diagonal of the stratum-based covariance function.
We consider the split-plot design that was described in Example 3.2.
Example 3.3 (Example 3.2 continued: split-plot design) The model for the null experiment
is expressed as follows:
y(t) = δ 0(t)+Z1δ L(t)+Z2δ S(t)+ ε (t), t ∈ T , (3.16)
where δ0∼GP(0,θ0), δ L1 , . . . ,δ Lq1
i.i.d.∼ GP(0,θ1), δ S1 , . . . ,δ Sq1 p1
i.i.d.∼ GP(0,θ2) and ε1, . . . ,εN
i.i.d.∼
GP(0,θe) indicate the random effects of U , B1, B2 and E . We calculate the functional
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sums of squares for block factors by:
SSU (t) = y(t)T PW(U )y(t) = y(t)T PV(U )y(t) = 1N y(t)
T Jy(t)
SSB1(t) = y(t)
T PW(B1)y(t) = y(t)
T PV(B1)y(t)−SSU (t)





T PW(B2)y(t) = y(t)
T PV(B2)y(t)−SSU (t)−SSB1(t)





SSE (t) = y(t)T PW(E )y(t) = y(t)T PV(E )y(t)−SSU (t)−SSB1(t)−SSB2(t)
= y(t)T [I− 1rB2
Z2ZT2 ]y(t),
where rB1 = p1 p2 and rB2 = p2, since in this split-plot design each small block has p2
observational units and each large block has p1 small blocks. Furthermore, the stratum-
based covariance functions are derived by:
ΛU (s, t) = Nθ0(s, t)+ p1 p2θ1(s, t)+ p2θ2(s, t)+θe(s, t)
ΛB1(s, t) = p1 p2θ1(s, t)+ p2θ2(s, t)+θe(s, t)
ΛB2(s, t) = p2θ2(s, t)+θe(s, t)
ΛE (s, t) = θe(s, t).
All above calculations for the split-plot design are summarised in the null ANOVA table
(Table 3.2). The first three columns of the table summarise the strata structure, while degrees
of freedom are shown in the fourth column. Functional sums of squares and functional
expected mean squares are displayed in the last two columns. The null ANOVA table can be
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Table 3.2: Null ANOVA table for the split-plot design in Example 3.2
Stratum Source W-subspace dW SS(t) EMS(t)
mean U V(U ) 1 1N y(t)
T Jy(t) Nθ0(t, t)+ p1 p2θ1(t, t)+
p2θ2(t, t)+θe(t, t)
large blocks B1 C(Z1)∩V(U )⊥ q1−1







small blocks B2 C(Z2)∩C(Z1)⊥ q2−q1













Total RN N y(t)T y(t)
extended to a general ANOVA, which summarises both the block structure and the treatment
structure, as will be shown in the next section.
From this example, we can see that the null ANOVA is applied to analyse the null
experiment (or the block structure) based on the decomposition of the whole space: RN =
W(U )⊕W(B1)⊕·· ·⊕W(BK)⊕W(E ), as introduced in part (2) of Theorem 3.1.
3.4 Analysis of treatment structure
In an orthogonal design with the block structure B and the treatment structure T, by applying
Theorem 3.2, we can determine the stratum that a treatment factor belongs to. If one stratum
contains no treatment factor, the analysis remains the same as in the null ANOVA. Otherwise,
the stratum is decomposed into treatment W-subspaces and the corresponding residual W-
subspace by applying Equation (3.3).
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3.4.1 Functional treatment and residual sums of squares
In order to derive the general ANOVA, we calculate the functional sum of squares and func-
tional expected mean square for a treatment factor in the similar way to a block factor,
however, based on the set Tφ of induced block factors. According to Equation (3.7), for
a treatment factor Gu ∈ T the functional sum of squares is:
SSGu(t) = y(t)
T PW(G φu )y(t), t ∈ T , (3.17)
since the induced block factor G φu describes how to assign levels of the treatment factor Gu
to observational units. Moreover, PV(G φu ) = Xu(X
T
u Xu)−1XTu in Equation (3.9) implies that
the treatment sum of squares in Equation (3.17) is the same as that commonly used in the
linear regression.
The functional expected mean square is derived by the following theorem.
Theorem 3.6 The functional expected mean square for Gu, which belongs to a stratum







η (t)T PW(G φu )η (t), t ∈ T ,
where ΛBk(t, t) is the functional expected mean square of the stratum and η (t) = E[y(t)].
Proof. In Theorem 3.6, dGu is the degrees of freedom for treatment factor dGu , which also
denotes the dimension of W(Gu) and is equal to the dimension of W(G φu ) as explained in
Section 3.1.4.
The mean and covariance functions for y(t) are calculated by using Equation (3.7) as:








ZkZTk θk(s, t)+ Iθe(s, t),
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where I is an N×N identity matrix.






which can be proved in the way similar to the proof of Theorem 3.4. In addition, Ri(t) =
uTi y(t) and ui is an orthonormal eigenvector of PW(G φu ) with the corresponding eigenvalue
being equal to 1, for i = 1, . . . ,dGu . The mean and covariance functions for Ri(t) are calcu-
lated by:








ZkZTk θk(s, t)+ Iθe(s, t)]ui = ΛBk(s, t),






























and by applying the SVD of PW(G φu ), η (t)




[uTi η (t)]2 can be proved.
Thus, EMSGu(t) = ΛBk(t, t)+
1
dGu
η (t)T PW(G φu )η (t) is proved.
Similarly, the functional sum of squares for the residual term in the stratum W(Bk) is
calculated by:
SSresk(t) = y(t)
T PW(resk)y(t), t ∈ T
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and the functional expected mean square is derived by the following theorem.
Theorem 3.7 The functional expected mean square for the residual term in the stratum





Proof. In an orthogonal design, W(resk)⊥C(Xu) for u = 0, . . . ,U . By using the same nota-
tions as in the proof of Theorem 3.6, we have uTi E[y(t)] = uTi ∑
U
u=0 Xuβ u(t) = 0 with ui as
an eigenvector of PW(resk) and EMSresk(t) = ΛBk(t, t) can be proved by the similar method
as Theorem 3.6.
3.4.2 General ANOVA table
All above calculations for an orthogonal design can be summarised in a general ANOVA
table, which is obtained from the null ANOVA table by adding the analysis of the treatment
structure. We use the split-plot design continued from Example 3.2 and Example 3.3 as an
example.
Example 3.4 (Example 3.3 continued: split-plot design) The general ANOVA is shown in
Table 3.3, where details of orthogonal projections and stratum-based covariance functions
are not given.
In a null ANOVA table (e.g. Table 3.2) each stratum is summarised in one row, whereas
in a general ANOVA table (e.g. Table 3.3) the stratum which contains treatment factors are
shown in several rows.
The general ANOVA table can be viewed as the pointwise analysis of variance without
the hypothesis test. Although pointwise F tests can be easily derived from this ANOVA table
by performing univariate F tests at discrete points independently, we are more interested in
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Table 3.3: General ANOVA table for the split-plot design in Example 3.2
Stratum Source dW SS(t) EMS(t)
mean U 1 y(t)T PW(U )y(t) ΛU (t, t)+η (t)
T PW(U )η (t)
large blocks B1 q1−1 y(t)T PW(B1)y(t) ΛB1(t, t)
small blocks





res2 q2−q1− p1 +1 y(t)T PW(res2)y(t) ΛB2(t, t)
total q2−q1 y(t)T PW(B2)y(t)
plots












rese N−q2− p1(p2−1) y(t)T PW(rese)y(t) ΛE (t, t)
total N−q2 y(t)T PW(E )y(t)
Total N y(t)T y(t)
a global statistical test which takes the entire response functions into account, as will be
explored in the next chapter.
3.5 Conclusions
The main result of this chapter is the ANOVA for orthogonal designs with functional re-
sponses, which has been developed on the basis of orthogonal designs (Bailey, 2008) and the
functional mixed-effects model (Morris and Carroll, 2006). Although responses that we are
interested in are functions, the structure of experiments where functional data are collected
can be analysed in a similar way to classical experiments with univariate responses. More
specifically, at each time point, the univariate ANOVA is applied to study the experimental
structure and we assume the structures are the same across different time points. There-
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fore, we apply a functional mixed-effects model with time-independent covariates (design
matrices) in this thesis. The equivalence between the column space of a design matrix and
the V-subspace of the corresponding factor in the design enables us to develop functional
ANOVA based on the model.
The simplest orthogonal design is a completely randomised design, where observational
units are unstructured and treatments are allocated randomly. One-way ANOVA and two-
way ANOVA for functional data from a completely randomised design was introduced in
Zhang (2013). In a classical completely randomised design, treatments are studied depend-
ing on the overall variability of observational units, while in a more complex orthogonal
design, treatments may be studied in different strata, that is, depending on different error
terms or different sources of error (Cheng, 2014). Similarly, in a completely randomised
design with functional responses, the functional ANOVA is derived based on the covariance
function of functional responses, whereas in a more complex design, the functional ANOVA
is derived based on the stratum-based covariance function, that is the covariance function of
the corresponding error term (or residual) in each stratum.
Although we have extended the classical orthogonal design principles to functional data
and used the terminology of comparative experiments, it is necessary to distinguish between
classical methods and our proposed method with respect to the meaning of stratum. In Bai-
ley (2008, p. 40), it is defined that “A stratum is an eigenspace of Cov(Y)”, where Y is the
vector of responses. Furthermore, Cov(Y) = ∑
allBk
ξBkPW(Bk), where Bk is a block factor
and W(Bk) is an eigenspace of Cov(Y) with the corresponding eigenvalue ξBk . In addition,
ξBk is the expected mean square of the stratum in a null experiment. However, the covari-
ance structure of functional responses can be viewed as a matrix with covariance functions
as diagonal elements and cross-covariance functions as off-diagonal elements. Hence the
spectral decomposition of the covariance matrix is not appropriate for functional responses
and strata are no longer eigenspaces. Moreover, we define expected mean square for each
stratum as a function of time and it is not an eigenvalue of the covariance matrix.
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At the end of this chapter, we place particular emphasis on ANOVA, which can be
viewed from two different perspectives. Under the first perspective, studies focus on model
equations, which can be either linear regression models or ANOVA models. By contrast,
under the second perspective, the emphasis is on the experimental structure, that is the rela-
tionship between factors, although model equations are sometimes used as a supplementary
tool. Nelder (1965a,b), Tjur (1984) and Bailey (2008) all studied orthogonal designs under
the second perspective.
The functional ANOVA in this study is developed under the second perspective, al-
though some of our results are derived by using the functional mixed-effects models. For
functional data measured from a design with many factors or a complicated structure, there
is no need to express the model equation and our proposed functional ANOVA and hypoth-
esis tests can be applied independently of model equations.
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Chapter 4
Functional F tests in orthogonal designs
The comparison of treatments is usually considered in the design of experiment. In a classical
ANOVA, it is common to apply an F test to assess whether there is a treatment effect or
not. However, it is more complicated to test functional data. A functional F test (Shen
and Faraway, 2004; Zhang, 2013) has been proposed for independent functional data, which
imply data are generated from a completely randomised design. In this chapter, we extend
the functional F test to orthogonal designs. A complete version of the functional ANOVA can
be constructed by taking functional F tests for treatments and interaction terms into account.
The proposed functional ANOVA is applied to gait data collected at the Human Per-
formance Laboratory, Queen Mary University of London. Two examples are considered in
this chapter. In the first example, gait data of 14 patients with cerebral palsy are analysed,
to examine the effects of ankle-foot orthoses (AFO). Functional F tests are applied to gait
kinematics, in comparison with pointwise F tests and univariate F tests. However, this ret-
rospective study has limitations, such as the lack of randomisation. Patients always walked
barefoot before walking with AFO during the data collection. Another limitation is the high
variability in gait of patients with cerebral palsy. In order to avoid these problems and to
achieve better statistical interpretation of gait analysis, the second study was designed to col-
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lect gait data from 9 healthy subjects. Gait data were collected from a split-plot experiment
with two treatment factors: AFO and the walking speeds. The treatment factors and their
interaction are examined by functional F tests.
In this chapter, functional F tests are introduced in Section 4.1. Gait data of patients with
cerebral palsy are analysed in Section 4.2, while healthy gait data collected from a split-plot
design are analysed in Section 4.3.
4.1 Functional F tests for treatments
4.1.1 Treatment comparisons
In a designed experiment with functional responses, the main effect of a treatment factor
is indicated by the corresponding vector of fixed-effect functions. For instance, in order
to examine the effect of a treatment factor Gu with pu levels in an orthogonal design, as
expressed in Equation (3.7), we test the null hypothesis:
H0 : βu,1(t) = βu,2(t) = · · ·= βu,pu(t).
This null hypothesis can be viewed from different perspectives, depending on whether β (t)
indicates a function across t ∈ T or the value of a function at a specific point t. Therefore, in
what follows, we distinguish between the pointwise test problem
(1) H0 : βu,1(t`) = βu,2(t`) = · · ·= βu,pu(t`)
versus
H1 : at least two parameters are different,
for t` ∈ T being the fixed time point, and the functional test problem
(2) H0 : βu,1(t) = βu,2(t) = · · ·= βu,pu(t) for all t ∈ T
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versus
H1 : at least two functions are different for some t ∈ T .
The hypotheses (1) lead to the development of pointwise F tests, which will be applied and
discussed in Section 4.2 and Section 4.3. However, Ramsay and Silverman (2005) pointed
out that the pointwise ANOVA problem at each specific time point was the same as the uni-
variate ANOVA problem, and thus the pointwise approach is not technically new. Therefore,
we focus more on global tests based on the hypotheses (2). We will derive the null dis-
tributions of functional sums of squares and develop a functional F test in the rest of this
section.
4.1.2 Null distribution of functional sum of squares
Consider an orthogonal design with the block structure B and the treatment structure T.
Suppose Equation (3.7) is the model for this orthogonal design. As introduced in Section
3.4, the set Tφ of induced block factors is used to derive the treatment sum of squares.
We will derive the null distributions of the sums of squares for both a treatment factor
and the corresponding residual in the same stratum.
Theorem 4.1 If a treatment factor Gu ∈ T belongs to the stratum W(Bk), Bk ∈B, with the
corresponding stratum-based covariance function ΛBk(s, t), the functional treatment sum of
squares for Gu can be expressed as:
SSGu(t) = y(t)





where R1, . . . ,RdGu are Gaussian processes with the common covariance function being equal









uTi Xu′β u′(t), (4.2)
74
where ui is an orthonormal eigenvector of PW(G φu ).
Proof. Equation (4.1) and the corresponding covariance function were proved in Theorem
3.6. Here, we concentrate on the mean function of Ri(t) for i = 1, . . . ,dGu .
According to the proof of Theorem 3.6, for Gu ∈ T the mean function of Ri(t) in Equa-
tion (4.1) is E[Ri(t)] = uTi η (t), where ui is an orthonormal eigenvector of PW(G φu ). By
applying Equation (3.7), we have













PW(G φu ) =







which implies that uTi Xu′ = 0 if G
φ
u′ is neither finer than nor equivalent to G
φ
u . Thus, we have
the following result:







where G φu′ is every treatment factor that is finer than or equivalent to G
φ
u in Tφ .
In what follows, we will calculate E[Ri(t)] in Equation (4.2) under the null hypothesis
H0 : βu,1(t) = βu,2(t) = · · · = βu,pu(t). Similar to the traditional ANOVA, a constraint is
needed for functional ANOVA.
Alternatively, we can also use the null hypothesis H0 : PW(G φu )η (t) = 0, as in Bailey
(2008). It is not difficult to prove that if PW(G φu )η (t) = 0 then E[Ri(t)] in Equation (4.2) is
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equal to zero. If PW(G φu )η (t) = 0, then we have

















PW(G φu )Xu′β u′(t) = 0.
(4.3)
In Equation (4.2), since ui is an eigenvector of PW(G φu ) with the corresponding eigenvalue

















uTi PW(G φu )Xu′β u′(t) = 0.





PW(G φu )Xu′β u′(t) = 0, if βu,1(t) = βu,2(t) =
· · ·= βu,pu(t) together with the constraint, which will be given later in Equation (4.4).
We will first prove that for every treatment factor G φu′ ∈ T
φ that is finer than
G φu , if βu,1(t) = βu,2(t) = · · · = βu,pu(t) and the constraint in Equation (4.4) holds,
PW(G φu )Xu′β u′(t) = 0. Suppose β u(t) = [βu,1(t), . . . ,βu,pu(t)]
T with βu,a(t) being the ef-




u , let na be
the number of levels of G φu′ that are nested within the same a-th level of G
φ
u . The vector
β u′(t) = [βu′,1(t), . . . ,βu′,pu′ (t)]
T can be re-expressed as
[βu′,1(1)(t), . . . ,βu′,n1(1)(t), . . . ,βu′,1(pu)(t), . . . ,βu′,npu(pu)(t)]
T ,
where βu′,b(a)(t) is the effect of Gu′ with the b-th level nested within the a-th level of Gu,





βu′,b(a)(t) = 0 for every a and for all t ∈ T . (4.4)
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The design matrices Xu and Xu′ can be re-expressed as:
Xu = [vu,1, . . . ,vu,pu] and Xu′ = [vu′,1(1), . . . ,vu′,n1(1), . . . ,vu′,1(pu), . . . ,vu′,npu(pu)],
where vu,a and vu′,b(a) for a = 1, . . . , pu and b = 1, . . . ,na are column vectors of the design
matrices Xu and Xu′ , respectively. Recall the description of the orthogonal projection onto
the V-subspace PV shown in (3.10). Then, for a = 1, . . . , pu,
PV(G φu )vu′,1(a) = · · ·= PV(G φu )vu′,na(a).
Since PW(G φu )vu′,b(a) = PW(G φu )PV(G φu )vu′,b(a), we have
PW(G φu )vu′,1(a) = · · ·= PW(G φu )vu′,na(a).
By using the constraint in Equation (4.4), we derive the following result:
PW(G φu )Xu′β u′(t) =PW(G φu )[vu′,1(1), . . . ,vu′,n1(1), . . . ,vu′,1(pu), . . . ,vu′,npu(pu)]β u′(t)
=[PW(G φu )vu′,1(1), . . . ,PW(G φu )vu′,n1(1), . . . ,
PW(G φu )vu′,1(pu), . . . ,PW(G φu )vu′,npu(pu)]β u′(t)
=[PW(G φu )vu′,1(1), . . . ,PW(G φu )vu′,1(1), . . . ,
PW(G φu )vu′,1(pu), . . . ,PW(G φu )vu′,1(pu)]β u′(t)
=PW(G φu )vu′,1(1)[βu′,1(1)(t)+ · · ·+βu′,n1(1)(t)]+ . . .














PW(G φu )vu′,1(a)×0 = 0.
We will then prove that for G φu ∈ Tφ , PW(G φu )Xuβ u(t) = 0 under the null hypoth-
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esis H0 : βu,1(t) = · · · = βu,pu(t). If Gu is not a universal factor and βu,1(t) = · · · =
βu,pu(t), then Xuβ u(t) = 1N×1βu,1(t) where 1N×1 is an N × 1 all-1 vector. We have
PW(G φu )Xuβ u(t) = PW(G φu )1N×1βu,1(t) = 0, since PW(G φu )⊥1N×1. To test the universal
factor G0 in T, PW(G φ0 )
X0β 0(t) = PW(G φ0 )
1N×1 × 0 = 0 holds under the null hypothesis
H0 : β0(t) = 0.
Therefore, under the null hypothesis H0 : βu,1(t) = · · ·= βu,pu(t) together with the con-





PW(G φu )Xu′β u′(t) = 0; and hence






Ri(t)Ri(t) with R1, . . . ,RdGu ∼ GP(0,ΛBk).
In addition, the cross-covariance function is zero, the proof of which is similar to Theorem
3.4.





























i.i.d.∼ χ2dGu and λ1 ≥ λ2 ≥ ·· · ≥ 0 are the eigenvalues of the covariance operator
that is associated with the stratum-based covariance function ΛBk(s, t).





























where R̃1, . . . , R̃dresk ∼GP(0,ΛBk) with the cross-covariance function of every two processes
being zero and (Ãr)∞r=1
i.i.d.∼ χ2dresk and λ1 ≥ λ2 ≥ ·· · ≥ 0 are the eigenvalues of the covariance
operator that is associated with the stratum-based covariance function ΛBk(s, t).
So far we have derived distributions for the integrated treatment and residual sums of
squares. We also need to confirm the independence between sums of squares before present-
ing the functional F test in the next subsection.
Since for a treatment factor Gu and the corresponding residual W(Gu)⊥W(resk), any
eigenvector ui of PW(Gu) for i = 1, . . . ,dGu is orthogonal to any eigenvector ũ j of PW(resk) for
j = 1, . . . ,dresk . Therefore, it is obvious that the cross-covariance function of
Ri(t) = uTi y(t) and R̃ j(t) = ũ
T
j y(t)
is Cov[Ri(s), R̃ j(t)] = 0 for all s, t ∈ T and each pair of i and j; and hence (Ar)∞r=1 in Equa-
tion (4.5) and (Ãr)∞r=1 in Equation (4.6) are independent, according to Theorem 2.3. Thus,
SS∗Gu which is a linear combination of (Ar)
∞
r=1 is independent of SS
∗
resk which is a linear
combination of (Ãr)∞r=1.
















where A1,A2, . . . and Ã1, Ã2, . . . are independent random variables that all follow χ2 distri-




4.1.3 Functional F test
In order to test the treatment effects in an orthogonal design with functional responses, we
consider a functional F test. For each treatment factor, the functional F test is conducted
within the stratum where the treatment factor is located. We test the hypotheses (2) in Section





We have proved that under the null hypothesis both the integrated treatment and residual
sums of squares can be transformed into linear combinations of independent random vari-
ables which follow χ2 distributions.
However, the exact distribution of a linear combination of χ2 random variables is
complicated. As suggested by Shen and Faraway (2004) and Zhang (2013), the Welch-
Satterthwaite approximation (Satterthwaite, 1941, 1946; Welch, 1947) can be applied to de-
rive the approximate distribution of the statistic in the functional F test.
Suppose X = c1x1 + · · ·+cnxn, where x1, . . . ,xn are independent random variables and
xi follows a χ2 distribution with degrees of freedom di, for i = 1, . . . ,n. Then X /κ can
be approximated by a χ2 distribution with degrees of freedom being equal to d f . Welch
(1947) proposed that the first two moments (mean and variance) of the approximating χ2
distribution should agree with X . Thus we have
E(X ) = κ×d f = c1d1 + · · ·+ cndn,
var(X ) = κ2×2d f = 2c21d1 + · · ·+2c2ndn,
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and parameters in the approximate distribution are calculated by:
d f =
(c1d1 + · · ·+ cndn)2
c21d1 + · · ·+ c2ndn
, κ =
c21d1 + · · ·+ c2ndn
c1d1 + · · ·+ cndn
.
By using a simulation approach, Zhang (2013, p. 97) showed that the χ2-approximation















with λ1 ≥ λ2 ≥ ·· · ≥ 0. Thus, SS∗Gu can be approximated by κχ
2


















= ∑∞r=1 λrÃr can be approximated by κχ
2
d f2 , where κ is the same as in












































Furthermore, since SS∗Gu and SS
∗
resk are independent, the null distribution of F can be approx-
imated by an F distribution:
F
approx.∼ F(d f1,d f2).
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Summary of functional F test
In order to test the functional null hypothesis H0 : βu,1(t)= βu,2(t)= · · ·= βu,pu(t) for all t ∈ T ,





approx.∼ F(d f1,d f2),
where d f1 and d f2 are called as the adjusted degrees of freedom and calculated by













with λ1 ≥ λ2 ≥ ·· · ≥ 0 as the eigenvalues of the covariance operator that is associated with
the stratum-based covariance function ΛBk(s, t).
Adjusted degrees of freedom calculated by Equation (4.9) are not always integers. Thus,
Shen and Faraway (2004) used an alternative distribution F([d f1], [d f2]), where [d f1] and
[d f2] indicate the closest integers to d f1 and d f2. A similar issue of non-integer degrees of
freedom in Welch’s test has been discussed in Derrick et al. (2016). Although integer degrees
of freedom, which are calculated by rounding down to the nearest integers, are required when
using the statistical table for critical values, commonly-used statistical software, such as R,
SPSS and Matlab, would conduct the test with non-integer degrees of freedom. Therefore,
we will still use d f1 and d f2 calculated by Equation (4.9), as suggested in Zhang (2013,
p. 98).
In a practical application of the functional F test, we need to derive the integrals in
the numerator and denominator of F and to calculate the eigenvalues of the corresponding
covariance operator.
More specifically, the interval T = [0,1] is discretised by superimposing a fine grid of
m equally spaced points t1, . . . , tm, where t1 = 0 < t2 < · · · < tm−1 < tm = 1. The integral
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∫
T SSGu(t)dt is approximated by the sum ∑
m
`=1 SSGu(t`). Likewise, as an approximation to
the integral
∫
T SSresk(t)dt, the sum ∑
m
`=1 SSresk(t`) is used. To calculate the eigenvalues, the
covariance function is estimated by:
Λ̂Bk(t`, tv) = y(t`)
T PW(resk)y(tv),
where y(t`) = [y1(t`), . . . ,yN(t`)]T and y(tv) = [y1(tv), . . . ,yN(tv)]T are vectors of observed
values at specific time points t`, tv for `,v = 1, . . . ,m. Thus, Λ̂Bk is an m×m matrix and the
eigenvalue λ̂r for r = 1, . . . ,m can be calculated.
4.2 Functional F test for gait data of patients with cerebral
palsy
4.2.1 Introduction
In this section, we apply functional F tests to examine the effects of AFO on 3-dimensional
kinematic gait data of children with cerebral palsy, which is a childhood condition with
impaired motor function caused by lesion of the brain (Miller, 2005, p. 3). Patients with
cerebral palsy usually have abnormal gait patterns leading to the prescription of fixed AFO.
Generally, AFO are expected to enhance the ambulatory function and to improve motions of
lower limb segments during the gait cycle (Wingstrand et al., 2014).
The effects of AFO on kinematics of patients with cerebral palsy have been examined
by several studies (Abel et al., 1998; Buckon et al., 2004; Abd El-Kafy, 2014; Kerkum et al.,
2015; Danino et al., 2016). However, without a proper statistical tool to analyse curves,
different kinematic variables were chosen in different studies. As a result, it is difficult to
summarise findings from different studies. It has been recommended to consider the effects
of AFO throughout the entire gait cycle to ensure that important findings are not neglected
(Hsu et al., 2008, p. 307). The FDA approach which can be applied to analyse whole gait
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curves would solve these problems.
In this retrospective study, the effect of wearing AFO on the gait kinematics of patients
with cerebral palsy was assessed. We aim to explore how the functional F test improves gait
analysis, compared to some other statistical tests, such as univariate F tests and pointwise F
tests. Material in this section is from the published paper by Zhang et al. (2017), which is
enclosed in Appendix A.
4.2.2 Data collection
The original clinical study was designed in accordance with the ethical guidelines of the
Declaration of Helsinki and was approved by East London NHS Research Ethics Committee
(Ethics REF 09/H0806/56). Written informed assent and consent, from all children and
parents respectively, was collected.
Time-dense gait data were collected from 14 patients with cerebral palsy (mean age
12.3±2.88years, mean height 1.44±0.15m, mean weight 39.57±11.78kg) by Dr Richard
Twycross-Lewis between 2010 to 2013 in Human Performance Laboratory. All recruited
children had been diagnosed with spastic cerebral palsy and prescribed fixed AFO (see Fig-
ure 4.1) for a minimum of six months. Children were initially assessed by a paediatric
orthopaedic consultant and only included if they were independently ambulatory and con-
sidered to have sufficient muscular endurance for gait measurements. Most recruited children
were classified to the Gross Motor Function Classification System (GMFCS) (Palisano et al.,
1997) level II and III and few children were classified at level IV.
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Figure 4.1: Bespoke, fixed AFO for
children with cerebral palsy
Data collection followed the commonly used
protocol (Ounpuu et al., 1991; Abel et al., 1998;
Brehm et al., 2008) whereby each patient was in-
structed to perform a series of walks both barefoot
and wearing AFO placed within shoes. Order was
not randomised and barefoot walking was conducted
first (Abel et al., 1998; Brehm et al., 2008). While
walking with AFO, patients were shod, owing to the
importance of footwear in the orthotic prescription
that AFO modify kinematics of segments only with
appropriate footwear (Hsu et al., 2008, p. 306).
More specifically, anthropometric information, including pelvic width and depth and
bilateral knee and ankle width, was obtained. Then kinetic data were collected while the
patient walked barefoot at a self selected pace along a 6-meter walkway with two ground
embedded force plates (Type 9281B Multicomponent Force Plate, Kistler Instruments Ltd,
Winterthur, Switzerland) that measured 3-dimensional ground reaction force. After 10 - 20
walks, patients then repeated walking tests whilst wearing their AFO over the same force
plates.
Kinematic data were collected using four 3D Cartesian Optoelectric Dynamics Anthro-
pometer systems (Charnwood Dynamics, Rotheley, Leicestershire, UK) that were placed at
distances of 2 - 3 meters from the force plates, oblique to the centre of the laboratory in order
to create a data collection volume. A modified Helen Hayes marker set protocol (Richards,
2008) was used, whereby active infra-red markers were placed bilaterally on the anterior
sacro-iliac spine (ASIS); posterior sacro-iliac spine (PSIS); lateral epicondyle of the knee
and the lateral malleolus; lateral aspect of the calcaneous and the 5th metatarsal. Instru-
mented marker wand sets were also placed superior and inferior to the knees (see Figure
4.2). Joint centres for the pelvis, hips, knees and ankles were calculated using Codamotion
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Figure 4.2: Modified Helen Hayes protocol for the gait data collection (Codamotion User Guide,
2005)
Figure 4.3: Codamotion Analysis software for the gait data collection (version 6.76.2-CX1/mpx30,
Charnwood Dynamics, Rotheley, Leicestershire, UK)
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Analysis software (see Figure 4.3) based on subject specific anthropometric data.
Gait events in each trial, from initial contact to toe off to the following initial contact (see
Figure 1.2), were marked using the vertical component of ground reaction force and velocity
of the calcaneous marker for both the ipsilateral and contralateral limbs. Standardised gait
graphs were then extracted by analysing the kinematic data offline using Matlab (version
2009a, The Mathworks, Natick, MA, USA). Furthermore, a standardised gait graph usually
contains 3×5 panels, where columns show the pelvis, hip joint, knee joint, ankle joint and
foot and rows are the coronal plane, sagittal plane and horizontal plane respectively.
4.2.3 Statistical analysis
The structure of gait data
For each subject, four gait curves were observed from two legs (left and right) and two
walking conditions (barefoot and wearing AFO). Figure 4.4 shows the rotations of knee
joints in the sagittal plane as an example. Each curve represents the gait of one leg in one
patient during walking under one condition. More specifically, the top and bottom panels
in Figure 4.4 display the gait data from barefoot walking and walks with AFO respectively.
Moreover, angles of the left and right knees are displayed in the left and right panels.
Model
In total 56 gait curves were obtained from 14 patients for each segment in each plane, which
can be indicated by y(t) = [y1(t), . . . ,yN(t)]T for N = 56 and t ∈ [0,1]. Hasse diagrams (see
Figure 4.5) and a skeleton ANOVA table (see Table 4.1) are used to illustrate the experimen-
tal structure. We can see that the treatment factor AFO is located in the walks-stratum.
The functional mixed-effects model to test the effects of AFO can be expressed as:




Zkδ k(t)+ ε (t), t ∈ [0,1], (4.10)
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Figure 4.4: Angles of knee joints in the sagittal plane of 14 children with cerebral palsy
U 1, 1









Figure 4.5: Hasse diagrams for the block structure
(left) and the treatment structure (right) of the exper-
iment where gait data of patients with cerebral palsy
were collected
Table 4.1: Skeleton ANOVA table for the
experiment where gait data of patients with
cerebral palsy were collected
Stratum Source dW
U U 1









where β 0(t) = 156×1β0(t) with 156×1 being an all-1 vector and β0(t) indicating the
overall mean function; β 1(t) = [β1,1(t),β1,2(t)]
T indicates the main effect of wear-
ing and respectively not wearing AFO; δ 1(t) = [δ1,1(t), . . . ,δ1,14(t)]T indicates the ran-
dom effects for the subjects; δ 2(t) = [δ2,1(1)(t), . . . ,δ2,2(14)(t)]T indicates the random
effects for the walks nested within subjects, and due to the experiment without ran-
domisation, the first walk is barefoot and the second walk is with AFO for each
subject; δ 3(t) = [δ3,1(1)(t), . . . ,δ3,2(14)(t)]T indicates the random effects for the limbs
nested within subjects; all other terms are similar to those in Equation (3.7). In ad-
dition, δ0 ∼ GP(0,θ0), δ1,1, . . . ,δ1,14
i.i.d.∼ GP(0,θ1), δ2,1(1), . . . ,δ2,2(14)
i.i.d.∼ GP(0,θ2),
δ3,1(1), . . . ,δ3,2(14)
i.i.d.∼ GP(0,θ3) and ε1, . . . ,εN
i.i.d.∼ GP(0,θe).
In order to test if the treatment factor AFO has an effect or not, we concentrate on the
walks-stratum. Functional sums of squares in this stratum are calculated by:
SSwalks(t) = y(t)T Pwalksy(t), SSAFO(t) = y(t)T PAFOy(t), SSresidual(t) = SSwalks(t)−SSAFO(t),
(4.11)














Functional sums of squares in Equation (4.11) are used by both pointwise F tests and
functional F tests. However, whereas the pointwise F tests also use the degrees of freedom
dW in Table 4.1 in order to assess the significance of the results, this is not the case for the
functional F test.
Pointwise F tests
The effect of AFO may be tested by adopting a multiple testing approach. However, this
does not take the functional nature of the data into account. This amounts to performing a
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series of separate F tests of
H0 : β1,1(t`) = β1,2(t`) versus H1 : β1,1(t`) 6= β1,2(t`)
at each of m equally spaced points t` ∈ [0,1], `= 1, . . . ,m, in the gait cycle. The test statistic





The resulting values F(t`) are plotted against t` for ` = 1, . . . ,m and can be assessed for
statistical significance at every time point.
Pointwise F tests face the usual problems surrounding multiple testing. In particular,
the familywise error probability (Hochberg and Tamhane, 1987, p. 7) can be much higher
than the nominal significance level of the individual tests, as will be illustrated later.
Functional F test
Alternatively, the functional F test summarises information across the whole gait cycle by
integrating the functional sums of squares SSAFO(t) and SSresidual(t) over [0,1]. Contrary to
the pointwise F tests, the hypotheses tested by the functional F test are given by
H0 : β1,1(t) = β1,2(t) for all t ∈ [0,1] versus H1 : β1,1(t) 6= β1,2(t) for some t ∈ [0,1],







We have already proved in Section 4.1 that under H0 the distribution of the above F can be
approximated by an F distribution as follows
F
approx.∼ F(dfAFO,dfresidual),


















where λ1 ≥ λ2 ≥ ·· · ≥ 0 are the eigenvalues of the covariance operator that is associated
with the walks-stratum-based covariance function Λwalks(s, t). Furthermore, Λwalks(s, t) =
2θ2(s, t)+θe(s, t), according to Theorem 3.4.
An attractive feature of the functional F test is that the integration over [0,1] can be
replaced with integration over subsets of [0,1]. This opens up the possibility to test the
effects of AFO in specific phases of the gait cycle as will be illustrated below.
4.2.4 Results
Observational results
Figures 4.6 and 4.7 show descriptive information for 3-dimensional segmental rotations of
lower limbs in patients during both barefoot and shod with AFO walking. Differences can
be seen in the overall kinematics with the application of the AFO: there is an overall increase
in maximal dorsiflexion from 10◦ to 15◦ of the ankle joint in the sagittal plane in gait with
AFO, however the magnitude of joint rotation does not change. Differences in the mean













































































































































































overall mean left mean right mean
Figure 4.6: Barefoot walking in 14 children with cerebral palsy. Data are normalised to percentage












































































































































































overall mean left mean right mean
Figure 4.7: Gait with AFO in 14 children with cerebral palsy. Data are normalised to percentage (%)
of the gait cycle and grey areas represent intervals [mean−s.d., mean+s.d.] at every point.
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Pointwise F tests
We first examined effects of AFO on different segmental rotations by using the multiple
pointwise F tests and results are shown in Figure 4.8. All individual tests used a significance
level of α = 0.05. In the figure, AFO have significant effects when the value of the F statistic
exceeds the critical value, which is the same at all time points (F0.05(1,13) = 4.67). We can
see that there is no panel where the whole curve of statistic values exceed the critical values.
However, we detect significant effects at some specific points.
In certain parts of the gait cycle AFO have significant effects on pelvis in the coronal
and horizontal planes; hip joint in the coronal and sagittal planes; knee joint in all three
planes; ankle joint in the coronal and sagittal planes and foot in the sagittal and horizontal
planes (Figure 4.8). Moreover, for different segments significant effects of AFO occur at
different time points along the gait cycle conferring a temporal effect. Referring to Figures
4.6 and 4.7, we can see that for the pelvis in the coronal and horizontal planes, hip joint and
ankle joint in the sagittal plane, AFO have significant effects roughly around the minimal
angles, whereas for the hip in the coronal plane and the knee in the sagittal plane effects of
AFO tend to occur near maximal angles.
The nominal significance level of every individual pointwise F test is α = 0.05. How-
ever, in every panel of Figure 4.8 many of those tests are performed on a grid of m = 201
points. Consequently, the familywise error rate, which is the probability of at least one incor-
rect rejection of the null hypothesis, of this multiple testing procedure can be much higher
than the nominal significance level if one looks at an interval rather than a single time point.
For instance, AFO affect hip rotation in the sagittal plane between 50-60% of the gait cy-
cle (see Figure 4.8). This section of the gait cycle contains approximately 20 grid points.
At each of these points the probability of a type I error is 0.05. However, an approximate
calculation under the simplifying (and surely not correct) assumption that the tests are inde-
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Figure 4.8: Multiple pointwise F tests at significance level α = 0.05 for effects of AFO on segmental
rotations. Grey dashed and solid lines are used to divide the whole gait cycle into phases: initial con-
tact, loading response, mid-stance, terminal stance, pre-swing, initial swing, mid-swing and terminal
swing (from left to right).
gait cycle can be as high as 1− (1−0.05)20 ≈ 0.64. This example illustrates that results of
pointwise tests need to be interpreted with care, since the “significance” of the results may
be overstated. Pointwise tests may suggest the presence of effects where there are actually
none.
Functional F test and univariate F tests
The first part of Table 4.2 presents the functional F test for each of the segments and planes.
The values of the test statistic F and the corresponding p-values are shown in the second
column of the table and the degrees of freedom of the approximate null distribution of F
in the first column. The degrees of freedom are reported in the form (dfAFO,dfresidual) and
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Table 4.2: Functional F tests for the whole gait cycle and F tests from the univariate ANOVA for min-
imal and maximal angles. Degrees of freedom for the univariate ANOVA are (1,13) and * indicates
significance at 0.05 significance level.
Functional F test Univariate ANOVA (F value (p.))
degrees of freedom F value (p.) minimal angle maximal angle
Pelvis
coronal (1.47,19.06) 2.80(0.10) 0.03(0.86) 0.34(0.57)
sagittal (1.16,15.04) 0.21(0.69) 0.20(0.66) 0.01(0.93)
horizontal (2.11,27.48) 3.45(0.04)∗ 8.32(0.01)∗ 1.19(0.30)
Hip
coronal (2.79,36.27) 1.32(0.28) 0.03(0.87) 0.29(0.60)
sagittal (1.92,24.92) 1.69(0.20) 4.28(0.06) 0.27(0.61)
horizontal (1.27,16.48) 0.15(0.76) 0.08(0.79) 0.08(0.79)
Knee
coronal (1.89,24.59) 1.11(0.34) 1.43(0.25) 1.14(0.31)
sagittal (3.21,41.68) 2.29(0.09) 1.68(0.22) 1.91(0.19)
horizontal (1.52,19.76) 2.90(0.09) 0.34(0.57) 7.45(0.02)∗
Ankle
coronal (1.11,14.45) 4.37(0.05)∗ 5.50(0.04)∗ 1.65(0.22)
sagittal (1.49,19.43) 6.44(0.01)∗ 19.3(< 0.01)∗ 3.35(0.09)
horizontal (1.27,16.46) 0.82(0.40) 2.52(0.14) 0.97(0.34)
Foot
coronal (1.15,14.97) 2.24(0.15) 2.52(0.17) 0.45(0.51)
sagittal (2.20,28.54) 2.63(0.08) 1.67(0.22) 13.37(< 0.01)∗
horizontal (1.69,21.99) 3.98(0.04)∗ 2.02(0.18) 4.81(0.05)∗
depend on the actual data. At a significance level of α = 0.05, the functional F tests detect
significant effects of AFO on the pelvis rotation in the horizontal plane, ankle rotation in the
coronal and sagittal planes and foot rotation in the horizontal planes. These results indicate
that AFO have significant effects on the overall motion of these segments over the whole gait
cycle.
The second part of Table 4.2 reports results of a univariate ANOVA with minimal an-
gle as the response variable in the third column of the table, and corresponding results for
maximal angle as the response variable in the fourth column. The F values in the table are
computed as for the pointwise F test with the only modification that all sums of squares are
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calculated at the time points of the gait cycle at which the minimum (respectively maximum)
angles occur. These time points do vary within and between patients. For both response vari-
ables, the null distribution of the test statistic is an F(1,13) distribution and thus the same as
for the pointwise F test.
With significance level α = 0.05 as before, the F tests from the univariate ANOVA
detect effects of AFO on minimal pelvis angle in the horizontal plane, ankle angle in the
coronal and sagittal planes, which agrees with the results of the functional F tests. For
maximal angle, the F tests from the univariate ANOVA find a significant effect on foot in
the horizontal plane, which is again in agreement with the result of the functional F test.
Moreover, the F test detects an effect on maximal knee angle in the horizontal plane and
maximal foot angle in the sagittal plane, where the corresponding functional F test for the
whole gait cycle is not significant.
Functional F test for gait phases
Besides the whole gait cycle, we are also interested in effects of AFO during the stance phase
(0-60% of gait cycle) and swing phase (60-100% of gait cycle) separately. In Figure 4.8, the
stance and swing phases are divided by grey solid lines.
In order to perform functional F tests for these phases, it is only necessary to replace
the interval [0,1] in the formula for F in Equation (4.12) with appropriate subintervals. For
the stance phase we replace [0,1] with [0,0.6] and for the swing phase we use (0.6,1]. For
simplicity, we continue to denote the resulting test statistics by F .
Results for the stance and gait phases are shown in Table 4.3. For significance level
α = 0.05, AFO only have significant effects during the stance phase on the ankle rotation
in the coronal and sagittal planes. In the swing phase, there are significant effects on pelvis
rotation in the coronal and horizontal planes, knee rotation in the horizontal plane, ankle
rotation in the sagittal plane and foot rotation in the horizontal plane.
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Table 4.3: Functional F tests for stance and swing phases of gait cycle with * indicating significance
at 0.05 significance level





















4.2.5 Comparison of statistical results
Results from the functional F test are also detected by pointwise F test and univariate F test.
As can be seen from Figure 4.8 and Table 4.2, significant effects of AFO on the pelvis in
the horizontal plane, ankle joint in the coronal and sagittal planes and on the foot in the
horizontal plane are detected by functional F tests as well as pointwise F tests and univariate
F tests.
In addition to these unequivocal findings, the pointwise F tests detect significant results
for certain parts of the gait cycle where the functional F test for the whole gait cycle and
the F tests in the univariate ANOVA do not show significant effects. More specifically,
only the pointwise F tests find effects on the pelvis in the coronal plane, on the hip in the
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coronal and sagittal planes, on the knee in all three plane and on the foot in the sagittal plane.
Significant results of pointwise F tests for the knee rotation in the sagittal and horizontal
planes and the foot rotation in the sagittal plane agree with the weakly significant effects
from the functional F test. Moreover, some of significant pointwise results are consistent
with results of functional F tests for the stance and swing phases. In particular, the significant
pointwise effects on the pelvis in the coronal and horizontal planes are also detected by
the functional F test for the swing phase. The significant pointwise effects on the hip in
the coronal plane at around 40% of the gait cycle agree with the weakly significant effects
detected by the functional F test for the stance phase.
With the univariate ANOVA, we can see that the significant effects on minimal ankle
angle in the coronal and sagittal planes are detected by the functional F tests in the stance
phase; the significant effect on the minimal pelvis angle in the horizontal plane, on the max-
imal knee angle in the horizontal plane, on the maximal foot angle in the horizontal plane
are also revealed by the functional F tests in the swing phase. Overall, the results from the
different approaches seem to inform each other.
4.2.6 Discussion
Gait data of 28 lower limbs in 14 patients with cerebral palsy, typically hemiplegia,
were modelled by a functional mixed-effects model. The effects of wearing AFO on 3-
dimensional joint rotations were assessed by three different methods: multiple testing with
pointwise F tests performed at separate points of a fine grid, a new functional F test which
was applied to entire gait curves, and univariate F tests, which were performed separately on
minimal and maximal joint angles. By comparing statistical results, we can see that the pro-
posed functional F tests provided additional information to pointwise F tests and univariate
F tests.
Although this study showed the applicability of functional ANOVA in gait analysis, we
did not have any further clinical information about patients in this retrospective study, such as
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the AFO configuration, GMFCS level and cerebral palsy type (spastic hemiplegia or spastic
diplegia cerebral palsy) of each patient. Moreover, there are some limitations of this study
due to the retrospective data collection, such as the data quality. As pointed out in another
retrospective study that using barefoot walking as the control condition was not ideal since
footwear affected the gait pattern (Brehm et al., 2008). In addition, the influences of footwear
on gait kinematics and on the effects of AFO have been investigated in Desloovere et al.
(2006), which found significant differences of maximum ankle dorsiflexion and maximum
knee flexion in the stance phase between barefoot and shod walking, while no difference
was found for the maximum hip extension in the stance phase and mean pelvic rotation.
Desloovere et al. (2006) also examined the effects of two types of AFOs and had different
results between the shod walking compared to walking with AFOs and the barefoot walking
compared to walking with AFOs, with respect to ankle and knee kinematics. Therefore, it is
difficult to distinguish whether the significant differences we found in this study are caused
by the effect of AFO or footwear. Furthermore, Abel et al. (1998) discussed the issue of
non-randomised design in the retrospective study, which is also a limitation in the present
study.
Another controversial issue of this study is the experimental structure, as shown in Fig-
ure 4.5 and Table 4.1, which is proper from a statistical perspective. However, the statistical
test based on this structure is equivalent to a paired two-sample test for the average of the
left and right limbs. From a clinical perspective, the diagnoses of recruited patients include
both hemiplegia cerebral palsy and diplegia cerebral palsy. Spastic hemiplegia implies the
paralysis on one side of the body, while spastic diplegia affects both legs although two sides
of the body may perform asymmetrically (Whittle, 2007, p. 197). Therefore, hemiplegia
always and diplegia may result in asymmetric gait patterns. Averaging the gait data from the
left and right legs may conceal the effects of AFO to some extent. Menz (2004) discussed
whether each subject or each leg of each subject should be considered as an observation but
concluded a lack of statistical solutions to this problem.
99
4.3 Functional F test for gait data from a split-plot design
4.3.1 Introduction
In this section we consider gait data collected from healthy subjects in a split-plot design.
In order to achieve a successful orthotic management it is necessary first to understand the
biomechanics of normal gait (Owen, 2010), although we focus more on statistical techniques
rather than clinical interpretation.
The effects of AFO and walking speeds on gait patterns of healthy subjects are tested
by functional F tests. The use of AFO, which partially corrects gait patterns of patients, may
constrain the gait of a healthy subject (Opara et al., 1985; Guillebastre et al., 2009). Thus,
we explore potential utilisations of the proposed functional F test to gait analysis, however,
do not make any clinical recommendation.
4.3.2 Experimental design
We consider two treatment factors in this experiment: AFO and speeds. During the data
collection, each participant was asked to walk on an instrumented treadmill under three con-
ditions: barefoot (BF), wearing one orthosis around the left leg (unilateral AFO) and wearing
two orthoses around both legs (bilateral AFO). Furthermore, under each orthotic condition,
gait data were collected at three different speeds that had been set for the treadmill: the self-
selected speed (medium), the speed which is 1km/h faster than the self-selected speed (fast)
and the speed which is 1km/h slower than the self-selected speed (slow).
In this experiment, each subject walked more than once and block factors are subjects
and time-periods. Within each subject, each level of treatment factor AFO is randomly
allocated to one of three time-periods. Moreover, each time-period is split into three sub-
periods, when the participant walked at different speeds. The total number of recruited
participants is 9 and the experimental structure is illustrated by Hasse diagrams (Figure 4.9)
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Figure 4.9: Hasse diagrams for the block structure (left)
and the treatment structure (right) of the experiment where
gait data of healthy subjects were collected
Table 4.4: Skeleton ANOVA table
for the experiment where gait data of
healthy subjects were collected
Stratum Source dW
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and a skeleton ANOVA table (Table 4.4), where the treatment factor AFO is located in the
periods-stratum, whereas the treatment factor speeds and the interaction term are located in
the E -stratum.
4.3.3 Data collection
The present study was performed in accordance with the ethical guidelines of the Declaration
of Helsinki and was approved by Queen Mary University of London Ethics of Research
Committee (REF QMREC2014/24/48). The written informed consent was obtained from all
participants. The ethical application form for approval including the Participant Information
Sheet and Informed Consent are enclosed in Appendix B.
During the experiment, each recruited participant was asked to walk on an instrumented
treadmill (Gaitway 2, h/p/cosmos sports & medical gmbh, Nussdorf-Traunstein, Germany)
under different walking conditions, which are combined by three AFO conditions crossed
with three speeds. Each trial under one walking condition lasts 30 - 60 seconds. Additionally,
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Figure 4.10: Ankle-foot orthoses (AFO)
Figure 4.11: Back view of the marker set with
red dots as infra-red markers and blue dots as
digitised virtual markers (Codamotion ODIN
user Guide, 2016)
the orthosis (medium size, footplate length 160mm and brace height 340mm) used in this
study is shown in Figure 4.10 and AFO were placed within participants’ own shoes. When
the subject walked with the unilateral AFO, the orthosis was always placed around the left
leg.
Furthermore, data were collected by using a modified CAST marker protocol (Richards,
2008), whereby a combination of 4 marker clusters were placed above and beneath the knees
on the lateral aspects of the thighs and shanks. Active infra-red markers were placed on the
anterior sacro-iliac spine and posterior sacro-iliac spine bilaterally, lateral aspect of the heel
and fifth metatarsal, which are indicated by red dots in Figure 4.11. In addition, digitised
virtual markers at the lateral and medial malleolus and epicondyles of the knees, which are
indicated by blue dots in Figure 4.11, were used to construct a gait model for the analysis of
human movement.
Gait data were measured and analysed by Codamotion ODIN (CX-1 system, Charn-
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wood Dynamics, Rotheley, Leicestershire, U.K.). Gait events of each trial, including initial
contact, toe off and the next initial contact, were marked according to the velocity of calca-
neous marker. Data were retrieved and stored for offline analysis by using Matlab (version
R2016a, The Mathworks, Natick, MA, USA). In this study, we again focus on the kinematic
data, which were calculated from the gait model constructed by the Codamotion ODIN anal-
ysis software. Raw kinematic data are rough and missing values exist in the dataset. There-
fore we smoothed the gait data by using the non-parametric smoothing technique (Zhang,
2013).
4.3.4 Statistical analysis
Based on the experimental structure introduced in Section 4.3.2, we apply the following
functional mixed-effects model
y(t) = β 0(t)+X1β
A(t)+X2β B(t)+X3β A∧B(t)+δ 0(t)+Z1δ L(t)+Z2δ S(t)+ ε (t),
(4.13)
to study the effects of AFO and speeds. Model equation (4.13) is an extension of
Equation (3.16) which is the model for the null experiment of the split-plot design
in Example 3.3. The main effects of AFO, speeds and their interaction are indi-










T and β A∧B(t) =
[β A∧B1 (t), . . . ,β
A∧B
9 (t)]
T , respectively. The random-effect terms δ L(t) and δ S(t) indicate
random effects for block factors sub jects and periods. All assumptions are the same as
those in Equation (3.16).
Functional F test for AFO
In order to test the effects of AFO under the hypotheses:
H0 : β A1 (t) = β
A
2 (t) = β
A
3 (t) for all t ∈ [0,1] versus H1 : ¬H0,
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approx.∼ F(d fAFO,d fres1),
where res1 indicates the residual in the periods-stratum. Moreover, the adjusted degrees of
freedom are calculated by:

















where λ1 ≥ λ2 ≥ ·· · ≥ 0 are the eigenvalues of the covariance operator that is associated
with the periods-stratum-based covariance function Λperiods(s, t).
Functional F tests for speeds and interaction
Similarly, in order to test the effects of speeds under the hypotheses:
H0 : β B1 (t) = β
B
2 (t) = β
B
3 (t) for all t ∈ [0,1] versus H1 : ¬H0,





approx.∼ F(d fspeeds,d fres2),
and in order to test the interaction under the hypotheses:
H0 : β A∧B1 (t) = · · ·= β A∧B9 (t) for all t ∈ [0,1] versus H1 : ¬H0,





approx.∼ F(d fAFO∧speeds,d fres2),
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where res2 indicates the residual in the E -stratum. Moreover, the adjusted degrees of free-
dom are calculated by:































where λ ∗1 ≥ λ ∗2 ≥ ·· · ≥ 0 are the eigenvalues of the covariance operator that is associated
with the E -stratum-based covariance function ΛE (s, t).
Contrast analysis for AFO
In the previous test for AFO, we considered whether there is a difference among walks bare-
foot, wearing unilateral AFO and wearing bilateral AFO. However, such a test is sometimes
not very informative, since one may be more interested in which treatment is different from
others (Hinkelmann and Kempthorne, 1994). Therefore, we also compare the barefoot walk-
ing with walks wearing AFO by applying the contrast analysis. A new Hasse diagram for
the treatment structure is shown in Figure 4.12. We can see that the treatment factor AFO
is partitioned into two parts: the comparison of walks barefoot with wearing AFO, which is
indicated by L1 : BF vs. AFO, and the comparison of walks wearing the unilateral AFO with
bilateral AFO, which is indicated by L2 : Unilateral AFO vs. Bilateral AFO. Moreover, the
interaction term is also split into two parts: L1∧ speeds and L2∧ speeds.
The block structure and the test for speeds remain the same in the contrast analysis,




In this example, we focus on the kinematics of the pelvis, hip joint, knee joint, ankle joint and
foot in the sagittal plane. Mean gait curves of all subjects for walks under different walking
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Figure 4.12: Hasse diagram for the treatment structure in the orthogonal contrast analysis
conditions are shown in Figure 4.13.
Clinical visual analysis of these plots was carried out, as might often be the case with
individual case analysis, albeit without a normal database plot and no visual indication of
variance. In summary, the plots are found to indicate little effect of walking speeds on pelvis
movement, but a possible differential effect of AFO conditions that varies with speed - with
the unilateral AFO altering pelvis movement more at higher speed, the bilateral more at
medium speed and little effect at low speed, possibly due to there being enough flexibility
in the musculoskeletal system to allow for compensation at low but not medium or high
speed. There is a general trend of range of motion being higher at faster speeds at the hip,
knee, ankle and foot but not pelvis. Little effect of AFO conditions is seen at the hip but an
interesting interaction between speed and AFO is seen lower down the kinetic chain. Specif-
ically, the effect of the AFO at fast speed is especially seen at the foot and ankle, whereas it
is more seen at the knee for medium speed and minimally seen at slow speed. Whether these
results would be clinically meaningful would depend on the patient’s presenting complaint
and other assessment findings - such as the effect of lower limb dysfunction on everyday life


























































































Figure 4.13: Mean gait curves of 9 healthy subjects during walking under different AFO conditions
at different walking speeds. UniAFO indicates the walk wearing the unilateral AFO and BiAFO
indicates the walk wearing the bilateral AFO.
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Functional F tests for all segments
For each of the pelvis, hip joint, knee joint, ankle joint and foot in the sagittal plane, we
constructed functional F tests for AFO, speeds and their interation. Results are summarised
in Table 4.5 and we can see that the walking speeds have statistically significant effects on
the hip joint, knee joint, ankle joint and foot at significance level α = 0.05. Moreover, no
significant difference has been found among the walks barefoot, wearing unilateral AFO and
bilateral AFO on all five segments at significance level α = 0.05. This may be caused by
the fact that we measured gait in healthy subjects instead of patients. Although AFO provide
sagittal plane support for abnormal gait, healthy subjects have sufficient joint flexion range
and control during walking due to normal coordination and musculature of the lower limbs
(Whittle, 2007). Therefore, any effects of AFO in gait on healthy subjects are minimal.
Finally, in the last column of the table, there is no significant effect of interaction on all
five segments. Since we only collected gait data of 9 subjects, the study may be somewhat
underpowered for the small sample size.
Table 4.5: Functional F tests for AFO, speeds and the interaction with * indicating significance at
0.05 significance level
F value (p.)
AFO speeds AFO∧ speeds
Pelvis 2.07 (0.15) 0.12 (0.91) 1.38 (0.25)
Hip 0.52 (0.69) 13.12 (< 0.01)∗ 0.49 (0.90)
Knee 0.87 (0.69) 17.95 (< 0.01)∗ 0.88 (0.58)
Ankle 2.06 (0.1) 9.67 (< 0.01)∗ 0.94 (0.52)
Foot 0.50 (0.77) 19.86 (< 0.01)∗ 0.94 (0.50)
Results from functional F tests are consistent with the clinical interpretation of Figure
4.13. At the pelvis there is a higher p value for the effect of the walking speeds and lower p
value for the effects of AFO and the interaction term. We found strong effects of the walking
speeds on joints below pelvis according to p values which are smaller than 0.01. Functional
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F tests reveal no effects of AFO and the interaction term for the movements of the hip, knee
joints and foot, whereas there is a weak effect of AFO on ankle joint movement with the p
value of functional F test equal to 0.1. Due to the important role that the ankle joint plays in
the assessment of AFO, we explore additional influences of AFO on the ankle rotation.
Additional analysis for the ankle joint
We explore further effects of AFO on the ankle joint by using the pointwise F tests and func-
tional F tests in the orthogonal contrast analysis. Figure 4.14 shows results of the pointwise
F tests of the hypotheses:
H0 : β A1 (t`) = β
A
2 (t`) = β
A
3 (t`) versus H1 : ¬H0,
for each of m equally spaced points t` ∈ [0,1], `= 1, . . . ,m in the gait cycle. The test statistic





We can see in Figure 4.14 that at the significance level α = 0.05, AFO affect the ankle
rotation during the transition from the stance to swing phase, which is from the 55% to 65%
of the gait cycle. This period is around the gait event of toe off (60% of gait cycle), when
the peak of ankle plantar flexion, that is the minimum of the ankle rotation, occurs for the
normal gait (Whittle, 2007).
Furthermore, from the ankle rotations that are shown in Figure 4.13 we can see that gait
curves during walking with unilateral and bilateral AFO are similar, however, in barefoot
gait, joint rotations for the ankle are more pronounced. In order to compare barefoot walking
with wearing AFO, we use the orthogonal contrast analysis with the treatment structure
shown in Figure 4.12. Results from the contrast analysis are summarised in Table 4.6. We
can see that functional F tests detect a significant difference between walks barefoot and
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Figure 4.14: Multiple pointwise F tests for effects of AFO on ankle joints at the significance level
α = 0.05. Grey dashed lines and the grey solid line are used to divide the whole gait cycles into
phases: initial contact, loading response, mid-stance, terminal stance, pre-swing, initial swing, mid-
swing and terminal swing phases (from left to right).
wearing AFO on the ankle joint, which is indicated by L1, whereas there is no difference
between walks wearing unilateral and bilateral AFO, which is indicated by L2. However,
neither interaction of contrasts and speeds is significant at 0.05 significance level.
4.3.6 Discussion
We consider a split-plot design to collect time-dense gait data from 9 healthy subjects. The
effects of AFO, speeds and their interaction on kinematics of the pelvis, hip joint, knee
joint, ankle joint and foot in the sagittal plane have been examined by functional F tests,
which detect significant effects of the walking speeds on segments lower than the pelvis
at 0.05 significance level and a weak effect of AFO on the ankle joint at 0.1 significance
level. Additional analysis is considered for rotations of the ankle joint. Pointwise F tests
detect significant effects of AFO on the ankle rotations around the gait event of toe off. The
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Table 4.6: ANOVA table for the orthogonal contrast analysis to compare the differences between
walks barefoot and wearing AFO on the ankle joint. * indicates significance at 0.05 significance
level.
Stratum Source dW F value (p.)
U U 1
sub jects sub jects 8
periods
L1 1 3.56 (0.03)∗




speeds 2 9.67 (< 0.01)∗
L1∧ speeds 2 1.49 (0.18)




orthogonal contrast analysis identifies the difference between walks wearing and not wearing
AFO, whereas no significant difference has been found between gait with the unilateral and
bilateral AFO.
This example illustrated how our proposed approach could be applied to analyse gait
curves observed from a complex experiment. However, the use of healthy subjects limits
the clinical utility of the present study, due to the differences between abnormal and normal
gait patterns. Thus this study will not provide clinical recommendation. Furthermore, there
is a limitation of this study with respect to the data processing procedure. Raw gait curves
which last 30 - 60 seconds were chopped by identifying gait events of initial contact and toe
off manually. Since there was no force plate on the treadmill, gait events were identified by
using data from markers of the heel and fifth metatarsal. The precision of data processing
is probably not as good as those in Section 4.2, where ground reaction force and data from
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markers were used to identify gait events.
Another concern is that gait data from the left and right lower limbs were averaged
for each participant during walking barefoot and with bilateral AFO, while only gait data
from the lower limb where the unilateral orthosis was placed were used during walking
with unilateral AFO. The statistical issue related to these calculations is that the variance of
averaged responses may vary from the variance of a single response. There are two possible
solutions to deal with this issue. One possibility is to analyse 15 instead of 9 gait curves
for each participant, that is, under each of three walking speeds there are two gait curves
from barefoot walking, one gait curve from walking with unilateral AFO and two gait curves
from walking with bilateral AFO. However, there is a non-uniform block factor in such
experimental structure, for which our proposed method is not applicable, and more details
can be found in Appendix C. Therefore, we consider another solution. We repeated the
analyses based on Model (4.13) but only used gait data from left lower limbs, where the
unilateral AFO was placed, under all three orthotic conditions. Results are similar to those
in Section 4.3.5, as shown in Appendix D.
4.4 Conclusions
Based on the experimental structure and functional mixed-effects model introduced in Chap-
ter 3, the functional F test has been developed to examine treatment effects in an orthogonal
design with functional responses. The test statistic is equal to the ratio of the integrated
treatment mean square and the corresponding integrated residual mean square. The null
distribution of such statistic is derived by the Welch-Satterthwaite χ2-approximation. To
summarise, under the null hypothesis the test statistic in a functional F test approximately
follows an F distribution with adjusted degrees of freedom, which can be calculated by using
eigenvalues of the estimated stratum-based covariance function.
Functional F tests are applied to examine the effects of AFO in gait studies of patients
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with cerebral palsy and healthy subjects in Section 4.2 and 4.3. In the first example, where
gait data were collected from patients with cerebral palsy, results from the functional F tests
are compared with pointwise F tests and F tests in the univariate ANOVA. Functional F tests
provide additional information to the traditional statistical tests. The analyses in Zhang et al.
(2017) where legs instead of patients are considered as independent observations, are useful
for clinical interpretation.
In the second example, where gait data were collected from healthy subjects in a split-
plot design, the effects of AFO, speeds and their interaction are examined in different strata.
The functional F tests detect significant effects of the walking speeds on four segments that
are lower than the pelvis and a weak effect of AFO on the ankle joint. In addition, the
pointwise F tests detect that significant effects of AFO on the ankle joint occur around the
transition from the stance phase to swing phase. Moreover, the orthogonal contrast analysis




The influence of gait analysis on
clinicians’ management of cerebral palsy:
a qualitative study
5.1 Introduction
The analysis of gait data in Chapter 4 illustrates how, by using the tests developed in this
thesis, statistical inferences about treatment effects can be drawn with confidence. In par-
ticular, gait patterns of patients with cerebral palsy were studied in Section 4.2. Although
similar to most statistical analyses in gait studies, the present statistical method has been
designed for the research purpose and targets a group or population of patients, it is possible
to apply functional ANOVA and functional F test proposed in previous chapters to clinical
gait analysis, such as assessing the effect of a therapy by using intra individual gait curves
or assessing the reliability of gait curves for individuals (Duhamel et al., 2006). However,
exploring the potential applications of novel statistical tools should be based on preliminary
research assessing stakeholder requirements and important to help researchers define the
required specifications for improved assessment tools, such as analytical approaches (Toro
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et al., 2003).
There is a long history of gait analysis, which dates back to Giovanni Alfonson Borelli
in the 1680s, but more accurate gait analysis with kinematics started in the late 19th century
(Richards, 2008, p. 51). It was not until the invention of the force plate (Elftman, 1939) that
kinetics was considered in gait analysis. Now, gait analysis usually refers to 3-dimensional
instrumented gait analysis (IGA) and is composed of kinematics, kinetics and electromyo-
graphy (EMG). Since 3-dimensional IGA requires advanced technology and equipment, it
is usually conducted in a gait laboratory. When clinicians do not have access to a full gait
laboratory, 2-dimensional gait analysis or visual (observational) gait analysis is considered.
Kirtley (2006, p. 299) provided a list of suggestions, including ten assessments and the cor-
responding technical requirements, such as the simple observational gait analysis which re-
quires a large area or the complex joint moments and powers analysis which requires a 3-
dimensional motion analysis system. Clinicians could choose appropriate gait analysis from
the list according to technology and time that they have.
Gait analysis in this thesis indicates instrumented gait analysis (or quantitative gait anal-
ysis). To avoid confusion, we use the term visual gait analysis to indicate visual inspection of
walking and the term video gait analysis to indicate visual assessment augmented with video
capture. Although IGA is supplemented by computer-based video capture as well, video gait
analysis can be simply conducted by cameras (e.g. phone or ipad) without data being col-
lected. Furthermore, according to Whittle (2007) clinical gait assessment is typically based
on history, physical examinations and special investigations. Figure 5.1 illustrates compo-
nents of clinical gait assessment, in which we particularly focus on 3-dimensional IGA.
The clinical assessment of patients focuses on the individual patient and the report from
a gait laboratory provides useful information for clinical decision making. However, the
clinical use of gait analysis is difficult, which has already been discussed in the literature.










Figure 5.1: Clinical gait assessment and gait analysis (IGA = instrumented gait analysis, 3-D = 3-
dimensional, 2-D = 2-dimensional)
analysis from a technical perspective. Toro et al. (2003) investigated clinical gait application
amongst UK physiotherapists and emphasised the importance of finding a balance between
the clinical utility and scientific merit for gait assessment tools.
Moreover, Toro et al. (2003) found physiotherapists’ need for gait analysis varied. For
instance, physiotherapists with degrees focused more on the reliability of gait analysis than
physiotherapists with diplomas. Hart et al. (1990) stated that physiotherapists’ roles affected
their professional attitudes and behaviors, such as the frequency of using more complex
procedures, like gait analysis or EMG, in routine clinical practice. Hart et al. (1990) dis-
tinguished whether physiotherapists involved in roles that allowed more professional judge-
ment, personal responsibility, decision making and self-direction in contrast to those whose
roles were more subordinate and structured. It is not clear whether the conclusions in Toro
et al. (2003) and Hart et al. (1990) can be generalised to other clinicians who are involved in
gait analysis rather than physiotherapists.
In this study we consider the following research question: the interaction between clin-
icians’ ability to utilise information from gait analysis and the requirements of the role that
116
they are in. To answer this question, we therefore explored clinical gait analysis by collecting
and analysing interview data from a group of clinicians who might be potential audiences
for and users of gait analysis which would be the context in which novel statistical tools
developed in this thesis are deployed. Qualitative information from a group of clinicians
with different clinical roles in the management of cerebral palsy has been gathered, since
the qualitative research has advantages in identifying processes, distinguishing factors that
lead to different perspectives and teasing out attitude, decisions and outcomes (Ritchie et al.,
2014).
5.2 Method
This qualitative study was approved by Queen Mary University of London Ethics of Re-
search Committee (REF QMREC2014/24/99) and written informed consent was obtained
from all participants. The ethical application form, Participant Information Sheet and In-
formed Consent are enclosed in Appendix E.
Data were collected using semi-structured interviews with participants recruited using
a purposive sampling strategy. Subjects were recruited by emails that were sent to possible
candidates in Southeastern and Eastern London. Participants were only included if they had
clinical experience of working with patients with cerebral palsy for a minimum of six months
and if their professional roles involved gait assessments.
The sampling framework is shown in Table 5.1. In total twelve clinicians were inter-
viewed, including five physiotherapists, four orthotists, two clinical scientists and one spe-
cialist orthopaedic surgeon. Moreover, there were seven males and five females and ten of
the participants had over 5 years of clinical experience. The sample covers clinicians who
are most frequently involved in the gait assessment for patients with cerebral palsy. Among
these clinicians, clinical scientists usually collect and analyse instrumented gait data in labo-
ratories and provide recommendations to other clinicians. Orthotists in the clinical team are
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Table 5.1: Classifications of 12 participants portrayed in relation to the purposive sampling frame
Clinical experience ≥ 5 years Clinical experience < 5 years
Male Female Male Female
Clinical scientists x y
Orthotists xxx x




responsible for orthotic management, such as designing measure, fitting orthoses and follow-
up (Hsu et al., 2008). Physiotherapists are considered to be the “mainstay” and “team leader”
in the rehabilitation management of the movement disorder for patients with cerebral palsy,
whose roles include assessing gross motor skills and functional mobility, performing ther-
apy and recommending equipment (Papavasiliou, 2009). Specialist orthopaedic surgeons
are usually involved in the treatment to improve musculoskeletal function and ambulation
for patients with cerebral palsy (Sharan, 2017). Moreover, as pointed out by Papavasiliou
(2009) that the treatment of the motor problems in patients with cerebral palsy used to be
solely orthopaedic surgeons’ responsibility, but now the treatment recommendations require
an interprofessional team (IPT) evaluation.
An initial topic guide for the interviews (see Table 5.2) was developed after discussions
within the research team and adjusted after a mock interview between the interviewer and
a clinician who met the inclusion criteria within the team. The mock interview was not
used in data analysis. Semi-structured face-to-face interviews, each of which lasted approx-
imately 60 minutes, were conducted either at the participants’ work place or at Queen Mary
University of London. All interviews were recorded using a smart phone, anonymised and
transcribed by the investigators and a transcription company.
The qualitative data from the interviews were analysed using the framework approach
described in Ritchie et al. (2014, p. 281) and the analysis process for this qualitative study is
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Table 5.2: Headings of interview topic guide
Background
Clinical experience (job title, description of current role, professional experience)
Patient group (diseases, age group)
Training about gait analysis
- Sample gait report showed as discussion prompt
Experience of using gait analysis
Gait assessment of patients with cerebral palsy in practice
Applications of 3-dimensional IGA
Collaboration with gait laboratory
Opinions of using gait analysis
Benefits
Barriers
illustrated in Figure 5.2.
All audio records were listened and all transcripts were read for the familiarisation of
the qualitative data. Then the initial framework with themes and sub-themes was constructed
based on the research objectives and data. Phrases, sentences and paragraphs of raw textual
data were located to particular themes or sub-themes (indexing) and then material for the
same theme or sub-theme was gathered together (sorting). The computer-assisted analysis
software (CAQDA) NVivo 11 was applied to construct the initial thematic framework and to
code the raw data under the themes and sub-themes.
Then, a framework matrix with each column for one theme or sub-theme and each row
for one participant to summarise the data was created by using Microsoft Excel. At this stage,
the language of participants was retained. The thematic framework was refined by reviewing
data extracts and categories were developed. A new framework matrix with updated themes
and subthemes was created in another Excel sheet. In this framework matrix, descriptive and














Figure 5.2: The process to analyse the qualitative data
which indicates the relation between phenomena with respect to the subgroups of the sample
was identified.
5.3 Results
The data yielded 21 sub-themes, grouped under 4 themes: Group characteristics and gait as-
sessment; Instrumented gait analysis; Gait report and Gait laboratory. The thematic frame-
work is shown in Table 5.3, where themes and sub-themes are listed in the first column
while main findings for each sub-theme are summarised in the second column along with
illustrative quotes in the last column. Under the theme of Group characteristics and gait as-
sessment, we summarised the patient group and the clinical gait assessments of patients with
cerebral palsy. Then we focused on Instrumented gait analysis, particularly 3-dimensional
IGA. Under this theme, we considered clinicians’ knowledge about IGA, clinical experience
of applying IGA to manage cerebral palsy and their opinions on IGA. Then, clincians’ feed-
back about the gait report and gait laboratory is summarised under the Gait report and Gait
laboratory themes.
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Table 5.3: Clinicians’ experience and views on gait analysis in the management of cerebral palsy
Themes Main findings Illustrative quotes
Group characteristics and gait assessment
Patient group
Diagnosis: cerebral palsy;
age: most patients are from
4 to 19 years old; GMFCS
levels: most patients are
GMFCS 1-3
“I would say predominately children with cerebral
palsy. I think they make about 75%-80% ” (A0525)
“Normally from about age four to ... we have nineteen,
probably the oldest” (C0427)
“[GMFCS levels] one to three...we have very very
ocassionally four, as you can understand gait analysis,








“The data collection takes long time; it’s about one and
a half to two hours” (A0525)
“The clinic I work at the moment, I got 15 minutes for
everything”; “you have to do everything quickly, you







walking and some other
activities; assess gait with
and without orthosis; assess
movement balance
“Watching them do walking with and without orthosis”
(P0518)
“Do they have reasonable sitting balance? When they
start crawling, are they symmetrical in movment or are
they dragging in one leg?” (V0413)
“we would do a couple of walks, up and down...we do






“Usually we get the information by either using vision
or using a camera” (M0608)
“We do clinical examination... video in two
orientations...then there are markers on them,
sometimes we don’t have kinetic data but we pretty
much always get kinematic data” (R0608)
Continued on next page
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Table 5.3 – Continued from previous page






treatments for the next year,
prescription of an orthosis
“I would advice what kind of footware” (C0427)
“We have developed to report about their walking and








developed with time and
experience
“Obviously we studied at university to begin” (M0608)
“I have done various gait analysis courses in the past”
(P0518)
“From colleagues, physiotherapist helped me” (R0329)









“I say more than 50% from orthopaedic surgeons”
(A0525)
“I referred three recently” (C0427)
“It’s a bit shame that as a practitioner in the community
we don’t have any access to that at all, I mean we don’t





and post operation analysis
“Generally people are seeking...some of these
orthopaedic surgeons are considering an intervention.
Rare...is about baseline measurement”(A0525)
“It tends to be ones that are very complicated” (M0608)
“So after we get the opinion from the gait lab, we do the
operation. It is essential and vital that the patient go
back, a year, 6 months, 2 years, to be analysed to see if
that is actually better or worse” (R0329)
Continued on next page
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Table 5.3 – Continued from previous page
Themes Main findings Illustrative quotes
Impact of IGA
Benefits patients who have
intervention; clinicians tend
to make better surgical
decisions and be more
confident
“Data sources analysis are accurate and reliable on
when you got clinicians looking at these together, they
make a better decision” (A0525)
“Highlight your reason behind doing something that





marker set; patient factor:
patients’ walking patterns
for gait analysis may be
different from their usual
gait
“There are some measures with poor marker set. We
may estimate about where their joint centres are”
(R0608)
“You ask a child to do gait analysis, for instance, they
will do their very best walk that doesn’t represent what





Visual gait analysis is
practical, easy, subjective,





“I do a video...slow it down and have a look at all the
stages of the gait as best as we can but it is not going to
be as good obviously as a proper gait analysis lab”
(D0330)
“You’ve actually got kinematics and it’s brilliant...you
are not lacking in any information, you’ve got
everything you can possible conceive, it is slow, it’s
exceptionally expensive and the data isn’t always
available immediately, you know, the analysis can take a







patients and equity of
selecting patients to gait
analysis
“I would definitely say money is an issue and I think
where money is an issue and you can’t refer lots of
children, the problem is deciding who you refer, so
inequity...how you make that fair and that’s a big
problem” (M0518)
“We try to communicate with the tertiary centre the best
we can...sometimes they don’t communicate back to us”
(V0413)
Continued on next page
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Report for IGA: patients’
history, findings of gait
analysis, recommendations,
graphs and data; report for
visual gait analysis:
descriptive information,
observed gait patterns and
weakness
“We will start words with history...and we write our
opinion which is backup with some evidence...and final
might be supported by recommendations”; “I think a
typical gait report have at least 18 graphs, often double
that or triple that” (R0608)
“We put all those assessment appointments together in
one report, so it’s a lot of information, we try to
summarise it, the report is just a summary”; “it was






never use in practice;
understand but never use in
practice, understand but not
use a lot; really familiar
“Never seen before, don’t know where to start” (C0427)
“I have never seen one in practice”; “ Once I have the
graphs, I am pretty sure that I can do the job of
interpreting” (C0331)
“Some of us have experience of looking at gait reports.
I imagine there are a lot of places where they would find
it quite difficult because they haven’t been shown as





Clinicians tend to follow a
gait report; impact
clinicians’ decision about
whether to have surgery or
not; not always being
followed by clinicians
“When everything is written down...it gives you a good
idea and I think they can lead you to the right
conclusion” (C0608)
“Generally if I get a report from them, I will kind of
follow.” (D0330)
“Sometimes we would recommend something and the
recommendations weren’t being followed, but that’s up
to the clinicians’ preference.” (R0608)
Patients’/parents’
feedback
Parents tend to follow the
recommendations
“Obviously parents get that as well and parents want to
follow because this comes from a big hospital” (D0330)
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and read; not routine in
clinical replacement; not
always matched up with
practicality; some clinicians
prefer descriptive information
“Sometimes the clinical decision...you can see the
clinical decision, all the theory behind that, but the
practicality in term of that child is not always married
up all the time” (D0330)
“I prefer things that are more descriptive” (C0427)
“They are intimidating because if you don’t come from
a mathematical background or you haven’t really looked




Know gait labs in this area;
don’t know gait lab
“In London itself, there are 3 clinical gait labs that will
serve cerebral palsy population” (A0525)
“In St. Thomas? ... St. Mary? ” (V0413)
Access to gait
labs
Have access; know gait labs
in this area but don’t have
access
“I started at a very well established gait lab”; “learn
about the surgical procedures that were available in
centain presentations in the laboratory” (C0608)
“Not the clinic I work ... not very accessible” (C0331)
Advantages of
gait labs
Great facility, good views of
gait; learn skills; centralise
information
“You can pick up skills there that’s transferable and you
know you can see it”; “I think that would be a valuable
tool for prosthetics, orthotics and physio rehab”; “I
think having a gait lab...you know it’s a great facility to
have (C0608)
“I think being able to do that just gives you really good
kind of lab show, anterior, posterior views as well”
(D0330)
“You don’t need a highly specialised gait lab in every
hospital. If having one or two, you can actually
centralise the data in one place” (R0329)
Continued on next page
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Disadvantages of
gait labs
Children are only seen for a
short time at a gait lab;
patients wait long time for
appointments; patients’
requests may be neglected
“I’m thinking that sometimes people can read too
deeply into that data and they don’t consider the
patient’s needs and requests” (A0525)
“It is hard...you only see them once a year or six
months” (D0330)
“I’ve got two children waiting for appointments for
about one and half years” (V0413)
5.3.1 Clinical gait assessment of cerebral palsy
For a patient with cerebral palsy, the clinical gait assessment is usually undertaken in a clinic,
community or gait laboratory. Common procedures usually start with the history taking and
physical examination, followed by visual gait analysis and, possibly, IGA. Clinicians may
select some or all of these procedures, according to the purpose of an assessment, the output
that they need, the time and staffing levels. However, due to the lack of a standard proto-
col, clinicians sometimes evaluate patients in their own ways. More details of clinical gait
assessment are displayed in Figure 5.3, where the gait assessment for a clinical appointment
usually contains the history taking, physical examinations and basic visual gait assessment.
At this stage, clinicians initially identify the gait pattern of a patient and based on these find-
ings a specific treatment may be prescribed. More details and subtle features of gait patterns
are usually examined in the community, where physiotherapists probably have more time and
space to observe gait visually and using a video record. In addition, video may be slowed
down and current gait may be compared with previous records. Some communities pro-
duce gait assessment reports for patients, which are used to make annual plans of treatment.
Copies of a report may be sent to the patient/parents and other clinicians that are involved
in the treatment of the patient. Physiotherapists’ opinions are appreciated by other clinicians
126
since it is likely that they have the most contact with patients over a period of months or
years.
...which we couldn’t able to know without the physio. Apparently, they really
know the kids well. (C0331, orthotist)
We run groups that children can go to as well as physios, it is an extra twenty-
six appointments a year if they go to; we do a sport club once every fortnight
plus they have hydrotherapy plus they can go to the gym plus they have one-to-
one [appointments]; so we can see children fifty...sixty appointments in a year.
(M0518, physiotherapist)
When a patient needs a more accurate gait assessment, he/she would be referred to a gait
laboratory, where usually procedures are carried out by clinical scientists or those who have
an equivalent role in IGA IPT. After the examination, most gait laboratories generate a gait
analysis report to send to the clinician who referred the patient. A typical gait analysis report
is composed of the history of the patient, IPT opinions based on evidence gathered from the
assessment, and recommendations. Graphs are used as evidence in the IGA and data are
sometimes provided in the appendix of the report. Once the leading clinician receives the
report, the treatment plan may be altered and therapeutic decisions adjusted accordingly.
An aspect which initially complicated the data analysis was the realisation that some
professionals may carry out multiple roles, and that the interaction of role and profession
differs according to the care delivery structure and skill-mix at any given facility. For exam-
ple, some laboratories have physiotherapists with high levels of technical ability who carry
out detailed gait analysis while that role may be fulfilled by a clinical scientist in another lab-
oratory. This was a major learning point for me in performing this study, and an illustration
of exactly why the qualitative study was needed, for instance, for the researcher to under-
stand the context in which innovations will be applied, who by and where in the process their




e.g. history taking, consent
Physical examinations
e.g. range of joint, muscle strength
Visual gait analysis (most patients)
e.g. observing gait pattern, abnormality,
balance, walking with and without orthosis
Prescription of AFO
e.g. compliance issues;
observing crawling, sitting and playing
Video gait analysis (some patients)
e.g. phone/ipad/digital camera;
comparing to the baseline assessment
Assessment report
& plan for the
next year
IGA (a few patients)
e.g. 3-dimensional motion capture system









Figure 5.3: Processes of clinical gait assessment in the management of cerebral palsy
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5.3.2 Instrumented gait analysis
Although most clinicians learn about IGA through either modules at university or short train-
ing courses, IGA is not a routine part of management of cerebral palsy for some clinicians.
IGA is commonly considered for a complicated patient or a difficult therapeutic decision
and some clinicians use IGA as a tool to assess whether the treatment is likely to improve
a patient’s condition. Moreover, the decision of patient referral to IGA is mainly made by
orthopaedic surgeons, although sometimes senior orthotists or physiotherapists also refer pa-
tients to a gait laboratory or may initiate the referral process, whereas junior clinicians are
seldom involved in IGA. However, the situation of referrals can vary, depending on the local
health care resource and the experience of relevant clinical teams. In some clinical settings,
even senior physiotherapists have little experience with IGA.
It is commonly agreed by interviewed clinicians that IGA is useful, particularly for a
patient with cerebral palsy undergoing orthopaedic surgery. Based on the evidence from
IGA, clinicians tend to be more confident and make better clinical decisions. Although
IGA is more reliable, accurate and informative, some clinicians still prefer visual gait anal-
ysis, which is quicker and easier to conduct and less challenging to interpret albeit far more
subjective. Most interviewees pointed out that visual gait analysis was “good enough”, con-
sidering the high cost of IGA. In addition, clinical observation is currently supplemented
by digital camera and computer-based video systems, which allow clinicians to slow videos
down and identify more subtle abnormalities of gait patterns.
However, visual gait analysis is subjective and the quality of assessment largely depends
on the experience and knowledge of clinicians. Because of complexity of cerebral palsy,
heterogeneity of this population and variety of manifestations, the surgical decision-making
can be very difficult in patients with cerebral palsy.
Cerebral palsy is a very heterogeneous group so what works for one kid will not
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necessarily work for another. (R0608, clinical scientist)
Hence, when the treatment of cerebral palsy is prescribed without objective gait analysis,
sub-optimal decisions of intervention are thought to be quite common (Whittle, 2007).
While most clinicians stated that the quality of IGA is better than visual gait analysis and
video gait analysis, some other clinicians raised doubts about the reliability of the technique.
One clinical scientist mentioned that the poor marker setting occasionally occurred during
data collection, which affected the quality of 3-dimensional gait data. Another concern about
IGA that was commonly mentioned by interviewees is whether the gait pattern of a patient in
the gait laboratory can represent the patient’s real walking pattern. The way a patient walks
in a clinical room is sometimes referred to as a “catwalk” by clinicians. In order to eliminate
or reduce the “catwalk” effect, clinicians use games to distract patients’ attention and make
the environment of the clinical room more friendly. However, interviewees have different
opinions on whether “catwalk” affects IGA or not, as will be discussed later.
Apart from these concerns, most interviewed clinicians considered the high cost as the
biggest barrier which prevented them from referring patients to IGA. It is difficult for a
gait laboratory to reduce cost since gait analysis is consuming with respect to time, human
resource and equipment. One gait laboratory may only have two appointments, each of
which needs the engagement of several technicians and clinical scientists. Furthermore, the
numbers of patients with cerebral palsy are increasing, while there are only “3 [gait labs] in
London and 14 labs in total in the UK” (A0525, clinical scientist). Thus, it is not surprising
that there are patients “waiting for appointments for about one and half years” (V0413,
physiotherapist). Although there is a lack of resource for gait analysis, some equipment is
idle in communities or hospitals, such as force plates. Besides money and knowledge, the
criterion of referrals is another barrier of IGA. Inequity in selecting patients for IGA results
from a lack of clear referral criteria.
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5.3.3 Gait report
As can be seen in Figure 5.3, the report from a gait laboratory is the outcome of IGA. In
addition, some communities also produce reports for clinical gait assessment based on visual
gait analysis. Both reports contain information about the patient, such as history and findings
of gait assessments. However, the report of clinical gait assessment from a community is
usually more descriptive, while the report of IGA is technical and systematic, including gait
graphs and data generated by computers.
Generally, it requires moderate knowledge and some experience with IGA to under-
stand gait reports generated from a gait laboratory. Thus, the report of IGA can be difficult
for many junior clinicians, who may have had fewer opportunities to attend training courses
or to access gait analysis outputs. During the interview, participants were shown a sample
gait report. Clinical scientists and orthopaedic surgeons were more familiar with the re-
port than orthotists and physiotherapists. In particular, some clinicians had seen a report of
IGA in training courses but never used one in practice. Some clinicians mentioned that they
would follow recommendations if they received a gait report, while others pointed out that
recommendations in the report did not always agree with the clinical decision, which should
be made by combining all information together, rather than simply following a gait analysis
report. Moreover, some interviewed clinicians argued that it was difficult to extract informa-
tion from gait graphs and they preferred a more descriptive report. Meanwhile, the IGA IPT
has realised the extent of this issue and are exploring better ways to communicate IGA find-
ings. However, there is no simple solution to this problem so far. Furthermore, generating
a report of IGA is time-consuming. It may take six weeks or even longer for clinicians to




We first consider accessibility under the Gait laboratory theme. It is obvious that clinical
scientists have access to gait laboratories. Since orthopaedic surgeons usually refer patients
to gait laboratories, they have more access than many other clinicians. For some senior
orthotists or physiotherapists, they may not have direct access to a gait laboratory but can
refer patients through other clinicians who have a closer collaboration with gait laborato-
ries. However, some other orthotists or physiotherapists, particularly those in more isolated
communities, would rarely have contact with a gait laboratory. Clinicians who have a better
perception about the gait laboratory tend to have a more positive view of IGA. For instance,
some interviewees thought a frequent attendance of a gait laboratory would help clinicians
to maintain knowledge.
From a clinical perspective, the gait laboratory also has some disadvantages. For ex-
ample, it was mentioned that clinical scientists usually saw a patient once every six months
or year in the gait laboratory. In order to better identify the gait pattern of a patient, it was
argued that physiotherapists involved in usual care, who were usually more familiar with
the patient, should be involved more in gait analysis. Some interviewed clinicians thought
the communication between clinical scientists and physiotherapists was insufficient. Fur-
thermore, some clinicians were concerned that too much concentration on the quantitative
analysis might result in relative neglect of patients’ needs and requests. It was also mentioned
that IGA had sometimes been considered as a marketing tool to attract patients.
We summarise the linkage between the need and knowledge of IGA and the access to
gait laboratories with respect to the classification of clinicians in Figure 5.4, where the dis-
tinction made between clinicians by profession is based on the most common role that these
professions undertake, while recognising that there is much variety. The need for IGA is
judged based on clinical roles that participants described during the interviews, although we
concluded that the data saturation may not have been reached by detecting 7 out of 12 empty
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User/potential user of IGA
Sufficient knowledge Insufficient knowledge
No clinical use of IGA






































- degree in science
- working in gait labs




- training courses, books
& peer review
- frequently refer patients











- never have access to a
gait lab / see a report
- design orthoses
- make plan for a patient
Junior physios
- never have access to
a gait lab / see a report
Figure 5.4: A linkage from the qualitative analysis between the need and knowledge of IGA and the
access to gait laboratories for clinicians. In this case, the roles are represented by professions although
it is clear that roles vary independent of profession.
panels in Figure 5.4. Clinicians are considered as potential users if the clinical assessment
and treatment may be improved by IGA. To assess whether a clinician has sufficient knowl-
edge about IGA or not, we consider training and understanding of the sample gait analysis
report. Therefore, we conclude that clinical scientists have sufficient knowledge about IGA,
since they usually have the scientific background to understand biomechanics. As mentioned
before, orthopaedic surgeons frequently refer patients to a gait laboratory and they have high
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needs for IGA to make surgical decisions. Sometimes orthopaedic surgeons need clinical sci-
entists’ or specialist physiotherapists’ help to fully understand IGA or a gait report. Whether
an orthotist or physiotherapist has access to a gait laboratory largely depends on the commu-
nity and his/her position in the community. According to the information we have gathered,
IGA is useful for orthotists to design an orthosis and for senior physiotherapists to make bet-
ter plans for a patient. Thus more training or more routine use of IGA should be considered
for them. Finally, it may not be necessary for junior physiotherapists to engage in IGA, since
their clinical role requires basic gait assessment and they may need more clinical experience
before they can benefit from using IGA.
5.4 Extension of results
In this thesis, I explored how the proposed statistical method could be utilised to improve the
analyses of 3-dimensional gait data and the goal of a further step is to explore whether the
gait analysis with the novel statistical analysis can potentially benefit patients with cerebral
palsy. This may be achieved through clinicians who have direct contact with patients or en-
gage in the IPT meeting for the management of cerebral palsy. In an IPT, which may consist
of paediatricians, neurologists, orthopaedic surgeons, physiotherapists, occupational thera-
pists, etc., the gait assessment is usually conducted by physiotherapists, orthotists, specialist
orthopaedic surgeons and clinical scientists. I consulted an academic clinician within the re-
search team, who helped to identify clinical roles that may be improved by IGA as follows:
(1) assessment, (2) monitoring, (3) surgical decision-making, (4) liaison, (5) recommenda-
tion, (6) orthotic prescription and (7) therapy prescription. Roles of clinicians with different
job titles are summarised in Table 5.4. Among all these roles, gait analysis with the proposed
statistical method is possibly applied to improve recommendation, orthotic prescription and
therapy prescription. For instance, functional F test may be applied to assess the effect of
an orthosis or a therapy on intra individual gait curves. Therefore, physiotherapists, ortho-
tists, orthopaedic surgeons and clinical scientists may benefit from the proposed statistical
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Table 5.4: Roles of interviewed clinicians with respect to reasons for gait analysis
Job title Reasons for gait analysis within clinical roles
Physiotherapists
assessment, monitoring, liaison, recommendation, therapy
prescription, orthotic prescription
Orthotists assessment, recommendation, orthotic prescription
Specialist orthopaedic
surgeons
assessment, monitoring, surgical decision-making, liaison,
recommendation, therapy prescription
Clinical scientists assessment, liaison, recommendation
analysis, albeit the person responsible for writing analysis code may be the primary direct
beneficiary. It may be that equipment manufacturers, who often provide proprietary gait
analysis software, would also benefit from novel statistical approaches.
5.5 Discussion
We have collected and analysed qualitative data from 12 clinicians who had experience of
gait assessment in patients with cerebral palsy. According to results of the qualitative data
analysis, we concluded that clinicians with different roles had different levels of knowledge
and experience on IGA, which had influences on the clinical applications of IGA.
Some findings agree with the conclusions of previous studies. Our results support that
IGA has been underutilised to some extent (Simon, 2004) and the main usage of IGA is still
to identify key problems for orthopaedic surgery (Franki et al., 2014). Although the need for
orthopaedic surgery probably motivated the development of IGA in the early stages, it now
prevents wider applications of IGA to some extent. Some clinicians consider IGA more for
multi-level surgeries and neglect other potential uses.
Furthermore, according to both the literature and our study, the cost of IGA is an im-
portant barrier. It is impossible for communities and hospitals to refer more patients to a gait
laboratory when the budget is limited. Therefore, it may be more efficient for clinicians to
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better utilise existing facilities. For instance, 2-dimensional gait data, collected by simpler
equipment, may provide sufficient information for some patients. However, basic knowledge
of the data collection and analysis is required, which is also a big barrier. The knowledge
of gait analysis can be obtained from training courses and is also developed with clinical
experience. We found that senior clinicians are more knowledgeable about gait analysis than
junior clinicians, which contradicts the statement in Franki et al. (2014), which mentioned
that younger therapists might be more familiar with 3-dimensional IGA than older therapists
due to engagement in courses about gait analysis in recent postgraduate paediatric rehabili-
tation programs without evidence of the statement or further exploration.
Apart from these conclusions, two controversial issues were articulated during the inter-
views. One of the issues is whether gait analysis should be considered as a second opinion.
Clinical scientists, or those who have an equivalent role in IGA IPT, apparently have differ-
ent views from clinicians outside the immediate IGA IPT, who usually consider gait analysis
to be a second opinion. Clinical scientists argued that other clinicians should trust inter-
pretations more in the gait report. Another issue is the “catwalk” effect. Some clinicians
considered this a serious limitation of gait analysis, while some other clinicians argued that
gait analysis was to examine patients’ ability and hence it was not a big problem if patients
walked well in a gait laboratory. These two questions could be explored more in future study.
There are some limitations to this study. We cover a wide range of clinicians, including
physiotherapists, orthotists, orthopaedic surgeons and clinical scientists in this study. Thus,
the sample size of each group is not yet large enough to reach data saturation. For example,
we only interviewed one orthopaedic surgeon and two clinical scientists. Some other clini-
cians in an IPT, such as paediatricians, may also be involved in the clinical gait assessment or
IGA. However, we excluded paediatricians, since they may not consider the gait assessment
as frequently as clinicians in the sample framework. During the initial analysis of this data,
a focus was put on professions with the underlying assumption that this reflected role. How-
ever, there is more diversity in the roles-profession interaction than that assumption suggests.
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Sampling was by profession, gender and experience level so analysis initially followed suit.
It is important to recognise that the characteristic professional role will not be consistent
between different IPT who deliver IGA.
The qualitative study will be continued and interviews will be conducted with more
orthopaedic surgeons and clinical scientists. Based on the analysis results summarised in
this chapter, the topic guide will be amended. Although it is usually difficult for statistical
analysis to benefit patients directly, this study has explored the potential and it is possible for
statistical analysis to improve patient outcome if communication with clinicians, in particu-
lar, clinical scientists and specialist orthopaedic surgeons, is enhanced.
There are indications that clinical scientists or those in an equivalent IGA IPT role,
are the key, but not only, audiences to reach with novel statistical techniques such as those
developed in this thesis. Amendment of testing protocols from applications of design of ex-
periments principles in conjunction with FDA may also be worthwhile exploring further to
enhance the decision-making return from limited data sets and maximisation of gait labora-
tory efficiency. When considered alongside the potential changes in interpretation indicated
in Chapter 4 and my published paper (Zhang et al., 2017), there is every possibility that





In this thesis, functional ANOVA has been developed to analyse data from complex designs
where the responses are curves and the proposed methods have been applied to time-dense
data depicting segmental rotations during gait.
6.1.1 Methodology development
The methodological research in the thesis generalises the classical univariate analysis of
experiments which use an orthogonal design to functional data. In a classical orthogonal
design, the block structure with random-effect block factors contributes to the covariance
between responses, and thus affects the hypothesis test which is used to compare “mean
responses” determined by the treatment structure. Similarly, in a complex design with func-
tional responses, the primary goal is to test treatment effects which are now however func-
tions and functional responses are correlated due to the block structure. To analyse such
data, techniques for orthogonal designs, hypothesis tests for functional data and correlated
functional data are combined. Figure 6.1 summarises the methodology development based
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Figure 6.1: Summary of methodology development (blue). DoE = design of experiment, FDA =
functional data analysis, Research Question: how to analyse data from complex experiments when
responses are curves. In Section 3.1: orthogonal designs, Section 3.2: functional mixed-effects model
and Section 4.1: functional F tests, white boxes show inputs, and blue boxes show outputs of the
relevant sections. As indicated by arrows, outputs of previous sections are inputs to the following
sections.
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tional mixed-effects model used to study correlated functional data, and functional F tests
serve as the main building blocks.
The methodology development starts with orthogonal designs in Section 3.1, where
methods in Bailey (2008) are applied to study the block and treatment structures. Then
in Section 3.2, with design matrices determined by the experimental structure, functional
responses are considered in a functional mixed-effects model which is similar to the model
proposed by Morris and Carroll (2006). As illustrated in Figure 6.1, assumptions of the func-
tional mixed-effects model are based on Chapter 2. More specifically, in addition to mod-
elling functional responses by using jointly measurable mean-square continuous stochastic
processes that are also random elements in L2(T ,B(T ), µ) space, all random-effect terms
and error terms are independent Gaussian processes. Under these assumptions, the func-
tional sum of squares for a factor can be represented as a sum of squared independent Gaus-
sian processes {R1(t) : t ∈ T}, {R2(t) : t ∈ T}, . . . , {Rd(t) : t ∈ T} with d being the degrees
of freedom for the factor, as introduced in Section 3.3 and 3.4. Sums of squares are derived
by using orthogonal projections. In Chapter 3, the ANOVA table summarises the analyses
of block and treatment structures, sums of squares and expected mean squares. In particular,
the expected mean square for a factor is derived from the mean and covariance function,
which is called the stratum-based covariance function, of independent Gaussian processes
{R1(t) : t ∈ T}, {R2(t) : t ∈ T}, . . . , {Rd(t) : t ∈ T}, as used to represent the functional sum
of squares.
Functional F tests for treatment comparisons which were previously proposed for com-
pletely randomised designs (Shen and Faraway, 2004; Zhang, 2013) are developed for gen-
eral orthogonal designs in Section 4.1. The general idea is similar to F tests for a classical
orthogonal designs, where a treatment factor is tested in the relevant stratum by using an F
ratio of treatment and residual sums of squares divided by degrees of freedom (Bailey, 2008).
Since functional sums of squares are random functions themselves, the F statistic of a func-
tional F test is calculated as a ratio of integrals of functional sums of squares (integrated sums
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of squares) divided by appropriate degrees of freedom. By applying Theorem 2.4 in Chapter
2, it was shown that an integrated sum of squares is a random variable whose distribution is
the same as that of a linear combination of independent χ2 random variables. The distribu-
tion of such a linear combination of independent χ2 random variables can be approximated
by using the Welch-Satterthwaite approximation. Consequently, under the null hypothesis of
no treatment effect the F statistic of the functional F test is approximately F distributed with
degrees of freedom that are calculated from the stratum-based covariance function.
The methods in Chapter 3 and the functional F test in Section 4.1 can be used to analyse
complex experimental designs with functional responses in situations where previously pro-
posed tests (Cuevas et al., 2004; Cuesta-Albertos and Febrero-Bande, 2010; Zhang, 2013)
cannot be used.
6.1.2 Applications
The proposed functional ANOVA was applied to gait data from patients with cerebral palsy
and healthy subjects in Sections 4.2 and 4.3 respectively, as summarised in Figure 6.2. More-
over, results of a qualitative study to investigate the clinical application of gait analysis were
reported in Chapter 5.
In Section 4.2, the effects of AFO on 3-dimensional kinematics of patients with cerebral
palsy were examined. Gait curves which represent joint rotations during walking barefoot
and with AFO were compared by functional F tests, in addition to pointwise F tests and uni-
variate F tests which used maximal and minimal angles as responses. Functional F tests were
also used to examine gait data in the stance phase and swing phase, respectively. Although
results from functional F tests, pointwise F tests and univariate F tests are not identical,
these approaches complement each other to provide a better statistical interpretation of gait
analysis.
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analysis in the man-
agment of cerebral
palsy (Chapter 5)
Applications for the research purpose Clinical application
Figure 6.2: Applications of functional ANOVA to gait analysis
collect gait data from healthy subjects. Three different orthosis conditions and three different
speeds were considered as two treatment factors, which were tested in different strata by
functional F tests. Significant effects of speed were detected on the rotations of hip, knee and
ankle joints and foot, whilst the ankle rotations were only weakly affected by the application
of AFO. Furthermore, an orthogonal contrast analysis with the ankle rotations as responses
was considered to split the treatment factor AFO into two parts: wearing or not wearing AFO
and wearing unilateral or bilateral AFO. Although walks were not significantly different
between wearing unilateral AFO around one leg and wearing bilateral AFO around both
legs, a significant difference between barefoot walking and walks with AFO was found by
the functional F test.
In Chapter 5, the clinical application of gait analysis was explored by using qualitative
data that were collected from semi-structured interviews conducted with clinical scientists,
a specialist orthopaedic surgeon, physiotherapists and orthotists. Instrumented gait analysis
has not played a prominent role in clinical routine due to barriers, such as the high cost of
gait analysis and the limited budget for patients being referred to instrumented gait analysis.
Although some clinicians have insufficient knowledge of gait analysis, which is likely due
to limited access to gait laboratories, benefits of instrumented gait analysis to patients are
recognised by clinicians. Furthermore, instrumented gait analysis is currently conducted in
gait laboratories by clinical scientists, who usually have a strong scientific background and a
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good understanding of statistics. Advanced statistical techniques, such as functional ANOVA
proposed in the current study, are likely to be implemented via clinical scientists to improve
gait analysis.
6.2 Conclusions
In this thesis, the ANOVA has been generalised to functional data and the functional F test for
completely randomised designs has been generalised to general orthogonal designs. These
approaches have been applied to gait data and these applications were further explored in a
qualitative study with scientists and clinicians.
The complexity of correlated functional data generated from a complex experiment
arises from the correlation existing both between and within functional responses. While the
correlation between functions is determined by the experimental structure, individual func-
tions are explored using FDA (Hsing and Eubank, 2015), where each function is viewed as a
sample path of a stochastic process and under specific conditions (detailed in Chapter 2) also
realisation of a random element. The two types of correlation were considered separately in
this thesis. First, the correlation between responses was handled as in a classical orthogonal
design with univariate responses, where the vector space of observations can be decomposed
into a direct sum of orthogonal subspaces and sums of squares were derived by using the
orthogonal projections of responses onto relevant subspaces. Likewise, in designs with func-
tional responses, sums of squares were also calculated by using orthogonal projections, but
they are functions. According to the singular value decomposition of the orthogonal projec-
tion matrix, each functional sum of squares was expressed as a sum of squared independent
stochastic processes. Furthermore, to analyse these stochastic processes individually, a use-
ful tool is the Karhunen-Loève expansion which represents a stochastic process by a series
of uncorrelated random variables and orthonormal eigenfunctions of the relevant covariance
operator.
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The distributions of functional sums of squares are complicated, but under assump-
tions expressed in the functional mixed-effects model integrating a functional sum of squares
gives a random variable, whose approximate distribution can be derived. Accordingly, the
integrated sums of squares were used in the development of functional F tests.
The functional ANOVA with the associated functional F tests was applied to gait anal-
ysis. I mainly considered two aspects of such data, that are, the structure of experiments
where gait data were collected and to compare entire gait curves collected under different
conditions. Hasse diagrams and skeleton ANOVA tables were useful to illustrate the ex-
perimental structures regardless of whether the gait comparison was considered for selected
characteristics of gait curves, such as maximal rotations, or the entire gait curves. Functional
F tests were applied to compare gait curves. Although it is difficult to conclude whether the
functional F test is preferable to the traditional univariate F test since conclusions may vary
depending on the specific research interest, the functional F tests have provided additional
results to the univariate statistical tests in this study. Furthermore, functional ANOVA can be
applied flexibly in gait analysis. According to specific research questions, functional F tests
can be applied to either the whole gait cycle or specific gait phases.
The qualitative study in Chapter 5 indicates that better application of gait analysis in the
management of cerebral palsy can be achieved by strengthening communication between
gait laboratories and physiotherapists and orthotists. Moreover, it is possible for the ad-
vanced statistical methods proposed in this study, which have been shown to be useful for
gait comparison, to be applied to clinical gait assessment and possibly to improve patient
outcome, with particular relevance to groups of patients.
6.3 Future work
Both the theoretical and practical results presented in this thesis can be extended for the
future study.
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Throughout this study, the methodology has been developed for orthogonal designs
where all block factors are uniform. However, as mentioned in Section 4.3, to analyse gait
data from both legs during walking barefoot and with bilateral AFO and gait data from the
single leg during walking with unilateral AFO, block factors of the experiment are non-
uniform. Thus, the experimental structure does not fulfil conditions of orthogonal design
summarised in Chapter 3 and the present method is not applicable. In the classical univariate
analysis of experiments, a mixed model can be used to analyse experiments which are non-
orthogonal or lack of uniformity (Brien and Bailey, 2006). Piepho et al. (2003) provided
the guidance of applying mixed models to analyse randomised experiments, which can be
extended to experiments where functional data are collected. Therefore, it is possible to
develop a functional mixed-effect model approach to analyse more general experiments with
functional responses. However, the present method for the covariance function estimation
can not be used in the functional mixed-effects model for non-orthogonal designs and the
Bayesian approach proposed by Morris and Carroll (2006) may be applied for the parameter
estimation.
The applications of functional ANOVA to gait analysis can be extended from two as-
pects. First, although functional ANOVA was only applied to gait analysis of a group of
patients in Chapter 4, this method may also be used to analyse gait patterns of individual
patients. One possibility, as mentioned in Chapter 5, is for the reliability analysis. To assess
the intrasubject reliability of gait analysis, statistical tools of intra-class correlation coeffi-
cient (ICC) and coefficient of multiple correlation (CMC) are commonly used (Kadaba et al.,
1989; Steinwender et al., 2000; Maynard et al., 2003; McGinley et al., 2009). However, the
within-curve correlation has yet taken into account for the reliability analysis. It is possible
to use the proposed functional ANOVA to improve the reliability analysis of gait curves.
Second, the present functional ANOVA and functional F test were applied to 1-dimensional
gait data and gait data in the coronal, sagittal and horizontal planes were analysed separately
in Section 4.2. Therefore, I have considered to extend functional ANOVA and functional F
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test to multi-dimensional data in the future work. This may be achieved either by applying
the Karhunen-Loève expansion for multiple stochastic processes (Balakrishnan, 1960; Kelly
and Root, 1960) or by combining the proposed methods with statistical parametric mapping
(Pataky et al., 2013).
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Zhang et al. (2017)
The published paper Testing Gait with Ankle-Foot Orthoses in Children with Cerebral Palsy
by Using Functional Mixed-Effects Analysis of Variance
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Testing Gait with Ankle-Foot 
Orthoses in Children with Cerebral 
Palsy by Using Functional Mixed-
Effects Analysis of Variance
Bairu Zhang1, Richard Twycross-Lewis2, Heiko Großmann3 & Dylan Morrissey2,4
Existing statistical methods extract insufficient information from 3-dimensional gait data, rendering 
clinical interpretation of impaired movement patterns sub-optimal. We propose an alternative approach 
based on functional data analysis that may be worthy of exploration. We apply this to gait data analysis 
using repeated-measurements data from children with cerebral palsy who had been prescribed fixed 
ankle-foot orthoses as an example. We analyze entire gait curves by means of a new functional F test 
with comparison to multiple pointwise F tests and also to the traditional method - univariate repeated-
measurements analysis of variance of joint angle minima and maxima. The new test maintains the 
nominal significance level and can be adapted to test hypotheses for specific phases of the gait cycle. 
The main findings indicate that ankle-foot orthoses exert significant effects on coronal and sagittal 
plane ankle rotation; and both sagittal and horizontal plane foot rotation. The functional F test 
provided further information for the stance and swing phases. Differences between the results of the 
different statistical approaches are discussed, concluding that the novel method has potential utility 
and is worthy of validation through larger scale patient and clinician engagement to determine whether 
it is preferable to the traditional approach.
Functional data analysis1–4 (FDA) is an umbrella term for statistical methods that are applicable when the meas-
ured responses are not numbers but functions of time, space or some other domain. When the domain is time, 
responses are typically represented by curves. Data of this kind arise commonly, for instance, in laboratory set-
tings where measurements can be taken almost continuously at densely spaced time points. Human gait research 
is an important clinical and experimental setting where functional data are collected to guide intervention deci-
sions. In this field, the curves of interest often depict the rotation of a joint during a stride, across a standardized 
time interval between one foot contact to the next by the same foot.
Early work on FDA for human gait data developed methods for estimating mean and covariance functions5 
and for calculating prediction regions for entire curves6, and applied these to samples of curves that were collected 
on healthy children. Other researchers1, 7–9 used the data5, 6 to illustrate various types of FDA techniques, includ-
ing functional principal components analysis, functional canonical correlation analysis and functional regression. 
Data from an experiment10 where volunteers were stepping in place have served as an example to demonstrate the 
use of functional analysis of variance10–12 (ANOVA) for investigating the effects of different orthosis conditions 
on moments at the knee. Despite these examples and the fact that the FDA approach appears to be particularly 
useful for studying gait curves13, only a few gait studies14–16 have used FDA to investigate questions of genuine 
clinical interest. Moreover, only relatively basic FDA methods1 seem to have been used in clinical applications. 
Possible reasons for this are that more advanced FDA techniques are less widely known and theoretically and 
computationally more complex.
This paper proposes a new method of functional mixed-effects ANOVA for studying gait data of children with 
cerebral palsy, who have abnormal gait patterns leading to fixed ankle-foot orthoses prescription. We analyze 
gait curves that were collected from a repeated-measurements design in which barefoot walking preceded walks 
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with ankle-foot orthoses. The use of ankle-foot orthoses to control movements of patients with cerebral palsy has 
a long history17 and the main purpose of an ankle-foot orthosis is to enhance function by improving motion of 
lower limb body segments during the gait cycle18. Ambulatory function, such as walking ability, balance and sta-
bility, is qualitatively assessed by physiotherapists. Quantitative gait analysis occurs in specialist centres when crit-
ical decisions, such as orthosis prescription or operative intervention consideration, are being made and require 
interpretation of complex data sets. In this study we investigate the effects of ankle-foot orthoses on quantitatively 
measured lower limb 3-dimensional joint rotation during gait, also known as the study of kinematics19.
The effects of ankle-foot orthoses on kinematic gait data of patients with cerebral palsy have previously been 
examined in several studies20–26. However, in these studies gait curves were not treated as analyzable entities and 
kinematic parameters reflecting particular characteristics of the curves were used as the response variable in a 
univariate analysis. Examples of such response parameters include joint rotation values at specific gait events such 
as heel strike or toe-off23–25, maximal or minimal rotation during the gait cycle or midpoints of identifiable gait 
phases such as stance21, 23–25, and mean and range of rotation for the whole or parts of the gait cycle26. Integrating 
findings that are based on different kinds of parameters is not always straightforward. Moreover, considering the 
effects of ankle-foot orthoses throughout the gait cycle has been recommended to ensure important findings are 
not neglected27 and the FDA approach would meet this criterion.
In what follows, we present a novel application of FDA to entire gait curves from children with cerebral palsy 
which allows us to test the effect of ankle-foot orthoses while accounting for the repeated-measurements nature 
of the data. Repeated measurements are modeled by a special case of a functional mixed-effects model28, although 
we avoid the complex computations that are involved when the model is fitted in a Bayesian manner28–31. We 
propose a new functional F test which integrates information over the whole gait cycle and compare the results 
of its application with those of multiple pointwise F tests that are performed at equally spaced time points in the 
gait cycle. In addition, the functional F test is also compared with the traditional univariate F test in a one-way 
repeated-measurements ANOVA32, which is commonly used in gait studies22–24.
The main purpose of this study is to explore suitable FDA techniques that can be applied to complex data 
by developing a better tool for testing functional data collected from repeated-measurements experiments, in 
which multiple curves are collected from each subject. In the specific case considered here, the functional F test 
is applied to examine the global effects of ankle-foot orthoses at a group level to guide clinicians. This application 
will also facilitate utilization of functional F tests in other domains with similar data.
Tests for functional mixed-effects models have only been considered in a few reports33, 34. The new test gen-
eralizes previous work on functional F tests3, 35 for independent curves, to repeated measurements in which 
the curves are correlated. The proposed functional F test preserves the nominal significance level, whereas the 
multiple testing approach based on pointwise tests is subject to a potentially large familywise error probability. 
Moreover, the functional test can be easily modified to test the effect of the orthoses for different well-defined 
phases of the gait cycle36, 37, thereby enabling the researcher to tailor the analysis to specific research questions. 
We report corresponding results for the stance and swing phases respectively.
Method
Data collection. The present study was performed in accordance with the ethical guidelines of the 
Declaration of Helsinki and was approved by East London NHS Research Ethics Committee (Ethics REF 09/
H0806/56). Written informed assent and consent, from all children and parents respectively, was collected.
Time-dense gait data were collected from fourteen children (mean age 12.3 ± 2.88years, mean height 
1.44 ± 0.15 m, mean weight 39.57 ± 11.78 kg) at the Human Performance Laboratory, Queen Mary University of 
London. All recruited children had been diagnosed with spastic cerebral palsy and prescribed fixed ankle-foot 
orthoses (see Fig. 1) for a minimum of six months. Children were initially assessed by a paediatric orthopaedic 
consultant and only included if they were independently ambulatory and considered to have sufficient muscular 
endurance for gait measurements. This study was designed after the clinical assessment had taken place, and 
hence we were not approved to access the medical records of patients nor was the direct clinical interpretation 
our primary focus. Nonetheless, we consulted the physiotherapist who accompanied patients for data collection 
and she confirmed that most recruited children were classified to the Gross Motor Function Classification System 
(GMFCS)38 level 2 and 3 and few children were classified at level 4.
Data collection followed the commonly used protocol20, 25, 39 whereby each patient was instructed to per-
form a series of walks both barefoot and wearing ankle-foot orthoses placed within shoes. Order was not ran-
domised and barefoot walking was conducted first20, 25. While walking with ankle-foot orthoses, patients were 
shod, owing to the importance of footwear in the orthotic prescription that ankle-foot orthoses modify kine-
matics of segments only with appropriate footwear27. More specifically, anthropometric information, including 
pelvic width and depth and bilateral knee and ankle width, was obtained. Then kinetic data were collected while 
the patient walked barefoot at a self selected pace along a 6-meter walkway with two ground embedded force 
plates (Type 9281B Multicomponent Force Plate, Kistler Instruments Ltd, Winterthur, Switzerland) that meas-
ured 3-dimensional ground reaction force. After 10–20 walks, patients then repeated walking tests whilst wearing 
their ankle-foot orthoses over the same force plates.
Kinematic data were collected using four 3D Cartesian Optoelectric Dynamics Anthropometer systems 
(Charnwood Dynamics, Rotheley, Leicestershire, UK) that were placed at distances of 2–3 meters from the force 
plates, oblique to the centre of the laboratory in order to create a data collection volume. A modified Helen 
Hayes marker set protocol19 was used, whereby active infra-red markers were placed bilaterally on the anterior 
sacro-iliac spine (ASIS); posterior sacro-iliac spine (PSIS); lateral epicondyle of the knee and the lateral malleolus; 
lateral aspect of the calcaneous and the 5th metatarsal. Instrumented marker wand sets were also placed superior 
and inferior to the knees. Joint centers for the pelvis, hips, knees and ankles were calculated using Codamotion 
Analysis software (version 6.76.2-CX1/mpx30, Charnwood Dynamics, Rotheley, Leicestershire, UK) based on 
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subject specific anthropometric data. Gait events in each trial, from initial contact to toe off to the following ini-
tial contact, were marked using the vertical component of ground reaction force and velocity of the calcaneous 
marker for both the ipsilateral and contralateral limbs. Standardized gait graphs were then extracted by analyzing 
the kinematic data offline using Matlab (version 2009a, The Mathworks, Natick, MA, USA).
Statistical model. For testing the effect of ankle-foot orthoses, we consider the functional mixed-effects 
ANOVA model
µ α β γ ε= + + + + ∈ =y t t t t t t t( ) ( ) ( ) ( ) ( ) ( ), [0, 1], (1)ijk i j i k ijk( ) 
where µ(t) is the overall mean function; αi(t) for i = 1, …, 14 is the i th subject-specific random effect; βj(i)(t) for 
j = 1, 2 is the random effect for the j th lower limb nested within the i th subject; γ k(t) for k = 1, 2 is the fixed effect 
for wearing (or respectively not wearing) ankle-foot orthoses and εijk(t) is the error term. The total number of 
response curves y t( )ijk  is n = 56. The random effect terms αi(t), β t( )j i( )  and the error term ε t( )ijk  are assumed to be 
independent zero-mean Gaussian processes, each with its own covariance function. More specifically, by using 
the generic notation θGP(0, ) for a zero-mean Gaussian process with covariance function θ θ≡ s t( , ), it is 
assumed that α θ∼t GP( ) (0, )i a , β θ∼t GP( ) (0, )j i b( )  and ε θ∼t GP( ) (0, )ijk e  for = …i 1, , 14, j = 1, 2 and k = 1, 2, 
all independent.
Since for all curves yijk(t), µ(t), αi(t), βj(i)(t), γk(t) and εijk(t) we use the same time points of the gait cycle, at 
every fixed time point ∈t   equation (1) can be regarded as the model equation of a univariate 
repeated-measurements ANOVA model. Hence, at every fixed t, pointwise sums of squares SS(t) and expected 
mean squares EMS(t) for the different terms in the model can be calculated as for the univariate model. However, 
Figure 1. Bespoke, fixed ankle-foot orthoses for children with cerebral palsy.
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when t traverses the whole gait cycle, both SS(t) and EMS(t) become functions of t, which we refer to as the func-
tional sum of squares and the functional expected mean squares respectively.
The pointwise ANOVA table for fixed ∈t   is presented in Table 1 in which the various means are given by
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The breakdown of the total sum of squares in the table into sums of squares for the different sources of varia-
tion is valid at every point t and, hence, also for the functional sums of squares. Equation (1) together with the 
usual constraint γ γ+ =t t( ) ( ) 01 2  for all ∈t  implies that for every t the expected mean squares for the sums of 
squares = ∑ −.. ...SS t y t y t( ) { ( ) ( )}AFO i j k k, ,
2 and = ∑ − − +. .. ...SS t y t y t y t y t( ) { ( ) ( ) ( ) ( )}residual i j k ijk ij k, ,
2 come out as 
shown in Table 1.
The ANOVA in Table 1 provides the basis for testing if ankle-foot orthoses have an effect. Both types of test, 
the pointwise F tests and the functional F test, use the sums of squares in the table. However, whereas the point-
wise F tests also use the degrees of freedom in the table in order to assess the significance of the results, this is not 
the case for the functional F test.
Pointwise F tests. The effect of ankle-foot orthoses may be tested by adopting a multiple testing approach. 
This amounts to performing a series of separate F tests of
γ γ γ γ= ≠
   
H t t H t t: ( ) ( ) versus : ( ) ( ) (3)0 1 2 1 1 2
at each of m equally spaced points ∈

t  , = … m1, , , in the gait cycle. We refer to these tests as pointwise F 
tests. The test statistic of the pointwise F test at 






F t SS t
SS t






The resulting values 

F t( ) are plotted against 

t  for = … m1, ,  and can be assessed for statistical significance at 
every time point.
Pointwise F tests do not take the functional nature of the data into account. Moreover, this approach faces the 
usual problems surrounding multiple testing40. In particular, the familywise error probability can be much higher 
than the nominal significance level of the individual tests as will be illustrated later.
Functional F test. As an alternative to multiple testing with pointwise F tests we propose a new functional F 
test. The functional F test summarizes information across the whole gait cycle by integrating the functional sums of 
squares SSAFO(t) and SSresidual(t) over   and uses the ratio of the integrals as the test statistic. Contrary to the point-
wise F tests, the hypotheses tested by the functional F test refer to the whole curves γ t( )k , k = 1, 2, in Equation (1). 
More specifically, the testing problem is given by
 γ γ γ γ= ∈ ≠ ∈ .H t t t H t t t: ( ) ( ) for all versus : ( ) ( ) for some (5)0 1 2 1 1 2
The null hypothesis H0 states that the two functions γ1(t) and γ2(t) are equal, whereas the alternative hypothesis 












Under the null hypothesis H0 of no effect, by using arguments similar to the case of independent curves3, 35, 
the distributions of the integrated sums of squares in (6) can be shown to be mixtures of independent chi square 
distributions34. More precisely, under H0 it holds that
Degrees of freedom SS(t) EMS(t)






subjects 13 ∑ ∑ ∑ −= = = .. ...{ }y t y t( ) ( )i j k i114 12 12
2
limbs 14 ∑ ∑ ∑ −= = = . ..{ }y t y t( ) ( )i j k ij i114 12 12
2
AFO 1 ∑ ∑ ∑ −= = = .. ...{ }y t y t( ) ( )i j k k114 12 12
2
γ θ× × ∑ += t t t14 2 ( ) ( , )k k e1
2 2
residual 27 by subtraction θ t t( , )e






Table 1. Pointwise ANOVA table with “AFO” indicating the factor for wearing/not wearing ankle-foot orthoses.
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In (7), the means ε... t( ), ε . t( )ij  and ε.. t( )k  of the random errors ε t( )ijk  in equation (1) are computed like the corre-
sponding means of the responses in (2). Moreover, λ ≥( )r r 1 is the sequence of eigenvalues of the covariance oper-
ator4 associated with the covariance function θ s t( , )e  and λ χ∑ =
∞
r r1 1
2 denotes the distribution of a mixture of 




2  represents a similar mixture of independent random variables, each having a chi square distribution 
with 27 degrees of freedom.
The sums of squares SS t( )AFO  and SS t( )residual  are independent for every ∈t  and it can be shown that this 
property carries over to the integrals ∫ SS t dt( )AFO  and ∫ SS t dt( )residual . The same arguments
35 as in the deriva-
tion of the functional F test for the functional linear fixed-effects-only model then show that under H0 the distri-
bution of   in (6) can be approximated by an F distribution as follows
∼
. F df df( , ), (8)
approx
AFO residual





























The practical application of the functional F test requires the approximation of the integrals in the numerator 
and denominator of   and also the approximate computation of the eigenvalues that are needed for calculating 
the degrees of freedom dfAFO and dfresidual. To this end, we adapt the approaches
3, 35 that have been used for the case 
of independent curves and which essentially amount to turning the functional problem into a multivariate 
problem.
More precisely, the interval  = [0, 1] representing the gait cycle is discretized by superimposing a fine grid of 
m equally spaced points 

t , = … m1, , , where = < < … < < =−t t t t0 1m m1 2 1 . The integral ∫ SS t dt( )AFO  is 
then approximated by the sum ∑ = SS t( )
m
AFO1 . Likewise, as an approximation to the integral ∫ SS t dt( )residual  the 
sum ∑ = SS t( )
m
residual1  is used. In the calculation of dfAFO and dfresidual , the sequence λ ≥( )r r 1 of eigenvalues is 
replaced by m estimated eigenvalues λ λ…ˆ ˆ, , m1  which are obtained as the eigenvalues of the ×m m matrix 
Σ θ=

ˆ ˆ t t( ( , ))e q , where for = … q m, 1, ,
θ =
∑ − − + − − +
.. .. ... . .. ...

   ˆ t t y t y t y t y t y t y t y t y t( , ) { ( ) ( ) ( ) ( )}{ ( ) ( ) ( ) ( )}
27 (9)e q
i j k ijk ij k ijk q ij q k q q, ,
is an estimate of θ

t t( , )e q . Hence, in practice the degrees of freedom of the approximate null distribution of   are 




































. Simple linear algebra shows, that the sums in the 
numerator and denominator of dfAFO and dfresidual can be calculated respectively as the sum of the diagonal ele-
ments of the matrix Σ̂ and the sum of the diagonal elements of Σ = ΣΣˆ ˆ ˆ2 . In what follows, we use the value 
m = 201 which corresponds to splitting the gait cycle into two hundred intervals of equal width.
An attractive feature of the functional F test is that the integration over   can be replaced with integration 
over subsets of  . This opens up the possibility to test the effect of ankle-foot orthoses in specific phases of the gait 
cycle as will be illustrated below.
Results
Observational results. Figures 2 and 3 show descriptive information for 3-dimensional segmental rotations 
for the lower body in 14 children with cerebral palsy during both barefoot and shod with ankle-foot orthoses 
walking respectively. In the figures, gait data are presented as a standardized gait report where columns show 
the pelvis, hip joint, knee joint, ankle joint and foot and rows are the coronal plane, sagittal plane and horizontal 
plane of rotation respectively. Differences can be seen in the overall kinematics with the application of the ankle-
foot orthoses: there is an overall increase in maximal dorsiflexion from 10° to 15° of the ankle joint in the sagittal 
plane in gait with ankle-foot orthoses, however the magnitude of joint rotation does not change. Differences in 
the mean curves shown in Figs 2 and 3 are not immediately apparent.
Pointwise F tests. We first examined effects of ankle-foot orthoses on different segmental rotations by using 
the multiple pointwise F tests shown in Fig. 4. All individual tests used a signifiance level of α = 0.05. In the figure, 
ankle-foot orthoses have significant effects when the value of the F statistic exceeds the critical value, which is the 
same at all time points ( = ..F (1, 27) 4 210 05 ).
Effects of ankle-foot orthoses are more evident in the sagittal plane than in the coronal and horizontal planes. 
Generally, ankle-foot orthoses affect ankle joint and foot more than other segments, although there are also effects 
on the pelvis and the knee and hip joints. More specifically, in certain parts of the gait cycle ankle-foot orthoses 
have significant effects on pelvis in the coronal and horizontal planes; hip joint in the sagittal plane; knee joint in 
the sagittal and horizontal planes; ankle joint in the coronal and sagittal planes and foot in all three planes (Fig. 4). 
Moreover, for different segments significant effects of ankle-foot orthoses occur at different time points along 
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the gait cycle conferring a temporal effect. Referring to Figs 2 and 3, we can see that for the pelvis in the coronal 
and horizontal planes, hip joint and ankle joint in the sagittal plane, ankle-foot orthoses have significant effects 
roughly around the minimal angles, whereas for the knee in the sagittal plane effects of ankle-foot orthoses tend 
to occur near maximal angles.
The nominal significance level of every individual pointwise F test is α = 0.05. However, in every panel of 
Fig. 4 many of those tests are performed on a grid of m = 201 points. Consequently, the familywise error rate40, 
which is the probability of at least one incorrect rejection of the null hypothesis, of this multiple testing procedure 
can be much higher than the nominal significance level if one looks at an interval rather than a single time point. 
For instance, ankle-foot orthoses affect hip rotation in the sagittal plane between 40–63% of the gait cycle (see 
Fig. 4). This section of the gait cycle contains approximately 46 grid points. At each of these points the probabil-
ity of a type 1 error is 0.05. However, an approximate calculation under the simplifying (and surely not correct) 
assumption that the tests are independent shows that the familywise error rate for the 46 tests in the 40–63% 
interval of the gait cycle can be as high as 1 − (1 − 0.05)46 ≈ 0.90. This example illustrates that results of pointwise 
tests need to be interpreted with care, since the “significance” of the results may be overstated. Pointwise tests may 
suggest the presence of effects where there are actually none.
Functional F test and univariate repeated-measurements analysis. The first part of Table 2 pre-
sents the functional F test for each of the segments and planes in Fig. 4. The values of the test statistic   and the 
corresponding p-values are shown in the second column of the table and the degrees of freedom of the approxi-
mate null distribution of   in the first column. The degrees of freedom are reported in the form df df( , )AFO residual  
and depend on the actual data. At a significance level of α = .0 05, the functional F tests detect significant effects 
of ankle-foot orthoses on knee rotation in the sagittal plane = . = .p( 3 07, 0 02) ; ankle rotation in the coronal 
= . = .p( 5 95, 0 02)  and sagittal  = . < .p( 8 25, 0 01)  planes and foot rotation in the sagittal 
= . = .p( 3 61, 0 03)  and horizontal planes = . = .p( 5 27, 0 01) . These results indicate that ankle-foot orthoses 
have significant effects on the overall motion of these segments over the whole gait cycle.
The second part of Table 2 reports results of a univariate repeated-measurements ANOVA with minimal angle 
as the response variable in the third column of the table, and corresponding results for maximal angle as the 
response variable in the fourth column. The F values in the table are computed as for the pointwise F test with the 
Figure 2. Barefoot walking in 14 children with cerebral palsy. Data are normalized to percentage (%) of the gait 
cycle, which starts from heel strike. Grey areas represent intervals [mean − s.d., mean + s.d.] at every point.
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only modification that all squared differences that enter the sums of squares in Table 1 are calculated at the time 
points of the gait cycle at which the minimum (respectively maximum) angles occur. These time points do vary 
within and between patients. For both response variables, the null distribution of the test statistic is an F(1, 27) 
distribution and thus the same as for the pointwise F test.
With significance level α = 0.05 as before, the F tests from the univariate repeated-measurements ANOVA 
detect effects of ankle-foot orthoses on minimal ankle angle in the coronal and sagittal planes, which agrees with 
the results of the functional F test, and, contrary to the functional F test, an effect on minimal hip angle in the 
sagittal plane. For maximal angle, the F tests from the univariate repeated-measurements ANOVA find significant 
effects on foot in the sagittal and horizontal planes as well as on ankle in the sagittal plane and these results are 
again in agreement with those of the functional F tests. Moreover, the repeated-measurements F test detects an 
effect on maximal knee angle in the horizontal plane where the corresponding functional F test for the whole gait 
cycle is not significant. Contrary to the functional F test, the repeated-measurements F tests with both minimal 
and maximal angle as the response do not detect a significant effect of ankle-foot orthoses on the knee joint in 
the sagittal plane.
Functional F test for gait phases. Besides the whole gait cycle, we are also interested in effects of 
ankle-foot orthoses during the stance and swing phases separately. In normal gait, the stance phase accounts for 
the first 60% of the gait cycle and is defined as the period when the foot is in contact with the ground. Conversely, 
the swing phase accounts for approximately 40% of the gait cycle and is defined as the period when the foot does 
not have contact with the ground and is propelled forward ready for the next step41. This can also be seen in Fig. 4, 
where the stance and swing phases are divided by grey solid lines.
In order to perform functional F tests for these phases, it is only necessary to replace the interval  = [0,1] in 
the formula for   in (6) with appropriate subintervals. For the stance phase we replace   with = .[0, 0 6]1  and 
for the swing phase we use  = .(0 6, 1]2 . Previous comments regarding the discretization of the interval   apply 
analogously to 1  and 2 . For simplicity, we continue to denote the resulting test statistics by  .
Results for the stance and gait phases are shown in Table 3. For significance level α = 0.05, ankle-foot orthoses 
have significant effects during the stance phase on hip rotation in the sagittal plane, ankle rotation in the coronal 
Figure 3. Gait with ankle-foot orthoses in 14 children with cerebral palsy. Data are normalized to percentage 
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and sagittal planes, as well as on foot rotation in all three planes. In the swing phase, there are significant effects 
on knee rotation in the sagittal and horizontal planes, ankle rotation in the sagittal plane and foot rotation in the 
horizontal plane.
Comparison of statistical results. As can be seen from Fig. 4 and Table 2, all three methods of analysis 
consistently detect statistically significant effects of ankle-foot orthoses on the ankle joint in the coronal and 
Figure 4. Multiple pointwise F tests at significance level α = 0.05 for effects of ankle-foot orthoses on segmental 
rotations. Grey dashed and solid lines are used to divide the whole gait cycle into phases: initial contact, loading 
response, mid-stance, terminal stance, pre-swing, initial swing, mid-swing and terminal swing (from left to 
right).
Functional F test Univariate R-M ANOVA (F value (p.))
degrees of freedom   value (p.) minimal angle maximal angle
Pelvis
coronal (2.12, 57.30) 1.89(0.16) 0.02(0.88) 0.16(0.69)
sagittal (1.41, 38.02) 0.38(0.61) 0.39(0.54) 0.02(0.89)
horizontal (1.77, 47.83) 1.61(0.21) 0.58(0.07) 0.51(0.48)
Hip
coronal (2.77, 74.76) 0.98(0.40) 0.02(0.88) 0.24(0.63)
sagittal (2.37, 63.99) 2.53(0.08) 7.21(0.01)* 0.48(0.49)
horizontal (1.29, 34.98) 0.18(0.74) 0.08(0.77) 0.09(0.77)
Knee
coronal (1.66, 44.82) 1.04(0.35) 1.06(0.31) 1.00(0.33)
sagittal (3.53, 95.36) 3.07(0.02)* 2.08(0.16) 3.42(0.08)
horizontal (1.38, 37.39) 2.60(0.10) 0.26(0.61) 8.02(<0.01)*
Ankle
coronal (1.12, 30.23) 5.95(0.02)* 6.85(0.01)* 2.71(0.11)
sagittal (1.42, 38.44) 8.25(<0.01)* 21.1(<0.01)* 4.15(0.05)*
horizontal (1.21, 32.72) 0.87(0.38) 2.45(0.13) 0.95(0.34)
Foot
coronal (1.15, 30.96) 3.10(0.08) 2.85(0.10) 0.68(0.42)
sagittal (2.29, 61.80) 3.61(0.03)* 2.49(0.12) 21.5(<0.01)*
horizontal (1.72, 46.39) 5.27(0.01)* 3.05(0.09) 7.09(0.01)*
Table 2. Functional F tests for the whole gait cycle and F tests from univariate repeated-measurements (R-M) 
ANOVA for minimal and maximal angles. Degrees of freedom for the univariate R-M ANOVA are (1, 27) for all 
segments and *indicates significance at the 0.05 significance level.
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sagittal planes and on the foot in the sagittal and horizontal planes. With the repeated-measurements ANOVA 
the former effects are significant when one looks at minimal angles (for maximal angles significance occurs only 
in the sagittal plane), while the latter effects are only significant for maximum angles. These results are also cor-
roborated by the functional F tests for the stance and swing phases in Table 3.
In addition to these unequivocal findings, the pointwise F tests detect significant results for certain parts of 
the gait cycle where the functional F test for the whole gait cycle and the repeated-measurements ANOVA do not 
show significant effects. In particular, only the pointwise F tests find effects on the pelvis in the coronal and hori-
zontal planes and on the foot in the coronal plane. For the pelvis in the horizontal plane, the significant pointwise 
F tests at around 80% of the gait cycle may be regarded as a false rejection due to the increased familywise error 
probability of the multiple testing approach or may be attributed to potential effects on minimal angles during the 
swing phase, although the corresponding p-values in Tables 2 and 3 are equal to p = 0.07 in both cases. Similarly, 
for the pelvis in the coronal plane, the visual impression from Fig. 4 is supported by the p-value of p = 0.07 of 
the corresponding functional F test for the swing phase (Table 3). A similar statement applies to the foot in the 
coronal plane and the corresponding functional F test for the stance phase.
By looking at the sagittal plane for the hip and knee joints in Fig. 4 one can see that the pointwise F tests detect 
significant effects just before and just after the point of transition from the stance to the swing phase. For the hip 
joint, these effects are also identified by the repeated-measurements ANOVA on minimal angles (Table 2) and 
the functional F test for the stance phase (Table 3). For the knee, the effect in the sagittal plane is detected by the 
functional F test for the swing phase and also by the functional F test for the whole gait cycle, although changes 
of the angles at around 20% may also have contributed to the latter result. For the knee joint in the horizontal 
plane the pointwise F tests signal some effect toward the end of the gait cycle, and this effect is also detected by 
the repeated-measurements ANOVA on maximal angles (Table 2) and the functional F test for the swing phase 
(Table 3). Overall, the results from the different approaches seem to inform each other.
Discussion
We collected time-dense gait data for 28 lower limbs in 14 children with cerebral palsy, typically hemiplegia, in a 
repeated-measurements design where every individual was measured while walking both barefoot and shod with 
ankle-foot orthoses. Gait curves depicting rotations for lower limb segments in different planes were modeled by 
a functional mixed-effects model. The data were analyzed by using three different methods: multiple testing with 
pointwise F tests performed at separate points of a fine grid, a new functional F test which uses entire gait curves, 
and univariate repeated-measurements ANOVA, which was performed separately on minimum and maximum 
rotations. The results obtained by these approaches had many fundamental commonalities, but there were also 
some differences which warrant further explanation. In what follows, we first interpret the results and discuss 
some limitations of the approach and the current study. We then discuss some methodological issues and exten-
sions of the proposed functional F test to more complicated experimental designs.
Biomechanical effects of ankle-foot orthoses, including direct effects to the limb segments contained within 
the orthoses and indirect effects to the rest of the body, mainly shank kinematics27, are consistent with the results 
from functional F tests. Moreover, ankle-foot orthoses can be seen to have a greater effect on sagittal joint rota-
tions as compared to coronal and horizontal planes. This is likely due to the design of bespoke ankle-foot orthoses 
for patients with cerebral palsy (Fig. 1). The rigid L shaped ankle-foot orthoses with an upright portion behind the 
calf greatly limits plantar flexion and dorsiflexion of the ankle and foot. Moreover, the distal anterior ankle strap 
and the foot plate have a joint fixing effect which is associated with decreased orthogonal plane rotations. Thus, 
effects on ankle rotation in the coronal plane and foot rotation in the horizontal plane, which were detected by the 
functional F tests, are possibly due to some compensatory mechanism.
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There are some limitations to this study. One of the issues we debated at length was that of using each leg of 
each subject as an independent observation. The literature is divided on this issue42, however we felt this was 
justified because the between limb correlation was low, subjects typically had hemiplegia and therefore moved 
asymmetrically and the purpose of the study was to compare different models rather than make definitive clinical 
or applied scientific recommendations. Moreover, depending on severity of spasticity, children with cerebral palsy 
are prone to fatigue after short bouts of low to medium intensity activity43. In order to minimize patient fatigue 
and to maximize data output, patients were asked to walk barefoot and without walking aids, if possible, before 
walking with ankle-foot orthoses. As a consequence, the effect of wearing/not wearing ankle-foot orthoses is con-
founded with a potential effect of the walking condition testing order. To strengthen the study design, the order 
of walking conditions should be randomized to eliminate or reduce potential systematic biases44–47, if possible.
Another limitation of this study is that we only studied a sample of 14 patients. While this is considered 
small for many statistical applications, it is not uncommon for studies of this type, in this patient population, 
to have similar sample sizes48. This issue has been commonly addressed in gait study reports investigating cer-
ebral palsy49–51 and is mainly due to the restricted inclusion criteria necessary for enrolment, necessary due to 
the extremely heterogeneous nature of movement impairments in people with cerebral palsy51. Other studies 
to assess the effects of ankle-foot orthoses in patients with cerebral palsy22–24, 52–61 have used sample sizes that 
are similar to that of the current study, and our approach and findings are therefore justifiable and comparable 
respectively. Furthermore, in the present study we examined retrospective data but have not explored clinical 
patient information (i.e. gait type, severity of spasticity). Our focus was to quantitatively validate the functional 
mixed-effects ANOVA as a means of determining differences in gait between barefoot walking versus the use of 
ankle-foot orthoses in a relatively homogeneous but clinically relevant patient group. Therefore, at this stage we 
have excluded detailed clinical discussion.
We now give possible reasons why there are sometimes discrepancies between the statistical results. 
Differences between the functional F tests and the repeated-measurements ANOVA for minimal and, respec-
tively, maximal angles may arise from the fact that the former tests consider the whole gait cycle, whereas the 
repeated-measurements ANOVA provides a univariate analysis in which the values of the response variable cor-
respond to the most extreme observations that occur throughout the gait cycle. These extremes, e.g. minimal 
angles, occur at points of the gait cycle that vary within and between patients. For example, for the hip joint in the 
sagittal plane we examined the data and found that for most patients and most walks minimal angles occurred 
well before the end of the stance phase, but there were also two patients for whom minimal angles occurred dur-
ing the swing phase.
Regarding differences in the results between the pointwise F tests and the repeated-measurements ANOVA, 
we note that with respect to comparing the conditions of wearing and not wearing ankle-foot orthoses every sin-
gle pointwise F test as well as the repeated-measurements F test is mathematically equivalent to a standard paired 
t test62 on 28 pairs of observations, where every pair consists of observations for a single leg that is observed with 
and without orthoses. If, for example, the minimal angle always occurred at the same time point, then the F test of 
the repeated-measurements ANOVA on minimal angles would coincide with the pointwise F test at this particu-
lar point in time. However, since minimal angles occur at different time points, results from both tests will be dif-
ferent. Put differently, although all pointwise F tests and the repeated-measurements F test use the same formula 
for calculating the test statistic, the tests apply this formula to different data with a difference in results of findings.
Differences in the results of pointwise F tests and functional F tests may be caused by the fact that the familywise 
error probability63 for the whole or parts of the gait cycle of the multiple testing approach exceeds the nominal 
significance level of the individual pointwise tests. One way to alleviate this problem would be to apply a Bonferroni 
correction to the nominal significance level of the pointwise F tests. If this were to be done for the whole gait cycle, 
each of those tests would need to use a significance level that was equal to, for instance, 0.05 divided by the number 
of tests. In the current study, we used 201 separate pointwise tests and hence, in Fig. 4, the critical value represented 
by  t he  l ine  wou ld  ne e d  to  b e  adjus te d  f rom = ..F (1, 27) 4 210 05  to  = ..F (1, 27) 17 780 05/201 64  
with the consequence that only the effects in the sagittal plane on the ankle joint and foot would remain signifi-
cant. Thus the Bonferroni correction would be overly conservative which is one reason why it is not recom-
mended in the FDA literature65. Notwithstanding, some adjustment of the nominal significance level that is used 
for the pointwise F tests would seem to be appropriate in order to avoid too many type I errors. Although not 
designed for this purpose, the functional F tests appear to achieve this goal by integrating information over the 
whole or parts of the gait cycle while maintaining the pre-specified significance level.
We believe that the different types of analysis considered in this paper should be regarded as being comple-
mentary rather than competing. Although we would not recommend pointwise testing alone, we nevertheless 
find this approach useful since from results like those in Fig. 4 one can see very easily where in the gait cycle 
effects occur. However, we think of pointwise tests as more of an exploratory rather than a confirmatory tool, so 
when reporting an effect as being significant we would prefer to base this decision on a functional F test. With 
respect to detecting effects in specific parts of the gait cycle very little seems to be lost by this approach, since, as 
shown in Table 3, the functional F test can be flexibly applied to different phases of the gait cycle. Analyzing spe-
cific gait features, like the minimum and maximum angles in the current study, may also be useful but we believe 
this type of analysis should be motivated by biomechanical considerations or specific clinical questions and not 
be used for the reason that it sidesteps the difficult analysis of entire curves.
The functional mixed-effects ANOVA model in this paper and the method for obtaining functional F tests 
can be generalized to more complex experimental designs in which, like in the present study, there is correlation 
between entire curves. More precisely, the methodology can be applied to experiments with an orthogonal block 
structure66–68 and to general orthogonal designs47. These designs include, for example, randomized complete 
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block designs, row-column and split-plot designs. Current treatments3 of testing problems for functional ANOVA 
models appear to only consider experiments whose layout is given by a completely randomized design.
Further validation, including structured clinician and patient engagement, is warranted to clarify whether our 
interpretation of the individually or collectively applied statistical analyses in this paper adds value in practice. 
Ultimately, the litmus test of whether this novel statistical analysis is truly useful would be improved patient out-
comes, a subject for future work.
Data Availability. The datasets generated and analysed during the current study are available from the cor-
responding author on reasonable request.
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Bairu Zhang (School of Mathematical Sciences, QMUL): 
bairu.zhang@qmul.ac.uk Tel: +44 7547807008 
Dr Richard Twycross-Lewis (Sports & Exercise Medicine, School of 
Engineering and Material Science, QMUL): r.twycross-lewis@qmul.ac.uk Tel: 
+44 2078826072 
Dr Dylan Morrissey (Sports & Exercise Medicine, QMUL): 
d.morrissey@qmul.ac.uk Tel: ＋44 7941710273 
Dr Heiko Grossmann (School of Mathematical Sciences, Otto-von-Guericke-
University Magdeburg): heiko.grossmann@ovgu.de Tel: +49 2514841774 
Dr Wolfram Just (School of Mathematical Sciences, QMUL): 
w.just@qmul.ac.uk 
 
4 Proposed timetable 
 
13/July/2015- 20/July/2015: Ethics approval   
13/July/2015- 20/July/2015: Experimental design and priori analysis 
July/2015- September/2016: collect and process the data  
October/2016: data analyses 
5 Other organisations involved 
 
Not applicable 
6 Other REC approval 
 
Not applicable 
7  Nature of project e.g. undergraduate, postgraduate 
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This data collection is part of the PhD project.  
8  Purpose of the research 
 
Purpose from gait study perspective: 
Gait analysis is a powerful tool to study the human movement (Whittle 2007). 
The primary propose of the project is to study the abnormal gait patterns of 
cerebral palsy (CP) patients. Gait data for CP children have already been 
collected by Dr Richard Twycross-Lewis in the Human Performance 
Laboratory. We have tried data analysis using the existing CP gait data. In 
previous study, we focused on two aspects: how does the Ankle-Foot 
Orthosis (AFO) change the gait patterns of CP patients? Do the bilateral lower 
limbs of CP patients perform synchronously during walking?  
 
In order to compare and detect the abnormality of the CP gait patterns, the 
study of healthy gait is also crucial. In this part of study. We aim to find out 
both the common features and differences between healthy and CP gait 
patterns. More specifically, we will concentrate on the effects of AFO on 
healthy subjects and the synchronization of the normal walking patterns. After 
this research, we may have a better understanding of the gait patterns and 
are able to give good interpretations to results from data analysis. 
 
Purpose from experimental design perspective: 
Randomization is not always considered carefully in the complicated data 
collection. However, we can construct completely randomized designs to 
avoid the some bias (systematic bias, selection bias, accidental bias and 
cheating) of the data (Baily 2008) and increase the power of analysis. 
Theoretically, another way to increase the power of data analysis is to 
consider the effect of blocking, which is how the observational units are 
grouped. There will be more than one type of blocks applied in this study.  
 
Therefore, the data collected in this study will not only used in the gait 
analysis, but also to measure the effect of randomization and blocking on the 
experiment. 
9  Study design, methodology and data analysis 
 
This is an observational study to measure the effect of AFO on lower limb 
when healthy subjects are walking under different conditions.  
 
We will use 3D Cartesian Optoelectronic Dynamic Anthropometer (CODA) 
motion system to measure coronal, sagittal, and transverse plane kinematic 
data. Two experimenters (A and B) will affix the CODAmotion markers on 
different subjects respectively to study the effect of blocking. Markers are 
infra-red and the protocol for marker placement is the Helen Hayes protocol.  
 
About 20 healthy subjects will be recruited for this study. The specific sample 
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size will be determined by the priori power analysis later. General information, 
including gender, date of birth, height, weight, pelvic width and depth, knee 
width, ankle width and foot length, will be recorded. The experimenter, who 
will be randomly selected from the two, will affix markers on subjects.  
 
Each subject will be required to walk on a treadmill under three conditions: 
normal walking, walking with AFO on one foot and walking with AFO on both 
feet. The order of three different trials for each subject will be randomized by 
3×3 Latin squares. In addition, the one AFO walking condition is not limited to 
one side of the body but will be done both left and right sides and order will be 
randomised as well. 
 
Kinematic data including pelvis, hip, knee, ankle, foot rotations in different 
planes will be measured by CODAmotion system. The data will be stored on 
the hard disc and standardized by an existing program. Several different 
methods such as continuous relative phase and functional mixed ANOVA 
model will be applied to analyse the data. 
10 Participants to be studied 
 
Healthy young adults; age=18-50 years. Subjects should be free from 
systemic injury and disease. The sample should contain both male and 
female. 
11 Selection criteria 
 
Inclusion criteria: 1) Subjects must be between the ages of 18 to 50 years.  
 
Exclusion criteria are: 1) subjects who suffer from neurological or 
musculoskeletal disease which would cause movement disorder, 2) subjects 
who had lower limb injuries that affected walking for >2 weeks in the past 6 
months, 3) subjects who had lower limb surgeries in the past 1 years, 4) 
pregnant women, 5) subjects who had problems of drug abuse or alcohol 
abuse in the past 3 months, 6) subjects whose cognitive functions prevent 
them from understanding the study.     
 
12 Recruitment (including incentives and compensation) 
 
Subjects will be recruited by posted adverts through emails and at the notice 
board in the student union building, mile end library and accommodation 
buildings at Queen Mary, University of London.   
13 Ethical considerations and risks to participants 
 
There are no known risks for the CODAmotion system. It has been 
successfully used in the Human Performance Laboratory without any record 
of harm. Anthropometric measurements will be done with standardised lab 
equipments, which have no known risks to subjects. 
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The treadmill walking will be done under the instruction of investigators. 
Subjects will have a short period to practice walking on the treadmill with 
lower speed. There are risks of losing balance or falling down, but risks of 
walking on the treadmill are low for healthy young adults. In addition, subjects 
can practice walking on the treadmill before experiments and will walk under 
the instruction of investigators. 
 
Subject will be required to walk with adult AFO, which will be borrowed from 
the hospital. The orthosis is used to support walking and fixed between foot 
and ankle. It is widely applied among patients with movement disorder and no 
known adverse effect for short term wearing.  
14 Confidentiality, anonymity, and data storage 
 
The data will only be used on research and names of subjects will not be 
recorded. The date of data collection will be used to identify the data in the 
computer. Only the research team will have the access to the data. Usually 
the data will be stored in the Bairu and Dr Richard Twycross-Lewis’s USB 
stick and computer. 
15  Information for participants 
 
See attached 
16 Consent  
 
See attached 
17 Signature of applicant and authorising signatories. 
 
 
                                              Principal Investigator 
 
 
                                              Other Applicant(s) 
 
 














Research study: The application of experimental design and functional mixed-
effects ANOVA model in healthy gait data 
 
We would like to invite you to be part of this research project, if you would like to.  If you 
choose not to take part there won’t be any disadvantages for you and you will hear no 
more about it. Please read the following information carefully as it will tell you why the 
research is being done and what you will be asked to do if you take part. Please ask if 
there is anything that is not clear or if you would like more information. If you decide to 
take part you will be asked to sign the attached form to say that you agree. 
You are still free to withdraw at any time and without giving a reason. 
 
We are studying the movement of the legs during walking. More specifically, we aim to 
detect any unusual walking features in patients who have movement disorders to improve 
clinical treatments. To do this, we want to compare existing information on walking 
patterns of people with problems to more regular walking patterns in healthy subjects. 
 
In this study we will also test the effect of Ankle-Foot Orthoses (AFO) on your walking. 
An AFO is a plastic brace placed around the ankle and foot but fitting inside the shoe. 
This is widely applied to patients with walking problems, such as people with cerebral 
palsy who we are particularly interested in. Walking patterns can be studied by using 
CODAmotion system, which is an instrumental 3D system, in the Human Performance 
Laboratory at Queen Mary, University of London.  
 
We would like to collect gait data in healthy young subjects 18 to 50 years old, and are 
interested in both males and females. Any gait differences between genders will also be 
analyzed in the study.   
 
Accepted subjects will be required to come to the Human Performance Laboratory at 
Queen Mary, University of London at an agreed time and date. Subjects will be expected 
to wear or bring shorts and a tee shirt. There is a changing room in the laboratory. 
Subjects will be required to sign the consent form before beginning data collection.  
 
We will measure your height, weight, and lower limb sizes. Before the main test, you can  
walk on the treadmill freely for around 3 to 5 minutes to make sure you are comfortable. 
Then we will ask you to walk on the treadmill under three conditions -normal walking in 
shoes, walking with an AFO on one foot and walking with AFOs on both feet. 
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We will attach small light emitting markers with tape to your legs and pelvis. Each trial 
will last 5 minutes. For each subject, the whole process should take 1-1.5 hours. 
 
All the instruments and orthoses are safe with minimal risk of injury. However, you may 
find it  difficult in walking on the treadmill if this is unfamiliar to you. We can stop at any 
time if you are not comfortable.   
 
The data will only be used for the research purpose. Names of subjects will not be 
recorded along with the data and dates of data collection will be used to identify the data 
in the computer. Only the research team will have the access to the data. Additional 
information sheet such as signed consent forms will be stored in the Center of Sports & 
Exercise Medicine at Queen Mary, University of London. Data will be stored in 
accordance with the Data Protection Act. 
 
It is up to you to decide whether or not to take part. If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form.  
If you have any questions or concerns about the manner in which the study was 
conducted please, in the first instance, contact the researcher responsible for the study.  
If this is unsuccessful, or not appropriate, please contact the Secretary at the Queen 
Mary Ethics of Research Committee, Room W117, Queen’s Building, Mile End Campus, 
Mile End Road, London or research-ethics@qmul.ac.uk. 
Contact details: 
Bairu Zhang (School of Mathematical Sciences, QMUL): 
bairu.zhang@qmul.ac.uk Tel: +44 7547807008 
 
Dr Richard Twycross-Lewis (Sports & Exercise Medicine, School of Engineering 







Please complete this form after you have read the Information Sheet and/or listened to 
an explanation about the research. 
 
Title of Study:  the application of experimental design and functional mixed-effects 
ANOVA model in healthy gait data. 
 
Queen Mary Ethics of Research Committee Ref: ________________ 
 
. • Thank you for considering taking part in this research. The person 
organizing the research must explain the project to you before you agree to take part.  
. • If you have any questions arising from the Information Sheet or 
explanation already given to you, please ask the researcher before you decide whether 
to join in. You will be given a copy of this Consent Form to keep and refer to at any time.  
. • I understand that if I decide at any other time during the research that I no 
longer wish to participate in this project, I can notify the researchers involved and be 
withdrawn from it immediately.  
. • I consent to the processing of my personal information for the purposes of 
this research study. I understand that such information will be treated as strictly 
confidential and handled in accordance with the provisions of the Data Protection Act 
1998.  
Participant’s Statement:  
I ___________________________________________ agree that the research 
project named above has been explained to me to my satisfaction and I agree to take 
part in the study. I have read both the notes written above and the Information Sheet 
about the project, and understand what the research study involves.  
Signed: Date:  
 
Investigator’s Statement:  
I ___________________________________________ confirm that I have carefully 
explained the nature, demands and any foreseeable risks (where applicable) of the 
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Title of study:             the application of experimental design and      
                                           functional mixed-effects model in healthy gait data                                                                                                                                                                   
Purpose of project:   we are studying the movement of the leg during walking            
                                           and the effect of Ankle-Foot Orthoses (AFO).   
Experimenter:            Dr Richard Twycross-Lewis, Bairu Zhang 
Location of study:     Human Performance Laboratory 
                                              (Mile end campus, Queen Mary University of London) 
Type of activity:        walking on the treadmill will small light infra-red  
                                          markers on pelvis and legs  
Approx. time:            1-1.5 hours 
Contact Details:        Bairu Zhang  
                                          Email: bairu.zhang@qmul.ac.uk 
                                          Tel:      + 44 (0)7547807008 
                                     Dr Richard Twycross-Lewis                                     
                                          Email:  r.twycross-lewis@qmul.ac.uk 




Hasse diagram for an alternative block
structure of the experiment in Section 4.3
In Section 4.3, I also consider an alternative structure of experiment, where 15 gait curves
rather than 9 gait curves are included for each participant. More specifically, gait data from
both left and right lower limbs are used during walking barefoot and with bilateral AFO,
while gait data from only the relevant left lower limbs are used during walking with unilateral
AFO.
The block structure of the experiment, where 15 responses for each participant are used,
is shown in Figure C.1. Compare to the Hasse diagram for the block structure of the experi-
ment (Figure 4.9), where only 9 responses for each participant are used, an additional block
factor limbs is included in Figure C.1. The block factor subperiods indicates the sub-periods
when participants walked at different speeds. The infimum of block factors periods and
limbs is indicated by periods∧ limbs, which is not a uniform factor. Moreover, the block
factor subperiods in Figure C.1 is the same as the block factor E in Figure 4.9, while the
factor E in Figure C.1 is the infimum of subperiods and periods∧ limbs.
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Figure C.1: Hasse diagram for the block structure of the experiment, where 15 gait curves rather than
9 gait curves are included for each participant, in Section 4.3
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Appendix D
Additional analysis for gait data in
Section 4.3
The analysis in Section 4.3 were repeated by using data from left lower limbs of subjects
only. In what follows, we will show that there are only slight changes in results compared to
results in Section 4.3.5.
Mean gait curves under different walking conditions can be seen in Figure D.2, which
is similar to Figure 4.13. Although in some panels, such as rotations of the ankle joint
and foot at the fast and medium speeds, we can see gait curves collected during walking
with unilateral AFO (blue, dashed) and bilateral AFO (red, dotted) are closer to each other
in Figure D.2 than Figure 4.13, it is difficult to distinguish further differences. Moreover,
similar to Table 4.5, results from functional F tests, where only data collected from left
lower limbs were used, are shown in Table D.1. Although F values and p values have slight
changes compared to Table 4.5, the significance of factors remains the same.
Likewise, since the p value in Table D.1 to assess the effect of AFO on the ankle joint
is 0.09, which implies a weak significance, we repeated the pointwise F tests and orthogonal
contrast analysis to the ankle joint. Results are shown in Figure D.1 and Table D.2, which
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are again close to those in Section 4.3.5.
Table D.1: Functional F tests for AFO, speeds and the interaction with * indicating significance at
0.05 significance level
F value (p.)
AFO speeds AFO∧ speeds
Pelvis 2.00 (0.16) 0.13 (0.91) 1.33 (0.27)
Hip 0.51 (0.69) 12.30 (< 0.01)∗ 0.33 (0.97)
Knee 0.71 (0.61) 16.04 (< 0.01)∗ 0.69 (0.72)
Ankle 2.16 (0.09) 8.68 (< 0.01)∗ 0.93 (0.53)
Foot 0.38 (0.86) 18.13 (< 0.01)∗ 0.93 (0.52)















Figure D.1: Multiple pointwise F tests for ef-
fects of AFO on ankle joints at the significance
level α = 0.05. Grey dashed lines and the grey
solid line are used to divide the whole gait cycles
into phases: initial contact, loading response, mid-
stance, terminal stance, pre-swing, initial swing,
mid-swing and terminal swing phases (from left to
right).
Table D.2: ANOVA table for the orthogonal con-
trast analysis to compare the differences between
walks barefoot and wearing AFO on the ankle
joint. * indicates significance at 0.05 signifi-
cance level.
Stratum Source dW F value (p.)
U U 1
sub jects sub jects 8
periods
L1 1 4.00 (0.03)∗




speeds 2 9.67 (< 0.01)∗
L1∧ speeds 2 1.60 (0.14)



































































































Figure D.2: Mean gait curves of 9 healthy subjects during walking under different AFO conditions
at different walking speeds. UniAFO indicates the walk wearing the unilateral AFO and BiAFO
indicates the walk wearing the bilateral AFO. All data are from left lower limbs of subjects.
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Appendix E
Ethics application form 2
Approved ethical application for the study The influence of gait analysis in the management
of cerebral palsy: a qualitative exploration of clinicians’ perspectives including the Partici-








Application form – Queen Mary Ethics of Research Committee 
1   Name, department and email address of applicant 
Augustine Adu-Amankwah, Sports & Exercise Medicine, QMUL  
a.adu-amankwah@smd14.qmul.ac.uk, Tel: +44(0)7946679673  
2  Title of study 
The influence of gait analysis on decision making in the management of Cerebral 
Palsy: a qualitative exploration of clinicians’ perspectives 
3  Investigators  
Principal Investigator: 
Augustine Adu-Amankwah, Sports & Exercise Medicine, QMUL 
Anna Hebda-Boon, Royal London Hospital,  
Hebda-Boon.Anna@bartshealth.nhs.uk, Tel: +44(0)7595264209 
Research Supervisors: 
Bairu Zhang, School of Mathematical Sciences, QMUL 
 bairu.zhang@qmul.ac.uk,  Tel: +44(0)7547807008 
Dr Dylan Morrissey, Sports & Exercise Medicine, QMUL d.morrissey@qmul.ac.uk , 
Tel: +44 (0)7941710273 
4 Proposed timetable 
For Office Use Only: 
Rec Reference ……………. 




Queen Mary Research Ethics Committee sitting: 12 January 2017 
Proposed Recruitment: 16/Jan/2017 - 28/April/2017 
Data Collection:  1/Mar/2017 – 31/May/2017 
Data Analysis and Triangulation: 1/Jun/2017 – 30/Jun/2017 
Write and Submission: 1/Jul/2017 – 31/Aug/2017 
Completion date: 31 August 2018 
5 Other organisations involved 
N/A organizations involved.  
Research undertaken as part of fulfilment for MSc in Sports & Exercise Medicine 
6 Other REC approval 
None 
7  Nature of project e.g. undergraduate, postgraduate 
Postgraduate MSc research project  
8  Purpose of the research 
Overall aims: 
To explore the effects of the use of gait laboratory analysis in the management of 
patients with Cerebral Palsy (CP) from clinicians’ perspectives in order to improve 
the patient’s outcome. 
     Subsidiary aims: 
a) This project will investigate clinicians’ experience and opinions of applying 
gait data including barriers and facilitators. 




clinical assessment and treatment of CP. 
c) Identify the applicable barriers to gait analysis and bridge the gap between gait 
laboratory data and clinical application. 
Why this study? 
CP is a common neurology disorder often affecting paediatric patient. CP is 
characterised by loss of muscle selectivity spasticity, motor and sensory disturbance, 
and premature muscle firing. The gait of children with CP is often asymmetric and 
less stable.  
In recent years, the use of laboratory based gait analysis has increased over the last 
three to four decades to help clinicians’ decision-making.  The effects of gait analysis 
on clinical decision-making are widely known among orthopaedic surgeons.  
However, the effects of gait analysis for clinical treatment are still controversial.  
Despite the recent advancement in technology and better quality data, the role of 
laboratory based gait analysis among clinicians is widely variable depending on 
locations practice, resources available and access to gait laboratory. As a result, 
clinician’s application of gait analysis data in their daily clinical practice is variable 
and not regarded to some extent as essential component of clinical practice. 
Null Hypothesis: n/a 
9  Study design, methodology and data analysis 
Qualitative research with semi-structured interview 
 
1) Face-to-face interviews with participants. 
 
2) Sample size is 10 initially and we continue the data collection until data 





3) Topic guide will be used to guide the interview whilst adopting a predominantly 
open style to allow participants to feel at ease and express themselves freely in 
order to capture the true meaning of what they are saying. 
 
4) Interviews will last about one hour. 
 
5) Interviews will be recorded by using two electronic devices to avoid the technical 
problem of the recording equipment. This would be checked immediately before 
and after interviews. 
 
6) Interviews will be outside of clinical time. 
 
7) Interviews will be within the premises convenient to the participant (their place of 





Recording of each interview would be transcribed verbatim on the computer using 
Microsoft Word software. We will take the text line by line to generate a code or 
categories and framework approach will be utilised to analyse the data.   
Participants will have the opportunity to see their transcribed interviews before 
writing up the final project, providing a further opportunity to debrief and for 
participants to air any views. 
All participants will be made aware of my supervisors’ details, should they wish to 
contact them about a concern they do not wish to discuss with me directly. 
 
10 Participants to be studied 
Participants will be Health Professionals (Physiotherapist, Orthotics, Prosthetics and 
Consultant) who has had practical application of gait analysis. 
Participants would be recruited across 4 locations in London:  




   - Kaleidoscope Child Development Centre 
   - Sunshine House Specialist Child Development Centre 
   - Bowley Close Rehabilitation centre 
11 Selection criteria 
Inclusion Criteria: 
1) Health Professionals who have experience of working children with CP 
2) Clinicians whose professional roles involve gait analysis as part of their 
assessment or treatment 
Exclusion Criteria: 
1) Clinical staff who does not practice within paediatric sector or patient diagnosed 
with CP 
2) Clinical staff who has less than six months’ clinical experience working with 
such patient groups 
3) Clinical staff that has no experiences or practical of performing gait analysis or 
of applying their results, either laboratory based or through their day-to-day 
patient assessment 
12  Recruitment (including incentives and compensation) 
1) Participants will be recruited across four London based paediatric services who 
specialise in assessment and treatment of patients diagnosed with CP. 
2) Purposive sampling is applied and participants are selected according to: gender, 
profession and experience of working with CP.   
3) No incentives (e.g. financial incentives) will be offered to the participants and no 




13 Ethical considerations and risks to participants 
1) There will be no physical risk or career risks to the participants. 
2) The study is not expected to touch on topics that are highly emotive, however, 
there is the need to be sensitive due to the fact that the information is still personal 
to the participant.  
3) In event that a participant suffers any psychological stress, they will be able to 
stop the interview at any time.   
4) The participants will be informed they can terminate the interview at any time or 
opt out of the study at any time. 
5) The interview will take place away from the members of the public or colleagues 
of the participant. 
14 Confidentiality, anonymity, and data storage 
The data will only be used for research and full names of participants will not be 
recorded. Initials of participants will be used to identify the data. The principal 
investigator will keep accurate records throughout the period of study. 
 Data storage and access: 
1) Signed consent form will be kept in a locked cabinet in the Centre for Sports and 
Exercise Medicine at QMUL. They will be kept under Participant’s data 
protection and research data gathering guidelines after completion of the study. 
2) Participants identifiable data will be anonymized and kept separate from study 
data in a secure locked cabinet located at QMUL. 
3) Electronic data will be stored on a password protected PC.  




will act as custodian of the data. 
15  Information for participants 
See attached 
16 Consent  
See attached 
17 Signature of applicant and authorising signatories. 
 
                                              Principal Investigator……………………………….. 
                                              Other Applicant(s)……………………………….…... 





Pro forma information sheet and consent form 
 
Information sheet 
Study Title: The influence of gait analysis in decision making in the management of 
Cerebral Palsy: a qualitative exploration of clinicians’ perspectives. 
We would like to invite you to be part of this research project.  You should only agree to 
take part if you want to, it is entirely up to you.  If you choose not to take part, there 
won’t be any disadvantages for you and will hear no more from me.  
Please read the following information carefully before you decide to take part; this will 
tell you why the research is being done and what you will be asked to do if you take part. 
Please ask if there is anything that is not clear or if you would like more information.   
If you decide to take part, you will be asked to sign the attached form to say that you 
agree. You can withdraw at any time from the study and without giving a reason, 
although once your data has been anonymously combined with that of others it will 
not be possible to exact it. 
In recent years, the use of laboratory based gait analysis has increased to help clinical 
decision-making.  However, sometimes clinicians feel they do not know how to fully 
make sense of the data. Through face-to-face interviews, this research will explore the 
effects of laboratory gait analysis in the management of patient with Cerebral Palsy from 
clinicians’ perspectives. More specifically, the research will investigate clinicians’ 
experience and opinions of applying gait data including barriers and facilitators. This 




to the clinicians’ decision making in the management of children diagnosed with Cerebral 
Palsy. Finally, we will make recommendations that might improve communication about 
laboratory based gait analysis between clinicians and scientist. 
What will happen? This would involve an interview at location of your choice, where it 
is familiar to you (work place office) or at Queen Mary University of London. The 
interview would last for approximately one hour. The experience and opinion shared will 
be recorded by using digital mobile device. The opinions and experience shared will be 
annonymised and kept in the strictest of confidence. After the interview, the information 
would be fully transcribed to develop theme that arises out of the interview.  
There will be no physical or career risk to you. The data will only be used for the 
research purpose. Full name will not be recorded along with the data and initials will only 
be used to identify the data in the computer. The information would be not shared with 
anyone other than those participating on the research. The identity information will be 
stored in a secure locked cabinet located at Queen Mary University of London and only 
accessible to the research team. 
What happens if there is a problem or you have a question? 
If you have any questions or concerns about the manner in which the study was 
conducted please, in the first instance, contact the researcher responsible for the study:  
Augustine Adu-Amankwah, a.adu-amankwah@smd14.qmul.ac.uk +44(0)7946679673  
or Anna Hebda-Boon, Hebda-Boon.Anna@bartshealth.nhs.uk +44(0)7595264209. 
If this is unsuccessful, or not appropriate, please contact the Secretary at the Queen Mary 
Ethics of Research Committee, Room W104, Queen’s Building, Mile End Campus, Mile 







Please complete this form after you have read the Information Sheet and/or listened to an 
explanation about the research. 
Title of Study: the influence of gait analysis on decision making in the management 
of Cerebral Palsy (CP): A qualitative exploration of the clinicians’ Perspective. 
 
Queen Mary Ethics of Research Committee Ref: ________________ 
 
Thank you for considering taking part in this research. Please read the statements below 
and initial the boxes if you are happy to proceed: 
 Please initial box 
1. I confirm that I have read the Participant Information sheet for the above study. I 
have had the opportunity to consider the information and ask questions which have 
been satisfactorily answered. 
 
2. If you have any questions arising from the Information Sheet or explanation 
already given to you, please ask the researcher before you decide whether to join 
in. You will be given a copy of this Consent Form to keep and refer to at any time. 
 




any time, without giving a reason and without any consequences to my care or 
legal rights, although once my data has been anonymously combined with that of 
others it will not be possible to extract it. 
4. I consent to the processing of my personal information for the purposes of this 
research study. I understand that such information will be treated as strictly 
confidential and handled in accordance with the provisions of the Data Protection 
Act 1998. 
 
5. I agree to take part in the above named study.  
 
Participant’s Statement:  
I ___________________________________________ agree that the research project 
named above has been explained to me to my satisfaction and I agree to take part in the 
study. I have read both the notes written above and the Information Sheet about the 
project, and understand what the research study involves.  
Signed: Date:  
Investigator’s Statement:  
I ___________________________________________ confirm that I have carefully 
explained the nature, demands and any foreseeable risks (where applicable) of the 
proposed research to the volunteer. 
Signed: Date:  
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